Therapeutic combinations for cardiovascular and inflammatory indications

Abstract

The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT inhibitor combined with COX-2 inhibitor. A further therapeutic combination comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor.

Description

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates to methods of treating cardiovascular, inflammatory and other diseases, and specifically relates to combinations of compounds, compositions, and methods for their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic or inflammatory conditions such as are associated with atherosclerosis, hypercholesterolemia, coronary plaque inflammation and other cardiovascular diseases in mammals. More particularly, the invention relates to apical sodium co-dependent bile acid transport inhibitors, cyclooxygenase inhibitors (e.g., cyclooxygenase-2 selective inhibitors), and HMG-CoA reductase inhibitors.

[0004] 2. Description of Related Art

[0005] It is well-settled in the literature that hyperlipidemic conditions associated with elevated concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol are major risk factors for coronary heart disease and particularly atherosclerosis. More recently, the role of inflammation in cardiovascular diseases has become much better understood. These findings serve to point out the acute need for prophylactic and therapeutic strategies for cardiovascular disease that are effective in simultaneously controlling both inflammatory and hyperlipidemic conditions.

[0006] The non-steroidal anti-inflammatory drugs (NSAIDs) are known to prevent the formation of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, in particular the enzyme cyclooxygenase (COX). For this reason the NSAIDs are effective in reducing the prostaglandin-induced pain and swelling associated with inflammatory processes. The recent discovery that there are two isoforms of the COX enzyme, COX-1 and COX-2, has given rise to new approaches for NSAID discovery and utilization, because it has been shown that COX-2 is the isoform specifically induced in many inflamed tissues. Many compounds have been identified which have activity as COX-2 inhibitors. A recent review of COX-2 selective inhibitors is provided by Carty and Marfat (Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs, 1 (20), 89-96 (1999)).

[0007] Atherosclerosis underlies most manifestations of coronary artery disease (CAD), a major cause of morbidity and mortality in modern society. High LDL cholesterol (above about 180 mg/dl) and low HDL cholesterol (below 35 mg/dl) have been shown to be important contributors to the development of atherosclerosis. Other diseases or risk factors, such as peripheral vascular disease, stroke, and hypercholesterolemia are also negatively affected by adverse HDL/LDL ratios.

[0008] A metabolic equilibrium generally exists between hepatic cholesterol and the bile acid pool. Interruption of the enterohepatic recirculation of bile acids results in a decrease in the liver bile acid pool and stimulates increased hepatic synthesis of bile acids from cholesterol, eventually depleting the liver's pool of esterified cholesterol. In order to maintain the liver cholesterol levels necessary to support bile acid synthesis, de novo synthesis of cholesterol increases in hepatocytes via an up-regulation of the activity of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HKG-CoA reductase), while liver uptake of serum cholesterol is increased as a result of the up-regulation of the number of hepatic cell surface receptors for low density lipoprotein cholesterol. The latter increase in hepatic receptors directly leads to a reduction in serum LDL cholesterol levels. Abundant epidemiological data have accumulated which indicate that such reduction leads to significant mitigation of the disease symptoms of atherosclerosis. The discovery of specific ASBT inhibitors is further reviewed by Booker and Arbeeny (Cardiovasc. Pulmon. Renal Invest. Drugs, 2, 208-215(2000)).

[0009] Various benzothiepine inhibitors of bile acid absorption have been disclosed by G. D. Searle (PCT Pat. Appl. WO 93/321146) for numerous uses, including regulation of fatty acid metabolism and treatment of coronary vascular disease.

[0010] PCT patent application No. WO 92/18462 lists other benzothiepines for use as hypolipemic and hypocholesterolemic agents. Each of the benzothiepine hypolipemic and hypocholesterolemic agents described in these individual patent applications is limited by an amide bonded to the carbon adjacent the phenyl ring of the fused bicyclobenzothiepine ring.

[0011] PCT patent application no. WO 93/16055, which describes a number of hypolipidemic benzothiazepine compounds. Additional hypolipidemic benzothiazepine compounds (particularly 2,3,4,5-tetrahydrobenzo-1-thi-4-azepine compounds) are disclosed in another PCT patent application no. WO 96/05188. Further hypolipidemic benzothiazepine compounds are also described in another world patent application (28).

[0012] Further ASBT inhibitor compounds include a class of lignan derivatives as described by Takashima et al. (Atherosclerosis, 107, 247-257 (1994)).

[0013] Another approach to the reduction of total cholesterol relies on the understanding that HMG-CoA reductase catalyzes the rate-limiting step in the biosynthesis of cholesterol (The Pharmacological Basis of Therapeutics, 9th ed., J. G. Hardman and L. E. Limberd, ed., McGraw-Hill, Inc., New York, pp. 884-888 (1996)). HMG-CoA reductase inhibitors (including the class of therapeutics commonly called “statins”) reduce blood serum levels of LDL cholesterol by competitive inhibition of this biosynthetic step.

[0014] Numerous antihyperlipidemic agents having other modes of action also have been disclosed in the literature as being useful for the treatment of hyperlipidemic conditions and disorders. These agents include, for example, commercially available drugs such as nicotinic acid, bile acid sequestrants including cholestryramine and colestipol, probucol, and fibric acid derivatives including gemfibrozil and clofibrate.

[0015] Some combination therapies for the treatment of cardiovascular disease have been described in the literature. A combinations of an ASBT inhibitor with HMG-a CoA reductase inhibitor useful for the treatment of cardiovascular disease is disclosed in PCT patent application no. WO 98/40375.

[0016] PCT Patent Application No. WO 99/20110 describes a therapeutic combination of a COX-2 selective inhibitor with an HMG CO-A reductase inhibitor.

[0017] While the above references indicate the value of the known combination therapies in reducing the impact of hyperlipidemia on cardiovascular disease, there is a continuing urgent need to find safe, effective agents for the prophylaxis or treatment of cardiovascular and metabolic diseases involving both inflammatory and hyperlipidemic conditions. The novel combinations of the present invention exhibit improved efficacy, improved potency, and/or reduced dosing requirements for the active compounds relative to combination regimens previously disclosed in the published literature.

SUMMARY OF THE INVENTION

[0018] To address the continuing need to find safe and effective agents for the prophylaxis and treatment of cardiovascular and other diseases, combination therapies of anti-inflammatory and anti-hyperlipidemic drugs are now disclosed.

[0019] Among its several embodiments, the present invention provides a combination therapy comprising treating a subject with an amount of an apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase-2 (COX-2) selective inhibitor or its prodrug, wherein the amount of the apical sodium co-dependent bile acid transport (ASBT) inhibitor and the amount of the cyclooxygenase-2 (COX-2) selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the compounds. For example, one of the many embodiments of the present invention is a combination therapy comprising therapeutic dosages of an ASBT inhibitor selected from Table 2 and a cyclooxygenase-2 (cox-2) selective inhibitor selected from Tables 4, 6 and 7A. A preferred embodiment of the present invention is a combination therapy comprising therapeutic dosages of a bicyclic benzothiepine ASBT inhibitor and a tricyclic cyclooxygenase-2 selective inhibitor.

[0020] In another embodiment, the present invention comprises a therapeutic combination containing an amount of an apical sodium co-dependent bile acid transport (ASBT) inhibitor and an amount of a cyclooxygenase-2 (COX-2) selective inhibitor or its prodrug, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport (ASBT) inhibitor and the amount of the cyclooxygenase-2 (COX-2) selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor selected from Table 2 and a cyclooxygenase-2 selective inhibitor selected from Tables 4, 6 and 7A. A preferred embodiment of the present invention is a combination comprising therapeutic dosages of a benzothiepine ASBT inhibitor and a tricyclic cyclooxygenase-2 selective inhibitor.

[0021] Alternatively, an aspect of the present invention is a cardiovascular combination therapy comprising treating a subject with an amount of an apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase-2 (COX-2) selective inhibitor or its prodrug and an amount of an HMG-CoA reductase inhibitor, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 (COX-2) selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination therapy comprising therapeutic dosages of an ASBT inhibitor selected from Table 2 and a cyclooxygenase-2 selective inhibitor selected from Tables 4, 6 and 7A and an HMG-CoA inhibitor selected from Table 8. A preferred embodiment of the present invention is a combination therapy comprising therapeutic dosages of a benzothiepine ASBT inhibitor, a tricyclic cyclooxygenase-2 (COX-2) selective inhibitor and a statin HMG-CoA inhibitor.

[0022] In yet another embodiment, the present invention comprises a therapeutic combination containing an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 (COX-2) selective inhibitor or its prodrug and an amount of an HMG-CoA reductase inhibitor, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 (COX-2) selective inhibitor and the amount of the HMG-CoA inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor selected from Table 2 and a cyclooxygenase-2 (COX-2) selective inhibitor selected from Tables 4, 6 and 7A and an HMG-CoA inhibitor selected from Table 8. A preferred embodiment of the present invention is a combination comprising therapeutic dosages of a benzothiepine ASBT inhibitor, a tricyclic cyclooxygenase-2 selective inhibitor and a statin HMG-CoA inhibitor.

[0023] In a further embodiment, the present invention provides a method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an apical sodium co-dependent bile acid transport (ASBT) inhibitor and an amount of a chromene cyclooxygenase inhibitor (e.g., chromene cyclooxygenase-2 (COX-2) selective inhibitor) or its prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the chromene cyclooxygenase inhibitor (e.g., chromene cyclooxygenase-2 (COX-2) selective inhibitor) together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the chromene cyclooxygenase inhibitor (e.g., chromene cyclooxygenase-2 (COX-2) selective inhibitor).

[0024] In a further embodiment, the present invention provides a method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an HMG Co-A reductase inhibitor and an amount of a chromene cyclooxygenase inhibitor (e.g., chromene cyclooxygenase-2 (COX-2) selective inhibitor) or its prodrug, wherein the amount of the HMG Co-A reductase inhibitor and the amount of the chromene cyclooxygenase inhibitor (e.g., chromene cyclooxygenase-2 (COX-2) selective inhibitor) together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the chromene cyclooxygenase inhibitor (e.g., chromene cyclooxygenase-2 (COX-2) selective inhibitor).

[0025] The present invention also provides a method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an HMG Co-A reductase inhibitor and an amount of a source of valdecoxib, wherein the amount of the HMG Co-A reductase inhibitor and the amount of the source of valdecoxib together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the source of valdecoxib.

[0026] Further scope of the applicability of the present invention will become apparent from the detailed description provided below. However, it should be understood that the following detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent from this detailed description to those skilled in the art.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] The following detailed description is provided to aid those skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention, inasmuch as modifications and variations in the embodiments discussed herein can be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.

[0028] The contents of each of the references cited herein, including the contents of the references cited within these primary references, are herein incorporated by reference in their entirety for all purposes.

[0029] a. Definitions

[0030] The following definitions are provided in order to aid the reader in understanding the detailed description of the present invention:

[0031] The term “subject” as used herein refers to an animal, preferably a mammal, and particularly a human being, who has been the object of treatment, observation or experiment.

[0032] The terms “dosing” and “treatment” refer to any process, action, application, therapy, or the like, wherein a subject, and particularly a human being, is rendered medical aid with the object of improving the subject's condition, either directly or indirectly.

[0033] “Therapeutic compound” means a compound useful in the prophylaxis or treatment of a hyperlipidemic and/or inflammatory condition, including atherosclerosis, plaque inflammation and hypercholesterolemia.

[0034] “Combination therapy” means the administration of two or more therapeutic compounds to treat a hyperlipidemic and/or inflammatory condition, for example atherosclerosis, plaque inflammation, and hypercholesterolemia. Such administration encompasses co-administration of these therapeutic compounds in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each compound. In addition, such administration also encompasses use of each type of therapeutic compound in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the cardiovascular or other condition.

[0035] The term “therapeutic combination” refers to the administered therapeutic compounds themselves and to any pharmaceutically acceptable carriers used to provide dosage forms such that the beneficial effect of each therapeutic compound is realized by the subject at the desired time, whether the compounds are administered substantially simultaneously or sequentially.

[0036] The phrase “therapeutically effective” is intended to qualify the combined amount of therapeutic compounds in the combination therapy. This combined amount will achieve the goal of avoiding or reducing or eliminating the hyperlipidemic condition and/or inflammatory condition.

[0037] The terms “cyclooxygenase-2 selective inhibitor” and “COX-2 selective inhibitor” interchangeably refer to a therapeutic compound which preferentially inhibits the COX-2 isoform of the enzyme cyclooxygenase.

[0038] The terms “cyclooxygenase-2 nonselective inhibitor” and “COX-2 nonselective inhibitor” interchangeably refer to a therapeutic compound which comparably inhibits both the COX-1 and COX-2 isoforms of the enzyme cyclooxygenase.

[0039] The term “prodrug” refers to a chemical compound that can be converted into a therapeutic compound by metabolic or simple chemical processes within the body of the subject. For example, a class of prodrugs of COX-2 inhibitors is described in U.S. Pat. No. 5,932,598, herein incorporated by reference.

[0040] b. Combinations

[0041] The combinations of the present invention will have a number of uses. For example, through dosage adjustment and medical monitoring, the individual dosages of the therapeutic compounds used in the combinations of the present invention will be lower than are typical for dosages of the therapeutic compounds when used in monotherapy. The dosage lowering will provide advantages including reduction of side effects of the individual therapeutic compounds when compared to monotherapy. In addition, fewer side effects of the combination therapy compared with monotherapies will lead to greater patient compliance with therapy regimens.

[0042] Another use of the present invention will be in combinations having complementary effects or complementary modes of action. For example, ASBT inhibitors frequently lower LDL lipoprotein but also induce de novo synthesis of cholesterol via upregulation of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase) activity. In contrast, HMG-CoA reductase inhibitors curtail the biosynthesis of cholesterol via inhibition of HMG-CoA reductase. A therapeutic combination of an ASBT inhibitor and a HMG-CoA reductase inhibitor will, when dosages are optimally adjusted, significantly lower LDL and reduce the biosynthesis of new cholesterol.

[0043] c. ASBT Inhibitors

[0044] The present invention discloses that treatment of a subject with one or more ASBT inhibitors and one or more cyclooxygenase-2 selective inhibitors results in the prophylaxis and/or treatment of cardiovascular conditions and/or disorders relative to other combination regimens. The method comprises treating the subject with an amount of an apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase-2 selective inhibitor or its prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds.

[0045] For example, one of the many embodiments of the present invention is a combination therapy comprising therapeutic dosages of a cyclooxygenase-2 selective inhibitor and a lignan ASBT inhibitor selected from the group of lignan ASBT inhibitors illustrated in Table 2 as compounds A-2 and A-3.

[0046] In another embodiment of the invention the ASBT inhibitor is selected from the group of bicyclic benzothiazepine ASBT inhibitors illustrated in Table 2 as compounds A-1, A-4 and A-5, including the diastereomers, enantiomers, racemates, salts, tautomers, conjugate acids, and prodrugs thereof.

[0047] In a preferred embodiment of the invention the ASBT inhibitor is selected from the group of benzothiepine ASBT inhibitors having the general Formula I shown below and possessing, by way of example and not limitation, the structures A-6 through A-22 disclosed in Table 2, including the diastereomers, enantiomers, racemates, salts, tautomers, conjugate acids, and prodrugs thereof.

TABLE 2
1
Examples of ASBT Inhibitors as Embodiments
Compound Number Structural Formula
A-1             2
A-2             3
A-3             4
A-4             5
A-5             6
A-6             7
A-7             8
A-8             9
A-9             10
A-10            11
A-11            12
A-12            13
A-13            14
A-14            15
A-15            16
A-16            17
A-17            18
A-18            19
A-19            20
A-20            21
A-21            22
A-22            23

[0048] The individual patent documents referenced in Table 3 below describe the preparation of the aforementioned ASBT inhibitors of Table 2 and are each herein incorporated by reference.

TABLE 3
References for Preparation of ASBT Inhibitors
                Patent/Literature Reference for
Compound Number Preparation of Compound Per Se
A-1             U.S. Pat. No. 5,817,652
A-2             Atherosclerosis, 107, 247-257
                (1994)
A-3             WO 94/24087
A-4             U.S. Pat. No. 5,910,494
A-5             WO 99/35135
A-6             U.S. Pat. No. 5,994,391
A-7             U.S. Pat. No. 5,994,391
A-8             U.S. Pat. No. 5,994,391
A-9             U.S. Pat. No. 5,994,391
A-10            U.S. Pat. No. 5,994,391
A-11            U.S. Pat. No. 5,994,391
A-12            U.S. Pat. No. 5,994,391
A-13            U.S. Pat. No. 5,994,391
A-14            U.S. Pat. No. 5,994,391
A-15            U.S. Pat. No. 5,994,391
A-16            U.S. Pat. No. 5,994,391
A-17            U.S. Pat. No. 5,994,391
A-18            U.S. Pat. No. 5,994,391
A-19            U.S. Pat. No. 5,994,391
A-20            U.S. Pat. No. 5,994,391
A-21            U.S. Pat. No. 5,994,391
A-22            U.S. Pat. No. 5,994,391

[0049] Another embodiment of the present invention comprises a pharmaceutical combination containing an amount of an apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase-2 selective inhibitor or its prodrug, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor selected from Table 2 and a cyclooxygenase-2 selective inhibitor selected from Tables 4, 6 and 7A below. A preferred embodiment of the present invention is a combination comprising therapeutic dosages of a benzothiepine ASBT inhibitor and a tricyclic cyclooxygenase-2 selective inhibitor.

[0050] d. Cyclooxygenase Inhibitors

[0051] The present invention discloses that treatment of a subject with one or more ASBT inhibitors and one or more cyclooxygenase-2 selective inhibitors results in the prophylaxis and/or treatment of cardiovascular conditions and/or disorders. The method comprises treating the subject with an amount of an ASBT inhibitor and an amount of a cyclooxygenase-2 selective inhibitor or its prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds.

[0052] For example, one of the many embodiments of the present invention is a combination therapy comprising a therapeutic amount of an ASBT inhibitor and a therapeutic amount of a cyclooxygenase inhibitor. The cyclooxygenase inhibitor can be, by way of example, a COX-2 nonselective inhibitor or a COX-2 selective inhibitor. Examples of COX-2 nonselective inhibitors include the well-known compounds aspirin, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, oxaprozin, flurbiprofen, piroxicam, tenoxicam, phenylbutazone, apazone, or nimesulide,or a pharmaceutically acceptable salt or derivative or prodrug thereof. In a preferred embodiment of the invention the COX-2 nonselective inhibitor is selected from the group comprising aspirin, acetaminophen, indomethacin, ibuprofen, or naproxen.

[0053] In another embodiment of the invention the cyclooxygenase inhibitor can be a cyclooxygenase-2 selective inhibitor, for example, the COX-2 selective inhibitor meloxicam, Formula B-1 (CAS registry number 71125-38-7) or a pharmaceutically acceptable salt or derivative or prodrug thereof. 24

[0054] In yet another embodiment of the invention the cyclooxygenase-2 selective inhibitor is the COX-2 selective inhibitor RS 57067, 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone, Formula B-2 (CAS registry number 179382-91-3) or a pharmaceutically acceptable salt or derivative or prodrug thereof. 25

[0055] In a preferred embodiment of the invention the cyclooxygenase-2 selective inhibitor is a COX-2 selective inhibitor of the chromene structural class that is a substituted benzopyran or a substituted benzopyran analog selected from the group consisting of substituted benzothiopyrans, dihydroquinolines, or dihydronaphthalenes having the general Formula II shown below and possessing, by way of example and not limitation, the structures disclosed in Table 4, including the diastereomers, enantiomers, racemates, tautomers, salts, esters, amides and prodrugs thereof.

TABLE 4
26
Examples of Chromene COX-2 Selective
Inhibitors as Embodiments
Compound
Number Structural Formula
B-3    27
       6-Nitro-2-trifluoromethyl-2H-1-
       benzopyran-3-carboxylic acid
B-4    28
       6-Chloro-8-methyl-2-trifluoromethyl-
       2H-1-benzopyran-3-carboxylic acid
B-5    29
       ((S)-6-Chloro-7-(1,1-dimethylethyl)-2-(trifluo
       romethyl-2H-1-benzopyran-3-carboxylic acid
B-6    30
       2-Trifluoromethyl-2H-naphtho[2,3-b]
       pyran-3-carboxylic acid
B-7    31
       6-Chloro-7-(4-nitrophenoxy)-2-(trifluoromethyl)-2H-1-
       benzopyran-3-carboxylic acid
B-8    32
       ((S)-6,8-Dichloro-2-(trifluoromethyl)-
       2H-1-benzopyran-3-carboxylic acid
B-9    33
       6-Chloro-2-(trifluoromethyl-4-phenyl-2H-
       1-benzopyran-3-carboxylic acid
B-10   34
       6-(4-Hydroxybenzoyl)-2-(trifluoromethyl)-
       2H-1-benzopyran-3-carboxylic acid
B-11   35
       2-(Trifluoromethyl)-6-[(trifluoromethyl)thiol]-
       2H-1-benzothiopyran-3-carboxylic acid
B-12   36
       6,8-Dichloro-2-trifluoromethyl-2H-1-
       benzothiopyran-3-carboxylic acid
B-13   37
       6-(1,1-Dimethylethyl)-2-(trifluoromethyl)-
       2H-1-benzothiopyran-3-carboxylic acid
B-14   38
       6,7-Difluoro-1,2-dihydro-2-(trifluoro
       methyl)-3-quinolinecarboxylic acid
B-15   39
       6-Chloro-1,2-dihydro-1-methyl-2-(trifluoro
       methyl)-3-quinolinecarboxylic acid
B-16   40
       6-Chloro-2-(trifluoromethyl)-1,2-dihydro
       [1,8]naphthyridine-3-carboxylic acid
B-17   41
       ((S)-6-Chloro-1,2-dihydro-2-(trifluoro
       methyl)-3-quinolinecarboxylic acid

[0056] The individual patent documents referenced in Table 5 below describe the preparation of the aforementioned COX-2 inhibitors of Table 4 and are each herein incorporated by reference.

TABLE 5
References for Preparation of Chromene
COX-2 Inhibitors
Compound Number Patent Reference
B-3             U.S. Pat. No. 6,077,850; example 37
B-4             U.S. Pat. No. 6,077,850; example 38
B-5             U.S. Pat. No. 6,077,850; example 68
B-6             U.S. Pat. No. 6,034,256; example 64
B-7             U.S. Pat. No. 6,077,850; example 203
B-8             U.S. Pat. No. 6,034,256; example 175
B-9             U.S. Pat. No. 6,077,850; example 143
B-10            U.S. Pat. No. 6,077,850; example 98
B-11            U.S. Pat. No. 6,077,850; example 155
B-12            U.S. Pat. No. 6,077,850; example 156
B-13            U.S. Pat. No. 6,077,850; example 147
B-14            U.S. Pat. No. 6,077,850; example 159
B-15            U.S. Pat. No. 6,034,256; example 165
B-16            U.S. Pat. No. 6,077,850; example 174
B-17            U.S. Pat. No. 6,034,256; example 172

[0057] In a more preferred embodiment of the invention the cycloxygenase-2 selective inhibitor is the substituted benzopyran (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, Formula B-8, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0058] In a further preferred embodiment of the invention the cyclooxygenase inhibitor is selected from the class of tricyclic cyclooxygenase-2 selective inhibitors represented by the general structure of Formula III 42

[0059] wherein A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

[0060] wherein R1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

[0061] wherein R2 is methyl or amino; and

[0062] wherein R3 is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0063] In a still more preferred embodiment of the invention the cyclooxygenase-2 selective inhibitor represented by the above Formula III is selected from the group of compounds, illustrated in Table 6, consisting of celecoxib (B-18), valdecoxib (B-19), deracoxib (B-20), rofecoxib (B-21), etoricoxib (MK-663; B-22), JTE-522 (B-23), or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0064] In an even more preferred embodiment of the invention the COX-2 selective inhibitor is selected from the group consisting of celecoxib, rofecoxib and etoricoxib.

TABLE 6
Examples of Tricyclic COX-2 Selective
Inhibitors as Embodiments
Compound
Number Structural Formula
B-18   43
B-19   44
B-20   45
B-21   46
B-22   47
B-23   48

[0065] In another highly preferred embodiment of the invention parecoxib, B-24, which is a therapeutically effective prodrug of the tricyclic cyclooxygenase-2 selective inhibitor valdecoxib, B-19, may be advantageously employed as a source of a cyclooxygenase inhibitor (U.S. Pat. No. 5,932,598, herein incorporated by reference). 49

[0066] The individual patent documents referenced in Table 7 below describe the preparation of the aforementioned cyclooxygenase-2 selective inhibitors B-18 through B-24 and are each herein incorporated by reference.

TABLE 7
References for Preparation of Tricyclic
COX-2 Inhibitors and Prodrugs
Compound Number Patent Reference
B-18            U.S. Pat. No. 5,466,823
B-19            U.S. Pat. No. 5,633,272
B-20            U.S. Pat. No. 5,521,207
B-21            U.S. Pat. No. 5,840,924
B-22            WO 98/03484
B-23            WO 00/25779
B-24            U.S. Pat. No. 5,932,598

[0067] Another embodiment of the present invention comprises a pharmaceutical combination containing an amount of an apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase inhibitor (e.g., cyclooxygenase-2 selective inhibitor) or its prodrug, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase inhibitor (e.g., cyclooxygenase-2 selective inhibitor) together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor selected from the aforementioned Table 2 and a COX-2 selective inhibitor selected from the aforementioned Tables 4, 6 and 7A. A preferred embodiment of the present invention is a combination containing therapeutic dosages of a benzothiepine ASBT inhibitor and a tricyclic COX-2 selective inhibitor.

[0068] Another preferred embodiment of the present invention is a combination containing therapeutic dosages of an ASBT inhibitor selected from Table 2 and a COX-2 selective inhibitor selected from Table 7A below.

TABLE 7A
Component 2 Name and/or Structure (COX-2 Selective Inhibitor)
D-1         50
            [2-(2,4-Dichloro-6-ethyl-3,5-dimethyl-phenylamino)-
            5-propyl-phenyl]-acetic acid;
D-2         51
            6-[[5- (4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-
            yl]methyl]-3(2H)-pyridazinone or RS 57067;
D-3         52
            6-Nitro-2 -trif1uoromethyl-2H-1-
            benzopyran-3-carboxylic acid;
D-4         53
            6-Chloro-8-methyl-2-trifluoromethyl-
            2H-1-benzopyran-3-carboxylic acid;
D-5         54
            ((S)-6-Chloro-7-(1,1-dimethylethyl)-2-(trifluo
            romethyl-2H-1-benzopyran-3-carboxylic acid;
D-6         55
            2-Trifluoromethyl-2H-naphtho[2,3-b]
            pyran-3-carboxylic acid;
D-7         56
            6-Chloro-7-(4-nitrophenoxy)-2-(trifluoromethyl)-2H-1-
            benzopyran-3-carboxylic acid;
D-8         57
            ((S)-6,8-Dichloro-2-(trifluoromethyl)-
            2H-1-benzopyran-3-carboxylic acid;
D-9         58
            6-Chloro-2-(trifluoromethyl)-4-phenyl-2H-
            1-benzopyran-3-carboxylic acid;
D-10        59
            6-(4-Hydroxybenzoyl)-2-(trifluoromethyl)-
            2H-1-benzopyran-3-carboxylic acid;
D-11        60
            2-(Trifluoromethyl)-6-[(trifluorornethyl)thio]-
            2H-1-benzothiopyran-3-carhoxylic acid;
D-12        61
            6 8-Dichloro-2-trifluoromethyl-2H-1-
            benzothiopyran-3-carboxylic acid;
D-13        62
            6-(1,1-Dimethylethyl)-2-(trifluoromethyl)-
            2H-1-benzothiopyran-3-carboxylic acid;
D-14        63
            6,7-Difluoro-1,2-dihydro-2-(trifluoro
            methyl)-3-quinolinecarboxylic acid;
D-15        64
            6-Chloro-1,2-dihydro-1-methyl-2-(trifluoro
            methyl)-3-quinolinecarboxylic acid;
D-16        65
            6-Chloro-2-(trifluoromethyl)-1,2-dihydro
            [1,8]naphthyridine-3-carboxylic acid;
D-17        66
            ((S)-6-Chloro-1,2-dihydro-2-(trifluoro
            methyl)-3-quinolinecarboxylic acid;
D-18        67
            celecoxib;
D-19        68
            valdecoxib;
D-20        69
            deracoxib;
D-21        70
            rofecoxib;
D-22        71
            etoricoxib;
D-23        72
            JTE-522
D-24        73
            parecoxib;
D-25        74
            ABT-963
D-26        75
            N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide
            or NS-398;
D-27        76
            6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-28        77
            6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-29        78
            8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-30        79
            6-chloro-8-(1-methylethyl)-2-fluoromethyl-2H-1-benzopyran carboxylic acid;
D-31        [INSERT STRUCTURE]
            2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid;
D-32        80
            7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-33        81
            6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-34        82
            8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-35        83
            6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-36        84
            5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-37        85
            8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-38        86
            7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-39        87
            6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-40        88
            7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-41        89
            7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-42        90
            6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid
D-43        91
            6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-44        92
            6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-45        93
            6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-46        94
            6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-47        95
            2-trifluoromethyl-3H-naptho[2,1-b]pyran-3-carboxylic acid;
D-48        96
            8-chloro-6-methyl-2-trifluoromethy1-2H-1-benzopyran-3-carboxylic acid;
D-49        97
            8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-50        98
            6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-51        99
            8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-52        100
            8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-53        101
            8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-54        102
            6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-55        103
            6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-56        104
            6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-57        105
            6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-58        106
            6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-59        107
            6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-60        108
            6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-61        109
            6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-62        110
            6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-63        111
            8-chloro-6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-
            1-benzopyran-3-carboxylic acid;
D-64        112
            6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-65        113
            6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-66        114
            8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-67        115
            6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-68        116
            6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-69        117
            6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-70        118
            6-[[N-(2-phenylethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-71        119
            6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-72        120
            7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-73        121
            6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid;
D-74        122
            BMS-347070
D-75        123
            8-acetyl-3-(4-fluorophenyl)-2-(4-methylsulfonyl)phenyl-
            imidazo(1,2-a)pyridine;
D-76        124
            5,5-dimethyl-4-(4-methylsulfonyl)phenyl-3-phenyl-2-(5H)-furanone;
D-77        125
            5-(4-fluorophenyl)-1-[4-(methylsulfonyl)pheuyl]-3-(trifluoromethyl)pyrazole;
D-78        126
            4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-
            3-(trifluoromethyl)pyrazole;
D-79        127
            4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-
            yl)benzenesulfonamide;
D-80        128
            4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
D-81        129
            4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide;
D-82        130
            4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
D-83        131
            4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-
            yl)benzenesulfonamide;
D-84        132
            4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-
            yl)benzenesulfonamide;
D-85        133
            4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-
            yl)benzenesulfonamide;
D-86        134
            4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide;
D-87        135
            4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-88        136
            4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
D-89        137
            4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-90        138
            4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-91        139
            4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-92        140
            4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-93        141
            4-[4-chloro-5-(4-chloropheny1)-3-(trifluoromethy1)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-94        142
            4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-95        143
            4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
D-96        144
            4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-97        145
            4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
D-98        146
            4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-99        147
            4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-100       148
            4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
D-101       149
            4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-102       150
            4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonaniide;
D-103       151
            5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
D-104       152
            4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
D-105       153
            6-(4-fluoropheny1)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene;
D-106       154
            5-(3-chloro-4-methoxyphenyl)-6-[4-
            (methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
D-107       155
            4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-
            yl]benzenesulfonamide;
D-108       156
            5-(3,5-dichloro-4-methoxyphenyl)-6-[4-
            (methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
D-109       157
            5-(3-chloro-4-fluorophenyl)-6[4-
            (methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
D-110       158
            4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
D-111       159
            2-(3-chloro-4-fluorophenyl)4-(4-fluorophenyl)-5-
            (4-methylsulfonylphenyl)thiazole;
D-112       160
            2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole;
D-113       161
            5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole;
D-114       162
            4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole;
D-115       163
            4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole;
D-116       164
            4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole;
D-117       165
            4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole;
D-118       166
            2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-
            [4-(methylsulfonyl)phenyl]thiazole;
D-119       167
            5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole;
D-120       168
            1-methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-
            2,4-dien-3-yl]benzene;
D-121       169
            4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-
            yl]benzenesulfonamide;
D-122       170
            5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl[spiro[2.4]hepta-4,6-diene;
D-123       171
            4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5-yl]benzenesulfonamide;
D-124       172
            6-(4-fluorophenyl)-2-methoxy-5-[4-(methylsulfonyl)phenyl]-pyridine-
            3-carbonitrile;
D-125       173
            2-bromo-6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyridine-
            3-carbonitrile;
D-126       174
            6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyl-pyridine-
            3-carbonitrile;
D-127       175
            4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-128       176
            4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-129       177
            4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-130       178
            3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-
            yl]pyridine;
D-131       179
            2-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)]-1H-imidazol-2-
            yl]pyridine;
D-132       180
            2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)]-1H-imidazol-2-
            yl]pyridine;
D-133       181
            2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)]-1H-imidazol-2-
            y]pyridine;
D-134       182
            4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-135       183
            2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-
            4-(trifluoromethyl)-1H-imidazole;
D-136       184
            4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-137       185
            2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole;
D-138       186
            2-(4-chlorophcnyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole;
D-139       187
            2-(4-chlorophenyl)-4-(4-fluorophenyl)-1[4-(methylsulfonyl)phenyl]-
            1H-imidazole;
D-140       188
            2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-
            4(trifluoromethyl)]-1H-imidazole;
D-141       189
            1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole;
D-142       190
            2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]4-trifluoromethyl-
            1H-imidazole;
D-143       191
            4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-144       192
            2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-
            4-(trifluoromethyl)-1H-imidazole;
D-145       193
            4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-146       194
            2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-
            1H-imidazole;
D-147       195
            4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-
            yl]benzenesulfonamide;
D-148       196
            1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-
            1H-imidazole;
D-149       197
            4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-
            yl]benzenesulfonamide;
D-150       198
            4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
D-151       199
            4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-
            yl]benzenesulfonamide;
D-152       200
            1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-
            1H-pyrazole;
D-153       201
            4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-
            yl]benzenesulfonamide;
D-154       202
            N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-
            5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
D-155       203
            ethyl[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-
            1H-pyrazol-1-yl]acetate;
D-156       204
            4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-
            1H-pyrazole;
D-157       205
            4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-
            5-(trifluoromethyl)pyrazole;
D-158       206
            1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-
            1H-pyrazole;
D-159       207
            5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-
            1H-imidazole;
D-160       208
            4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-
            1H-imidazole;
D-161       209
            5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl)-6-
            (trifluoromethyl)pyridine;
D-162       210
            2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-
            (trifluoromethyl)pyridine;
D-163       211
            5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-propynyloxy)-6-
            (trifluoromethyl)pyridine;
D-164       212
            2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-
            6-(trifluoromethyl)pyridine;
D-165       213
            4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide;
D-166       214
            1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene;
D-167       215
            5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole;
D-168       216
            4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
D-169       217
            4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
D-170       218
            4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
D-171       219
            4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide;
D-172       220
            1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-173       221
            1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-174       222
            1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-175       223
            1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-176       224
            1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]4-(methylsulfonyl)benzene;
D-177       225
            1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-178       226
            1-[2-(4-fluoropheny1)4,4-dimethylcyclopenten-1-yl]-
            4-(methylsulfonyl)benzene;
D-179       227
            4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
D-180       228
            1-[2-(4-chlorophenyl)-4,4-dimethylyclopenten-1-yl]-
            4-(methylsulfonyl)benzene;
D-181       229
            4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
D-182       230
            4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
D-183       231
            4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide;
D-184       232
            1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-185       233
            1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
D-186       234
            4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide;
D-187       235
            1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-
            4-(methylsulfonyl)benzene;
D-188       236
            4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
D-189       237
            4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide;
D-190       238
            ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-
            yl]-2-benzyl-acetate;
D-191       239
            2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid;
D-192       240
            2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyloxazole;
D-193       241
            4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
D-194       242
            4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole;
D-195       243
            4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-
            oxazolyl]benzenesulfonamide;
D-196       244
            6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-
            3-carboxylic acid;
D-197       245
            6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
D-198       5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methyl-sulphonyl-2(5H)-fluranone;
D-199       246
            6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid;
D-200       247
            4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-yl]benzenesulfonamide;
D-201       248
            4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
            yl]benzenesulfonamide;
D-202       249
            4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-
            pyrazol]benzenesulfonamide;
D-203       250
            3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-
            yl]pyridine;
D-204       251
            2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-
            imidazol-2-yl]pyridine;
D-205       252
            4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-
            yl]benzenesulfonamide;
D-206       253
            4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
D-207       254
            4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
D-208       255
            [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide;
D-209       256
            4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide;
D-210       4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-
            oxazolyl]benzenesulfonamide;
D-211       257
            [2-(2-Chloro-6-fluoro-phenylamino)-5-methyl-phenyl]-acetic acid or
            COX 189 or Lumiracoxib
D-212       258
            N-(4-Nitro-2-phenoxy-phenyl)-methanesulfonamide or Nimesulide
D-213       259
            N-[6-(2,4-Difluoro-phenoxy)-1-oxo-inden-5-yl]-methanesulfonamide or
            Flosulide
D-214       260
            N-[6-(2,4-Difluoro-phenylsulfanyl)-1-oxo-1H-inden-5-
            yl]-methanesulfonamide, soldium salt, or L-745337
D-215       261
            N-[5-(4-fluorophenylsulfanyl)-thiophen-2-
            yl]-methanesulfonaniide or RWJ-63556
D-216       L-784512
D-217       262
            (5Z)-2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-
            4(5H)-thiazolone or Darbufelone
D-218       CS-502
D-219       LAS-34475
D-220       LAS-34555
D-221       S-33516
D-222       SD-8381
D-223       L-783003;
D-224       263
            N-[3-(formylamino)-4-oxa-6-phenoxy-4H-1-benzopyran-7-
            yl]-methanesulfonamide or T614
D-225       D-1367
D-226       L-748731
D-227       264
            (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-
            dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid or CT 3
            CT3
D-228       CGP-28238
D-229       265
            4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]dihydro-2-
            methyl-2H-1,2-oxazin-3(4H)-one or BF-389
D-230       GR-253035
D-231       6-dioxo-9H-purin-8-yl-cinnamic acid
D-232       S-2474

[0069] Further, according to another embodiment of the present invention, in combination with an ASBT inhibitor of Table 2, the COX-2 selective inhibitors noted above (Table 7A) may be selected from D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8, D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17, celecoxib (D-18), D-19, D-20, rofecoxib (D-21), D-22, D-23, D-24, D-25, D-26, D-27, D-28, D-29, D-30, D-31, D-32, D-33, D-34, D-35, D-36, D-37, D-38, D-39, D-40, D-41, D-42, D-43, D-44, D-45, D-46, D-47, D-48, D-49, D-50, D-51, D-52, D-53, D-54, D-55, D-56, D-57, D-58, D-59, D-60, D-61, D-62, D-63, D-64, D-65, D-66, D-67, D-68, D-69, D-70, D-71, D-72, D-73, D-74, D-75, D-76, D-77, D-78, D-79, D-80, D-81, D-82, D-83, D-84, D-85, D-86, D-87, D-88, D-89, D-90, D-91, D-92, D-93, D-94, D-95, D-96, D-97, D-98, D-99, D-100, D-101, D-102, D-103, D-104, D-105, D-106, D-107, D-108, D-109, D-110, D-111, D-112, D-113, D-114, D-115, D-116, D-117, D-118, D-119, D-120, D-121, D-122, D-123, D-124, D-125, D-126, D-127, D-128, D-129, D-130, D-131, D-132, D-133, D-134, D-135, D-136, D-137, D-138, D-139, D-140, D-141, D-142, D-143, D-144, D-145, D-146, D-147, D-148, D-149, D-150, D-151, D-152, D-153, D-154, D-155, D-156, D-157, D-158, D-159, D-160, D-161, D-162, D-163, D-164, D-165, D-166, D-167, D-168, D-169, D-170, D-171, D-172, D-173, D-174, D-175, D-176, D-177, D-178, D-179, D-180, D-181, D-182, D-183, D-184, D-185, D-186, D-187, D-188, D-189, D-190, D-191, D-192, D-193, D-194, D-195, D-196, D-197, D-198, D-199, D-200, D-201, D-202, D-203, D-204, D-205, D-206, D-207, D-208, D-209, D-210, D-211, D-212, D-213, D-214, D-215, D-216, D-217, D-218, D-219, D-220, D-221, D-222, D-223, D-224, D-225, D-226, D-227, D-228, D-229, D-230, D-231, D-232, or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof. Even further, according to another embodiment of the present invention, in combination with the ASBT inhibitors of Table 2, the COX-2 selective inhibitors noted above (Table 7A) may be selected from D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36-D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-1l0, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-216 to D-220, D-221 to D-225, D-226 to D-230, D-231-D-232 or combinations thereof.

[0070] e. HENG-CoA Reductase Inhibitors

[0071] The present invention discloses that treatment of a subject with one or more ASBT inhibitors, one or more cyclooxygenase-2 selective inhibitors and one or more HMG-CoA reductase inhibitors results in the prophylaxis and/or treatment of cardiovascular conditions and/or disorders relative to other combination regimens. The method comprises treating the subject with an amount of an ASBT inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or its prodrug and an amount of an HMG-CoA inhibitor, wherein the amount of the ASBT inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds.

[0072] For example, one of the many embodiments of the present invention is a combination therapy comprising therapeutic dosages of an ASBT inhibitor described above, therapeutic dosages of a cyclooxygenase-2 selective inhibitor described above and therapeutic dosages of an HMG-CoA reductase inhibitor as herein provided.

[0073] HMG Co-A reductase inhibitors encompassing a wide range of structures are useful in the methods and combinations of the present invention. Such HMG Co-A reductase inhibitors may be, for example, statins that have been synthetically or semi-synthetically prepared, statins extracted from natural sources such as plants, or statins isolated as fungal metabolites from cultures of suitable microorganisms. Nonlimiting examples of HMG Co-A reductase inhibitors that may be used in the present invention include those HMG Co-A reductase inhibitors disclosed by way of example and not limitation in Table 8, including the diastereomers, enantiomers, racemates, salts, tautomers, conjugate acids, and prodrugs thereof. The therapeutic compounds of Table 8 can be used in the present, invention in a variety of forms, including acid form, salt form, racemates, enantiomers, zwitterions, and tautomers.

TABLE 8
Examples of HMG-CoA Reductase Inhibitors as
Embodiments
	CAS Numbers for
	Specific and
Compounds and	Representative
Compound Classes	Compounds	Reference
Benfluorex	23602-78-0	ES 474498, Servier
Fluvastatin	93957-54-1	EP 244364, Sandoz
Lovastatin	75330-75-5	EP 22478, Merck & Co.
Pravastatin	81093-37-0	DE 3122499, Sankyo
Simvastatin	79902-63-9	EP 33538, Merck & Co.
Atorvastatin	134523-00-5	EP 409281, Warner-
		Lambert
Cerivastatin	145599-86-6	JP 08073-432, Bayer
Bervastatin	132017-01-7	EP 380392, Merck KGaA
Rosuvastatin	147098-20-2	U.S. Pat. No. 5,260,440, Shionogi
(ZD-4522)
Itavastatin	141750-63-2	WO 97/23200, Kowa
Dalvastatin	132100-55-1	Kuttar et al., J.
		Chromatogr., A 678,
		259-63 (1994); Rhone-
		Poulenc Rorer
Mevastatin	73573-88-3	JP 56051992; Sankyo
ZD 9720		WO 97/06802
ZD 4522	147098-20-2	EP 521471; Bioorg.
	(calcium salt);	Med. Chem., 5, 437-444
	147098-18-8	(1997); Drugs Future,
	(sodium salt)	24, 511-513 (1999)
BMS 180431	129829-03-4	Sit et al., J. Med.
		Chem., 33, 2982-99
		(1990); Bristol-Myers
		Squibb
NK 104	141750-63-2	Takano et al.,
		Tetahedron: Assymetry,
		4, 201-4 (1993);
		Nissan Chemical
(Carboxydihydroxy-	148966-78-3, 139993-	EP 464845; Shionogi
heptenyl)-	44-5, 139993-
sulfonylpyrroles,	45-6, 139993-
including S 4522	46-7, 139993-47-
	8, 139993-48-9,
	139 993-49-0,
	139993-50-3, 139993-
	51-4, 139993-
	52-5, 139993-53-
	6, 139 993-54-
	7, 139993-55-8,
	139993-56-9, 139993-
	57-0, 139993-
	58-1, 139993-
	59-2, 139993-60-
	5, 139993-61-6,
	139993-62-7, 139993-
	63-8, 139993-
	64-9, 139993-
	65-0, 139993-
	66-1, 139993-67-
	2, 139993-68-3,
	139993-69-4, 139993-
	70-7, 139993-
	71-8, 139993-72-
	9, 139993-73-0,
	139 993-74-1,
	139993-75-2,
	139993-76-3,
	139993-77-4, 139993-
	78-5, 139993-
	79-6, 139993-80-
	9, 140110-63-0,
	140128-98-9, 140128-
	99-0, 140157-
	62-6
Boron analogs of di-	125894-01-1, 125894-	Sood et al., Eur. J.
and tripeptides	02-2, 125894-	Med. Chem., 25, 301-8
	03-3, 125894-04-	(1990); Boron
	4, 125894-05-5,	Biologicals
	125894-08-8, 125894-
	09-9, 125914-
	96-7
Zaragozic Acids	157058-13-4, 157058-	GB 2270312
	14-5, 157058-
	15-6, 157058-16-
	7, 157058-17-8,
	157058-18-9, 157058-
	19-0
Seco-oxysterol	157555-28-7,	Larsen et al., J. Med.
analogs, including U	157-555-29-8	Chem., 37, 2343-51
88156		(1994); Pharmacia &
		Upjohn
Pyridopyrimidines,	64405-40-9,	Hermecz et al., Hung.
including acitemate	101197-99-3	Arzneim-Forsch., 29,
		1833-5 (1979);
		Mitsubishi
BMS 22566	129829-03-4	Sit et al., J. Med.
		Chem., 33, 2982-99
		(1990); Bristol-
		Meyers-Squibb
Colestolone	50673-97-7	Raulston et al.,
		Biochem. Biophys. Res.
		Commun., 71, 984-9
		(1976); American Home
		Products
CP 83101	130746-82-6,	Wint and McCarthy, J.
	130778-27-7	Labelled Compd.
		Radiopharm., 25, 1289-97
		(1988); Pfizer
Dihydromevinolin	77517-29-4	Falck and Yang,
		Tetrahedron Lett., 25,
		3563-66 (1984); Merck
		& Co.
DMP 565		Ko et al., Abstr.
		Papers Am. Chem. Soc.
		(207th Nat. Meeting,
		Part 1, MEDI 10,
		(1994); Dupont Merck
Pyridyl and	122254-45-9	Beck et al., J. Med.
Pyrimidinylethenyl-		Chem., 33, 52-60
desmethylmevalonates		(1990); Hoechst Marion
including glenvastin		Roussel
GR 95030	157243-22-6	U.S. Pat. No. 5,316,765; Glaxo
		Wellcome
Isoxazolopyridyl-	130581-42-9, 130581-	EP 369323
mevalonates,	43-0, 130581-
carboxylic acids and	44-1, 130581-
esters	45-2, 130581-
	46-3, 130581-
	47-4, 130581-
	48-5, 130581-
	49-6, 130581-
	50-9, 130581-
	51-0, 13081-
	52-1, 130619-
	07-7, 130619-08-
	8, 130619-09-9
Lactones of 6-	127502-48-1,	Jenderella et al., J.
phenoxy-3,5-	13606-66-1,	Med. Chem., 34, 2962-83
dihydroxy-hexanoic	136034-04-3	(1991); Hoechst
acids		Marion Roussel
L 659699	29066-42-0	Chiang et al., J. Org.
		Chem., 54, 5708-12
		(1989); Merck & Co.
L 669262	130468-11-0	Stokker, J. Org.
		Chem., 59, 5983-6
		(1994); Merck & Co.
Pannorin	137023-81-5	Ogawa et al., J.
		Antibiot., 44, 762-7
		(1991); Toyoko Noko
		Univ
Rawsonol	125111-69-5	Cane et al.,
		Phytochemistry, 28,
		2917-19 (1989);
		SmithKline Beecham
RP 61969	126059-69-6	EP 326386; Phone-
		Poulenc Rorer
Bile acid-derived		Kramer et al.,
HMG Co-A reductase		Biochim. Biophys.
inhibitors; Na S		Acta, 1227, 137-54
2467 and S 2468		(1994); Hoechst Marion
		Roussel
SC 32561	76752-41-5	U.S. Pat. No. 4,230,626; Monsanto
SC 45355	125793-76-2	EP 329124; non-
		industrial source
Phosphorus-	133983-25-2	U.S. Pat. No. 5,274,155; Bristol-
containing HMG Co-A		Myers Squibb
reductase inhibitors
including SQ 33600
6-Aryloxymethyl-4-	135054-71-6, 136215-	EP 418648
hydroxytetrahydro-	82-2, 136215-
pyran-2-ones, car-	83-3, 136215-
boxylic acids and	84-4, 136215-
salts	85-5, 136315-18-
	9, 136315-19-0,
	136315-20-3, 136315-
	21-4, 136316-
	20-6
Atorvastatin calcium	134523-03-8	Baumann et al.,
(CI 981)		Tetrahedron Lett., 33,
		2283-4 (1992).
Mevinolin analogs		EP 245003
Pyranone derivatives		U.S. Pat. No. 4,937,259
1,2,4-Triazolidine-	16044-43-2	WO 9000897
3,5-diones
Isoazolidine-3,5-	124756-24-7	EP 321090
diones
CS 514	81181-70-6	DE 3122499
1,10-Bis(carboxy-	32827-49-9	DE 2038835
methylthio)decane
α, β-, and γ-		Huang and Hall, Eur.
Alkylaminophenone		J. Med. Chem., 31,
analogs, including		281-90 (1996)
N-phenyl-piperazino-
propiophenone
3-Amino-1-(2,3,4-		Huang and Hall, Arch.
mononitro-, mono- or		Pharm., 329, 339-346
dihalophenyl)propan-		(1996)
1-ones, including 3-
morpholino- or
piperidino-1-(3-
nitrophenyl)-propan-
1-ones
Substituted	64769-68-2	U.S. Pat. No. 4,049,813
isoxazolo
pyridinones
Biphenyl derivatives		JP 07089898
4-[1-(Substituted		Watanabe et al., Eur.
phenyl)-2-oxopyr-		J. Med. Chem., 29,
rolidin-4-yl]meth-		675-86 (1994)
oxybenzoic acids
Dihydroxy(tetra-		U.S. Pat. No. 5,134,155
hydro-indazolyl,
tetrahydrocyclo-
pentapyrazolyl, or
hexahydrocyclohepta-
pyrazole)heptenoate
derivatives
A 1233		Kitasato University
BAY-w-9533		Bayer
BB 476		British Biotech
BMS 180436		Bristol-Myers Squibb
Chiral HMG Co-A		Chiroscience
reductase inhibitors
Isoxazolopyridine		Nissan Chemical
HMG Co-A reductase
inhibitors
Seco-oxysterol HMG		Pharmacia & Upjohn
Co-A reductase
inhibitors
Thiophene HMG Co-A		Sandoz
reductase inhibitors
HMG Co-A reductase		Hoechest Marion
inhibitors, 6-phenoxy-		Roussel
3,5-dihydroxy-
hexanoic acids
N-((1-Methylpropyl)-		Sandoz
carbonyl)-8-(2-
(tetrahydro-4-hydroxy-
6-oxo-2H-pyran-
2-yl)ethyl)-per-
hydroisoquinoline
N-(1-Oxododecyl)-		Hoechst Marion Roussel
4α,10-dimethyl-8-
aza-trans-deca-3γ-ol
P 882222		Nissan Chemical
S 853758A		Hoechst Marion Roussel
(S)-4-((2-(4-(4-Fluorophenyl)-		Bristol-Myers Squibb
5-methyl-
2-(1-methylethyl)-6-
phenyl-3-pyridinyl)-
ethenyl)hydroxyphosphinyl)-
3-hydroxy-
butanoic acid,
disodium salt
SDZ 265859		Sandoz
(4R-(4α,6β (E)))-6-		Warner Lambert
(2-(5-(4-Fluoro-
phenyl)-3-(1-methyl-
ethyl)-1-(2-
pyridinylpyrazol-4-
yl)ethenyl)tetrahydro-
4-hydroxy-2H-
pyran-2-one
5β-aminoethyl-		Boehringer Mannheim
thiopentanoic acid
derivatives
6-Amino-2-mercapto-		North Carolina
5-methylpyrimidine-		University
4-carboxylic acid
6-Phenoxymethyl-and		Hoechst Marion Roussel
6-phenylethylen-(4-
hydroxy-
tetrahydropyran-2-
one)analogues

[0074] In a preferred embodiment of the present invention the HMG-CoA reductase inhibitors are described in Table 9 below. The individual patent documents referenced in Table 9 describe the prepraration of these statins and are each herein incorporated by reference.

[0075] In an even more preferred embodiment of the invention the HMG-CoA inhibitor is selected from the group of statins consisting of atorvastatin, simvastatin, pravastatin, lovastatin, rosuvastatin and itavastatin.

TABLE 9
References for Preparation of HMG-CoA Reductase
Inhibitors
			Patent/Literature
		CAS	Reference for
Compound		Registry	Preparation of Compound
Number	Common Name	Number	Per Se
C-1	Fluvastatin	93957-54-1	U.S. Pat. No. 4,739,073;
			U.S. Pat. No. 5,354,772
C-2	Lovastatin	75330-75-5	U.S. Pat. No. 4,231,938
C-3	Pravastatin	81093-37-0	U.S. Pat. No. 4,346,227
C-4	Simvastatin	79902-63-9	U.S. Pat. No. 4,444,784
C-5	Atorvastatin	134523-00-5	EP 409281;
			U.S. Pat. No. 5,273,995
C-6	Cerivastatin	145599-86-6	U.S. Pat. No. 5,177,080
C-7	Bervastatin	132017-01-7	EP 380392
C-8	Rosuvastatin	147098-20-2	U.S. Pat. No. 5,260,440
C-9	Itavastatin	141750-63-2	WO 97/23200, Kowa

[0076] Another embodiment of the present invention comprises a therapeutic combination containing an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or its prodrug and an amount of an HMG-CoA reductase inhibitor, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor selected from Table 2, a cyclooxygenase-2 selective inhibitor selected from Tables 4, 6 and 7A and an HMG-CoA inhibitor selected from Table 8 or Table 9. A preferred embodiment of the present invention is a combination comprising therapeutic dosages of a benzothiepine ASBT inhibitor, a tricyclic cyclooxygenase-2 selective inhibitor and a statin HMG-CoA inhibitor.

[0077] f. Dosages, Formulations, and Routes of Administration

[0078] Many of the compounds useful in the present invention can have at least two asymmetric carbon atoms, and therefore include racemates and stereoisomers, such as diastereomers and enantiomers, in both pure form and in admixture. Such stereoisomers can be prepared using conventional techniques, either by reacting enantiomeric starting materials, or by separating isomers of compounds of the present invention. Isomers may include geometric isomers, for example cis-isomers or trans-isomers across a double bond. All such isomers are contemplated among the compounds useful in the present invention. The compounds useful in the present invention also include tautomers.

[0079] The compounds useful in the present invention as discussed below include their salts, solvates and prodrugs.

[0080] The combinations of the present invention can be administered for the prophylaxis and treatment of hyperlipidemic and cardiovascular diseases or conditions by any means, preferably oral, that produce contact of these compounds with their site of action in the body, for example in the ileum of a mammal, e.g., a human.

[0081] For the prophylaxis or treatment of the conditions referred to above, the compounds useful in the combinations and methods of the present invention can be used as the compound per se. Pharmaceutically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compound. Such salts must clearly have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. The chloride salt is particularly preferred for medical purposes. Suitable pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, and alkaline earth salts such as magnesium and calcium salts.

[0082] The anions useful in the present invention are, of course, also required to be pharmaceutically acceptable and are also selected from the above list.

[0083] The compounds useful in the present invention can be presented with an acceptable carrier in the form of a pharmaceutical combination. The carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the combination and must not be deleterious to the recipient. The carrier can be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose combination, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound. Other pharmacologically active substances can also be present, including other compounds of the present invention. The pharmaceutical combinations of the invention can be prepared by any of the well known techniques of pharmacy, consisting essentially of admixing the components.

[0084] These compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic compounds or as a combination of therapeutic compounds.

[0085] The amount of compound which is required to achieve the desired biological effect will, of course, depend on a number of factors such as the specific compound chosen, the use for which it is intended, the mode of administration, and the clinical condition of the recipient.

[0086] In general, a total daily dose of an ASBT inhibitor can be in the range of from about 0.01 to about 20 mg/day, preferably from about 0.1 to about 10 mg/day, more preferably from about 0.5 to about 5.0 mg/day.

[0087] A total daily dose of a cyclooxygenase-2 selective inhibitor can be in the range of from about 0.3 to about 100 mg/kg body weight/day, preferably from about 1 to about 50 mg/kg body weight/day, more preferably from about 3 to about 10 mg/kg body weight/day.

[0088] A total daily dose of an HMG-CoA reductase inhibitor can generally be in the range of from about 0.1 to about 100 mg/day in single or divided doses. Lovastatin, atorvastatin, or mevastatin, for example, generally are each administered separately in a daily dose of about 10 to about 80 mg/day. Fluvastatin is generally administered in a daily dose of about 20 to about 40 mg/day. Cerivastatin is generally administered in a daily dose of about 0.1 to about 0.3 mg/day.

[0089] The daily doses described in the preceding paragraphs for the various therapeutic compounds can be administered to the patient in a single dose, or in proportionate multiple subdoses. Subdoses can be administered 2 to 6 times per day. Doses can be in sustained release form effective to obtain desired results.

[0090] In the case of pharmaceutically acceptable salts, the weights indicated above refer to the weight of the acid equivalent or the base equivalent of the therapeutic compound derived from the salt.

[0091] Oral delivery of the combinations of the present invention can include formulations, as are well known in the art, to provide prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms. These include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on the physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active drug from the dosage form. For some of the therapeutic compounds useful in the present invention (e.g., ASBT inhibitors), the intended effect is to extend the time period over which the active drug molecule is delivered to the site of action (e.g., the ileum) by manipulation of the dosage form. Thus, enteric-coated and enteric-coated controlled release formulations are within the scope of the present invention. Suitable enteric coatings include cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methacrylic acid methyl ester.

[0092] The combinations of the present invention can be delivered orally either in a solid, in a semi-solid, or in a liquid form. When in a liquid or in a semi-solid form, the combinations of the present invention can, for example, be in the form of a liquid, syrup, or contained in a gel capsule (e.g., a gel cap).

[0093] When administered intravenously, the dose for an ASBT inhibitor can, for example, be in the range of from about 0.01 mg to about 20 mg/day, preferably from about 0.1 to about 10 mg/day, more preferably from about 0.5 to about 5.0 mg/day.

[0094] For a cyclooxygenase-2 selective inhibitor the intravenously administered dose can, for example, be in the range of from about 0.003 to about 1.0 mg/kg body weight/day, preferably from about 0.01 to about 0.75 mg/kg body weight/day, more preferably from about 0.1 to about 0.6 mg/kg body weight/day.

[0095] An HMG-CoA reductase inhibitor can be intravenously administered, for example, in the range of from about 0.03 to about 5.0 mg/kg body weight/day, preferably from about 0.1 to about 1.0 mg/kg body weight/day, more preferably from about 0.4 to about 0.6 mg/kg body weight/day.

[0096] The dose of any of these therapeutic compounds can be conveniently administered as an infusion of from about 10 ng/kg body weight to about 100 ng/kg body weight per minute. Infusion fluids suitable for this purpose can contain, for example, from about 0.1 ng to about 10 mg, preferably from about 1 ng to about 10 mg per milliliter. Unit doses can contain, for example, from about 1 mg to about 10 g of the compound of the present invention. Thus, ampoules for injection can contain, for example, from about 1 mg to about 100 mg.

[0097] Pharmaceutical combinations according to the present invention include those suitable for oral, rectal, topical, buccal (e.g., sublingual), and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular compound which is being used. In most cases, the preferred route of administration is oral.

[0098] Pharmaceutical combinations suitable for oral administration can be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of at least one therapeutic compound useful in the present invention; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As indicated, such combinations can be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound(s) and the carrier (which can constitute one or more accessory ingredients). In general, the combinations are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet can be prepared by compressing or molding a powder or granules of the compound, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets can be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.

[0099] Pharmaceutical combinations suitable for buccal (sub-lingual) administration include lozenges comprising a compound of the present invention in a flavored base, usually sucrose, and acacia or tragacanth, and pastilles comprising the compound in an-inert base such as gelatin and glycerin or sucrose and acacia.

[0100] Pharmaceutical combinations suitable for parenteral administration conveniently comprise sterile aqueous preparations of a compound of the present invention. These preparations are preferably administered intravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations can conveniently be prepared by admixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable combinations according to the invention will generally contain from 0.1 to 5% w/w of a compound disclosed herein.

[0101] Pharmaceutical combinations suitable for rectal administration are preferably presented as unit-dose suppositories. These can be prepared by admixing a compound of the present invention with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

[0102] Pharmaceutical combinations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum jelly (e.g., Vaseline), lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof. The active compound is generally present at a concentration of from 0.1 to 50% w/w of the combination, for example, from 0.5 to 2%.

[0103] Transdermal administration is also possible. Pharmaceutical combinations suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain a compound of the present invention in an optionally buffered, aqueous solution, dissolved and/or dispersed in an adhesive, or dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%. As one particular possibility, the compound can be delivered from the patch by electrotransport or iontophoresis, for example, as described in Pharmaceutical Research, 3, 318 (1986).

[0104] In any case, the amount of active ingredient that can be combined with carrier materials to produce a single dosage form to be administered will vary depending upon the host treated and the particular mode of administration.

[0105] The solid dosage forms for oral administration including capsules, tablets, pills, powders, gel caps, and granules noted above comprise one or more compounds useful in the present invention admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate or solubilizing agents such as cyclodextrins. In the case of capsules, tablets, powders, granules, gel caps, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

[0106] Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such combinations may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

[0107] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or setting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0108] Pharmaceutically acceptable carriers encompass all the foregoing and the like.

[0109] In combination therapy, administration of two or more of the therapeutic agents useful in the present invention may take place sequentially in separate formulations, or may be accomplished by simultaneous administration in a single formulation or separate formulations. Administration may be accomplished by oral route, or by intravenous, intramuscular, or subcutaneous injections. The formulation may be in the form of a bolus, or in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, or a binder such as gelatin or hydroxypropylmethyl cellulose, together with one or more of a lubricant, preservative, surface active or dispersing agent.

[0110] For oral administration, the pharmaceutical combination may be in the form of, for example, a tablet, capsule, suspension, or liquid. Capsules, tablets, etc., can be prepared by conventional methods well known in the art. The pharmaceutical combination is preferably made in the form of a dosage unit containing a particular amount of the active ingredient or ingredients. Examples of dosage units are tablets or capsules. These may with advantage contain one or more therapeutic compound in an amount described above. For example, in the case of an HMG Co-A reductase inhibitor, the dose range may be from about 0.01 mg to about 500 mg or any other dose, dependent upon the specific inhibitor, as is known in the art.

[0111] The active ingredients may also be administered by injection as a combination wherein, for example, saline, dextrose, or water may be used as a suitable carrier. A suitable daily dose of each active therapeutic compound is one that achieves the same blood serum level as produced by oral administration as described above.

[0112] The therapeutic compounds may further be administered by any combination of oral/oral, oral/parenteral, or parenteral/parenteral route.

[0113] Pharmaceutical combinations for use in the treatment methods of the present invention may be administered in oral form or by intravenous administration. Oral administration of the combination therapy is preferred. Dosing for oral administration may be with a regimen calling for single daily dose, or for a single dose every other day, or for multiple, spaced doses throughout the day. The therapeutic compounds which make up the combination therapy may be administered simultaneously, either in a combined dosage form or in separate dosage forms intended for substantially simultaneous oral administration. The therapeutic compounds which make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step ingestion. Thus, a regimen may call for sequential administration of the therapeutic compounds with spaced-apart ingestion of the separate, active agents. The time period between the multiple ingestion steps may range from a few minutes to several hours, depending upon the properties of each therapeutic compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the therapeutic compound, as well as depending upon the effect of food ingestion and the age and condition of the patient. Circadian variation of the target molecule concentration may also determine the optimal dose interval. The therapeutic compounds of the combined therapy whether administered simultaneously, substantially simultaneously, or sequentially, may involve a regimen calling for administration of one therapeutic compound by oral route and another therapeutic compound by intravenous route. Whether the therapeutic compounds of the combined therapy are administered by oral or intravenous route, separately or together, each such therapeutic compound will be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations components. Examples of suitable pharmaceutically-acceptable formulations containing the therapeutic compounds for oral administration are given above.

[0114] g. Treatment Regimen

[0115] The dosage regimen to prevent, give relief from, or ameliorate a disease condition having hyperlipidemia and/or inflammation as an element of the disease, e.g., atherosclerosis, or to protect against or treat plaque inflammation or high-cholesterol plasma or blood levels with the compounds and/or combinations of the present invention is selected in accordance with a variety of factors. These include the type, age, weight, sex, diet, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.

[0116] Initial treatment of a patient suffering from a hyperlipidemic condition can begin with the dosages indicated above. Treatment should generally be continued as necessary over a period of several weeks to several months or years until the hyperlipidemic disease condition has been controlled or eliminated. Patients undergoing treatment with the compounds or combinations disclosed herein can be routinely monitored by, for example, measuring serum LDL and total cholesterol levels by any of the methods well known in the art, to determine the effectiveness of the combination therapy. Continuous analysis of such data permits modification of the treatment regimen during therapy so that optimal effective amounts of each type of therapeutic compound are administered at any point in time, and so that the duration of treatment can be determined as well. In this way, the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amount of the therapeutic compounds which together exhibit satisfactory effectiveness is administered, and so that administration is continued only so long as is necessary to successfully treat the hyperlipidemic condition.

[0117] A potential advantage of the combination therapy disclosed herein may be reduction of the amount of any individual therapeutic compound, or all therapeutic compounds, effective in treating hyperlipidemic conditions such as atherosclerosis and hypercholesterolemia.

[0118] One of the several embodiments of the present invention comprises a combination therapy comprising the use of an amount of an ASBT inhibitor and an amount of a cyclooxygenase inhibitor, wherein the amount of the ASBT inhibitor and the amount of the cyclooxygenase inhibitor together comprise an anti-hyperlipidemic condition effective amount or an anti-inflammatory condition effective amount of the ASBT inhibitor and the cyclooxygenase inhibitor. For example, one of the many embodiments of the present invention is a combination therapy comprising therapeutic dosages of an ASBT inhibitor and a cyclooxygenase-2 selective inhibitor. A preferred embodiment of the present invention is a combination therapy comprising therapeutic dosages of a benzothiepine ASBT inhibitor and a tricyclic cyclooxygenase-2 selective inhibitor.

[0119] Another embodiment of the present invention comprises a therapeutic combination containing an amount of an ASBT inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or its prodrug, and a pharmaceutically acceptable carrier, wherein the amount of the ASBT inhibitor, the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the ASBT inhibitor and the cyclooxygenase inhibitor. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor and a COX-2 selective inhibitor. A preferred embodiment of the present invention is a combination containing therapeutic dosages of a benzothiepine ASBT inhibitor and a tricyclic COX-2 selective inhibitor.

[0120] Another embodiment of the present invention is a combination therapy comprising an amount of an ASBT inhibitor, an amount of a cyclooxygenase-2 selective inhibitor and an amount of an HMG-CoA inhibitor, wherein the amount of the ASBT inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor, a COX-2 selective inhibitor and an HMG-CoA inhibitor. A preferred embodiment of the present invention is a combination containing therapeutic dosages of a benzothiepine ASBT inhibitor, a tricyclic COX-2 selective inhibitor and a statin HMG-CoA inhibitor.

[0121] Another embodiment of the present invention comprises a therapeutic combination containing an amount of an ASBT inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or its prodrug and an amount of an HMG-CoA reductase inhibitor, and a pharmaceutically acceptable carrier, wherein the amount of the ASBT inhibitor, the amount of the cyclooxygenase-2 selective inhibitor or its prodrug and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the said compounds. For example, one of the many embodiments of the present invention is a combination comprising therapeutic dosages of an ASBT inhibitor, a COX-2 selective inhibitor and an HMG-CoA inhibitor. A preferred embodiment of the present invention is a combination containing therapeutic dosages of a benzothiepine ASBT inhibitor, a tricyclic COX-2 selective inhibitor and a statin HMG-CoA inhibitor.

[0122] In a further embodiment, the present invention provides a method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a chromene cyclooxygenase inhibitor (e.g., a chromene COX-2 selective inhibitor) or its prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the chromene cyclooxygenase inhibitor (e.g., a chromene COX-2 selective inhibitor) together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the chromene cyclooxygenase inhibitor (e.g., a chromene COX-2 selective inhibitor).

[0123] In a further embodiment, the present invention provides a method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an HMG Co-A reductase inhibitor, an amount of a chromene cyclooxygenase inhibitor (e.g., a chromene COX-2 selective inhibitor) or its prodrug, wherein the amount of the HMG Co-A reductase inhibitor and the amount of the chromene cyclooxygenase inhibitor (e.g., a chromene COX-2 selective inhibitor) together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the chromene cyclooxygenase inhibitor (e.g., a chromene COX-2 selective inhibitor).

[0124] The present invention also provides a method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an HMG Co-A reductase inhibitor and an amount of a source of valdecoxib, wherein the amount of the HMG Co-A reductase inhibitor and the amount of the source of valdecoxib together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the source of valdecoxib. Preferably the source of valdecoxib is valdecoxib. However, the source of valdecoxib can advantageously be a prodrug of valdecoxib, for example parecoxib.

[0125] The embodiments of the present invention can comprise a combination therapy using two or more of the therapeutic compounds described or incorporated herein. The combination therapy can comprise two or more therapeutic compounds having a similar effect from different classes of chemistry, e.g., benzopyran cyclooxygenase-2 selective inhibitors can be therapeutically combined with tricyclic cyclooxygenase-2 selective inhibitors. Therapeutic combinations can also comprise more than two therapeutic compounds. For example, the therapy can comprise the use of an ASBT inhibitor, a cyclooxygenase-2 selective inhibitor, and an HMG-CoA reductase inhibitor. Alternatively, two or more compounds from the same therapeutic class of chemistry can comprise the therapy, e.g. a combination therapy comprising two or more benzothiepine ASBT inhibitors or two or more tricyclic cyclooxygenase-2 selective inhibitors.

[0126] h. Kits

[0127] The present invention further comprises kits that are suitable for use in performing the methods of treatment and/or prophylaxis described above. In one embodiment, the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 nonselective inhibitor in quantities sufficient to carry out the methods of the present invention. In a more preferred embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 selective inhibitor in quantities sufficient to carry out the methods of the present invention. In a still more preferred embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 selective chromene inhibitor identified in Table 4. In an even more highly preferred embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 selective tricyclic inhibitor identified in Tables 6 and 7A. In a particularly preferred embodiment, the kit contains a first dosage form comprising the bezothiepine ASBT inhibitor A-8 identified in Table 2 and a second dosage form comprising either celecoxib (B-18) or rofecoxib (B-21).

[0128] In another embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 nonselective inhibitor and a third dosage form comprising an HMG-CoA reductase inhibitor in quantities sufficient to carry out the methods of the present invention. In a more preferred embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 selective inhibitor and a third dosage form comprising an HMG-CoA reductase inhibitor in quantities sufficient to carry out the methods of the present invention. In a still more preferred embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 selective chromene inhibitor identified in Table 4 and a third dosage form comprising an HMG-CoA reductase inhibitor. In an even more highly preferred embodiment the kit contains a first dosage form comprising one or more of the ASBT inhibitors identified in Table 2 and a second dosage form comprising a COX-2 selective tricyclic inhibitor identified in Table 6 and a third dosage form comprising an HMG-CoA reductase inhibitor. In a particularly preferred embodiment the kit comprises a first dosage form comprising the bezothiepine ASBT inhibitor A-8 identified in Table 2 and a second dosage form comprising either celecoxib (B-18) or rofecoxib (B-21) and a third dosage form comprising a statin HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, simvastatin, pravastatin, lovastatin, rosuvastatin and itavastatin.

[0129] i. Biological Assays of Utility

[0130] The utility of the combinations of the present invention can be shown by the following assays. Assays are performed in vitro and in animal models using procedures well recognized to show the utility of the present invention.

In Vitro Assay of Compounds that Inhibit Recombinant COX-1 and/or COX-2 Activity

[0131] a. Preparation of Recombinant COX Baculoviruses

[0132] Recombinant COX-1 and COX-2 are prepared as described by Gierse et al. (J. Biochem., 305, 479-484 (1995). A 2.0 kb fragment containing the coding region of either human or murine COX-1 or human or murine COX-2 is cloned into a BamH1 site of the baculovirus transfer vector pVL1393 (Invitrogen) to generate the baculovirus transfer vectors for COX-1 and COX-2 in a manner similar to the method of D. R. O'Reilly et al. (Baculovirus Expression Vectors: A Laboratory Manual (1992). Recombinant baculoviruses are isolated by transfecting 4 pg of baculovirus transfer vector DNA into SF9 insect cells (2×108) along with 200 ng of linearized baculovirus plasmid DNA by the calcium phosphate method (M. D. Summers and G. E Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agric. Exp. Station Bull. 1555 (1987)). Recombinant viruses are purified by three rounds of plaque purification, and high-titer (107-108 pfu/mL) stocks of virus were prepared. For large-scale production, SF9 insect cells are infected in 10-liter fermentors (0.5×106/mL) with the recombinant baculovirus stock such that the multiplicity of the infection was 0.1. After 72 hours the cells are centrifuged, and the cell pellet homogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) containing 1% 3-[(3)-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The homogenate is centrifuged at 10,000×G for 30 minutes, and the resulting supernatant is stored at −80° C. before being assayed for COX activity.

[0133] b. Assay for COX-1 and COX-2 Activity

[0134] COX activity is assayed as PGE2 formed/jg protein/time using an ELISA to detect the prostaglandin released. CHAPS-solubilized insect cell wall membranes containing the appropriate COX enzyme are incubated in a potassium phosphate buffer (50 mM, pH 8.0) containing epinephrine, phenol, and heme with the addition of arachidonic acid (10 μM). Compounds are pre-incubated with the enzyme for 10-20 minutes prior to the addition of arachidonic acid. Any reaction between the arachidonic acid and the enzyme is stopped after 10 minutes at 37° C./room temperature by transferring 40 μL of reaction mix into 160 μL ELISA buffer and 25 μM indomethacin. The PGE2 formed will be measured by standard ELISA technology (Cayman Chemical).

[0135] c. Rapid assay for COX-1 and COX-2 Activity

[0136] COX activity is assayed as PGE2 formed/μg protein/time using an ELISA to detect the prostaglandin released. CHAPS-solubilized insect cell wall membranes containing the appropriate COX enzyme are incubated in a potassium phosphate buffer (50 mM potassium phosphate, pH 7.5, 300 μM epinephrine, 2 μM phenol, 1 μM heme) with the addition of 20 μL of 100 μM arachidonic acid (10 μM). Compounds are pre-incubated with the enzyme for 10 minutes at 37° C. prior to the addition of arachidonic acid. Any reaction between the arachidonic acid and the enzyme is stopped after 2 minutes at 37° C./room temperature by transferring 40 μL of reaction mix into 160 μL ELISA buffer and 25 μM indomethacin. The PGE2 formed is measured by standard, ELISA technology (Cayman Chemical).

In Vivo Assay of Anti-inflammatory Compounds in the Rat Carageenan Foot Pad Edema Test

[0137] The carageenan foot edema test for the in vivo evaluation of anti-inflammatory potency will be as performed essentially as described by Winter et al. (Proc. Soc. Exp. Biol. Med., 111, 544 (1962). Male Sprague-Dawley rats are selected in each group having average body weights as close as possible. Rats are fasted with free access to water for over sixteen hours prior to the test. The rats are dosed orally (1 mL) with compounds suspended in vehicle containing 0.5% methylcellulose and 0.025% surfactant, or with vehicle alone. One hour later a subplantar injection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% saline is administered, and the volume of the foot is measured with a displacement plethysmometer connected to a pressure transducer with a digital indicator. Three hours after the injection of the carrageenan the volume of the foot is again measured. The average foot swelling in a group of drug-treated animals is compared with that of a group of plecebo-treated animals, and the percentage inhibition of edema is determined (Otterness and Bliven, Laboratory Models for Testing NSAIDs, in Non-steroidal Anti-Inflammatory Drugs, J. Lombardino, ed., 1985).

In Vitro Assay of Compounds that Inhibit ASBT-mediated Uptake of [14C]Taurocholate (TC) in H14 Cells

[0138] Baby hamster kidney cells (BHK) transfected with the cDNA of human ASBT (H14 cells) are seeded at 60,000 cells/well in 96-well Top-Count tissue culture plates for assays to be run within in 24 hours of seeding, at 30,000 cells/well for assays run within 48 hours, and at 10,000 cells/well for assays run within 72 hours.

[0139] On the day of assay, the cell monolayer is gently washed once with 100 μl assay buffer (Dulbecco's Modified Eagle's medium with 4.5 g/L glucose+0.2% (w/v) fatty acid free-bovine serum albumin (FAF)BSA). To each well 50 μL of a two-fold concentrate of test compound in assay buffer is added along with 50 μL of 6 μM [14C]taurocholate in assay buffer (final concentration of 3 μM [14C]taurocholate). The cell culture plates are incubated for two hours at 37° C. prior to gently washing each well twice with 100 μL of Dulbecco's phosphate-buffered saline (PBS) at 40° C. containing 0.2% (w/v) (FAF)BSA. The wells are then gently washed once with 100 μL of PBS at 4° C. without (FAF)BSA. To each well 200 μL of liquid scintillation counting fluid is added, and the plates are heat sealed and shaken for 30 minutes at room temperature prior to measuring the amount of radioactivity in each well on a Packard Top-Count instrument.

In Vitro Assay of Compounds that Inhibit Uptake of [14C]Alanine

[0140] The alanine uptake assay is to be performed in an identical fashion to the taurocholate assay, with the exception that [14C]-labeled alanine was substituted for the radiolabelled taurocholate.

In Vivo Assay of Compounds that Inhibit Rat Ileal Uptake of [14C]Taurocholate into Bile

[0141] (The method to be used is similar to that described by Une at al., “Metabolism of 3α,7β-dihydroxy-7α-methyl-5β-cholanoic acid and 3α,7β-dihydroxy-7α-methyl-5β-cholanoic acid in hamsters,” Biochim. Biophys. Acta, 833, 196-202 (1985).)

[0142] Male wistar rats (200-300 g) are anesthetized with inactin @100 mg/kg. Bile ducts are cannulated with a 10″ length of PE10 tubing. The small intestine is exposed and laid out on a gauze pad. A cannula (tapered female adapter with ⅛″ luer lock) is inserted at 12 cm from the junction of the small intestine and the cecum. A slit is cut at 4 cm from this same junction (utilizing a 8 cm length of ileum). Warm Dulbecco's phosphate buffered saline (PBS) at pH 6.5 (20 mL) is used to flush out the intestinal segment. The distal opening is cannulated with a 20 cm length of silicone tubing (0.020″ I.D.×0.037″ O.D.). The proximal cannula is connected to a peristaltic pump and the intestine is washed for 20 minutes with warm PBS at 0.25 mL/min. The temperature of the gut segment is monitored continuously. At the start of the experiment, 2.0 mL of control sample ([14C]taurocholate @ 0.05 mCi/mL, diluted with 5 mM unlabelled taurocholate) is loaded into the gut segment using a 3-mL syringe, and bile sample collection is begun. Control sample is infused at a rate of 0.25 mL/min for 21 minutes. Bile sample fractions are collected for radioassay every three minutes for the first 27 minutes of the procedure. After 21 minutes of sample infusion, the ileal loop is washed out with 20 mL of warm PBS (using a 30-mL syringe), and the loop is further washed out for 21 minutes with warm PBS at 0.25 mL/min. A second perfusion is then initiated as described above, but with test compound being simultaneously administered as well (21 minutes of administration followed by 21 minutes of washout), and bile is sampled every 3 minutes for the first 27 minutes. If necessary, a third perfusion is performed as above using the control sample.

Measurement of Rat Hepatic Cholesterol Concentration (HEPATIC CHOL)

[0143] Rat liver tissue is weighed and homogenized in chloroform:methanol (2:1). After homogenization and centrifugation the supernatant is separated and dried under nitrogen. The residue is dissolved in isopropanol and the cholesterol content is measured enzymatically, using a combination of cholesterol oxidase and peroxidase, as described by Allain et al., Clin. Chem., 20, 470 (1974).

Measurement of Rat Hepatic HMG-CoA Reductase Activity

[0144] Rat liver microsomes are prepared by homogenizing liver samples in a phosphate/sucrose buffer, followed by centrifugal separation. The final pelleted material is resuspended in buffer and an aliquot is assayed for HMG-CoA reductase activity by incubating for 60 minutes at 37° C. in the presence of [14C]HMG-CoA (Dupont-NEN). The reaction is stopped by adding 6N HCl followed by centrifugation. An aliquot of the supernatant is subjected to separation using thin-layer chromatography, and the spot corresponding to the enzymatic product is scraped off the plate, extracted and assayed for radioactivity by scintillation counting (Akerlund and Bjorkhem, J. Lipid Res., 31, 2159 (1990).

Determination of Rat Serum Cholesterol (SER.CHOL, HDL-CHOL, TGI and VLDL+LDL)

[0145] Total rat serum cholesterol (SER.CHOL) is measured enzymatically using a commercial kit from Wako Fine Chemicals (Richmond, Va.); Cholesterol C11, Catalog No. 276-64909. HDL cholesterol (HDL-CHOL) is assayed using this same kit after precipitation of VLDL and LDL with Sigma Chemical Co. HDL cholesterol reagent, Catalog No. 352-3 (dextran sulfate method). Total serum triglycerides (blanked) (TGI) are assayed enzymatically with Sigma Chemical Co. GPO-Trinder, Catalog No. 337-B. VLDL and LDL (VLDL+LDL) cholesterol concentrations are calculated as the difference between total and HDL cholesterol.

Measurement of Rat Hepatic Cholesterol 7-α-Hydroxylase Activity (7α-HOase)

[0146] Rat liver microsolnes are prepared by homogenizing liver samples in a phosphate/sucrose buffer, followed by centrifugal separation. The final pelleted material is resuspended in buffer and an aliquot is assayed for cholesterol 7-α-hydroxylase activity by incubating for 5 minutes at 37° C. in the presence of NADPH. Following extraction into petroleum ether, the organic solvent is evaporated and the residue is dissolved in acetonitrile/methanol. The enzymatic product will be separated by injecting an aliquot of the extract onto a C18 reverse-phase HPLC column and quantitating the eluted material using UV detection at 240 nm. (Horton et al., J. Clin. Invest., 93, 2084 (1994)).

In Vivo Rat Gavage ASBT Assay

[0147] Male Wister rats (275-300 g) are administered ASBT inhibitors using an oral gavage procedure. Drug or vehicle (0.2% Tween 80 in water) is administered once a day (9:00-10:0 a.m.) for 4 days at varying dosages in a final volume of 2 mL per kilogram of body weight. Total fecal samples are collected during the final 48 hours of the treatment period and analyzed for bile acid content using an enzymatic assay as described below. Compound efficacy is determined by comparison of the increase in fecal bile acid (FBA) concentration in treated rats to the mean FBA concentration of rats in the vehicle group.

Measurement of Hamster Fecal Bile Acid Concentration (FBA)

[0148] Total fecal output from individually housed hamsters is collected for 24 or 48 hours, dried under a stream of nitrogen, pulverized and weighed. Approximately 0.1 gram is weighed out and extracted using an organic solvent (butanol/water). Following separation and drying, the residue is dissolved in methanol and the amount of bile acid present is measured enzymatically using the 3α-hydroxysteroid steroid dehydrogenase reaction with bile acids to reduce NAD. (Mashige et al. Clin. Chem., 27, 1352 (1981)).

[3H]Taurocholate uptake in Rabbit Brush Border Membrane Vesicles (BBMV)

[0149] Rabbit ileal brush border membranes are prepared from frozen ileal mucosa by the calcium precipitation method describe by Malathi et al. (Biochim. Biophys. Acta, 554, 259 (1979). The method for measuring taurocholate is similar to that described by Kramer et al. (Biochim. Biophys. Acta, 1111, 93 (1992)) except that the assay volume used is 200 μL instead of 100 μL. Briefly, at room temperature a 190-μl solution containing 2 μM [3H]taurocholate(0.75 μCi), 20 mM tris, 100 mm NaCl, 100 mM mannitol, pH 7.4, is incubated for 5 seconds with 10 μL of brush border membrane vesicles (60-120 μg protein). The incubation is initiated by the addition of the BBMV while vortexing and the reaction is quenched by the addition of 5 mL of ice-cold buffer (20 mM Hepes-tris, 150 mM KCl), followed immediately by filtration through a nylon filter (0.2 μm porosity) and washing with an additional 5 mL of quench buffer.

Dog Model for the Evaluation of Lipid-lowering Drugs (e.g., an ASBT Inhibitor or an HMG Co-A Reductase Inhibitor)

[0150] Male beagle dogs weighing 6-12 kg, are fed once a day for two hours and given water ad libitum. Dogs are randomly assigned to dosing groups consisting of 6 to 12 dogs each, corresponding to: vehicle, i.g.; 1 mg/kg, i.g.; 2 mg/kg, i.g.; 4 mg/kg, i.g.; 2 mg/kg, p.o. (powder in capsule). Intra-gastric dosing of a therapeutic compound dissolved in aqueous solution (for example, 0.2% Tween 80 solution [polyoxyethylene mono-oleate, Sigma Chemical Co., St. Louis, Mo.]) is performed using a gavage tube. Prior to initiation of dosing, blood samples are drawn from the cephalic vein before the morning feeding in order to evaluate serum cholesterol (total and HDL) and triglycerides. For several consecutive days animals are dosed in the morning prior to feeding. Animals are thereafter allowed to eat for two hours before remaining food was removed. Feces are collected over a 2-day period at the end of the study and were analyzed for bile acid or lipid content. Blood samples are also collected at the end of the treatment period for comparison with pre-study serum lipid levels. Statistical significance will be determined using the standard Student's T-test, with p<0.05.

Dog Serum Lipid Measurement

[0151] Blood is collected from the cephalic veins of fasted dogs using serum separator tubes (Vacutainer SST, Becton Dickinson and Co., Franklin Lakes, N.J.). The blood is centrifuged at 2000 rpm for 20 minutes and the serum decanted.

[0152] Total cholesterol is measured in a 96-well format using a Wako enzymatic diagnostic kit (Cholesterol CII) (Wako Chemicals, Richmond, Va.), utilizing the cholesterol oxidase reaction to produce hydrogen peroxide, which is measured calorimetrically. A standard curve from 0.5 to 10 μg cholesterol is prepared in the first two columns of the plate. The serum samples (20-40 μL, depending on the expected lipid concentration) or known serum control samples were added to individual wells in duplicate. Water is added to bring the volume to 100 μL in each well. A 100-μl aliquot of color reagent is added to each well, and the plates are read at 500 nm after a 15-minute incubation at 37° C.

[0153] HDL cholesterol is assayed using Sigma kit No. 352-3 (Sigma Chemical Co., St. Louis, Mo.), which utilizes dextran sulfate and Mg2+ to selectively precipitate LDL and VLDL. A volume of 150 μL of each serum sample is added to individual microfuge tubes, followed by 15 μL of HDL cholesterol reagent (Sigma 352-3). Samples are mixed and centrifuged at 5000 rpm for 5 minutes. A 50 μL aliquot of the supernatant is then mixed with 200 μL of saline and assayed using the same procedure as for total cholesterol measurement.

[0154] Triglycerides is measured using Sigma kit No. 337 in a 96-well plate format. This procedure measures the release glycerol from triglycerides with lipoprotein lipase. Standard solutions of glycerol (Sigma 339-11) ranging from 1 to 24 μg are used to generate the standard curve. Serum samples (20-40 μL, depending on the expected lipid concentration) are added to wells in duplicate. Water is added to bring the volume to 100 μL in each well and 100 μL of color reagent is also added to each well. After mixing and a 15-minute incubation, the plates will be read at 540 nm and the triglyceride values will be calculated from the standard curve. A replicate plate also will be run using a blank enzyme reagent to correct for any endogenous glycerol in the serum samples.

Dog Fecal Bile Acid Measurement

[0155] Fecal samples are collected to determine the fecal bile acid (FBA) concentration for each animal. Fecal collections are made during the final 48 hours of the study, for two consecutive 24-hour periods between 9:00 a.m. and 10:00 a.m. each day, prior to dosing and feeding. The separate two-day collections from each animal are weighed, combined and homogenized with distilled water in a processor (Cuisinart) to generate a homogeneous slurry. A sample of 1.4 g of the homogenate is extracted in a final concentration of 50% tertiary butanol/distilled water (2:0.6) for 45 minutes in a 37° water bath and centrifuged for 13 minutes at 2000×G. The concentration of bile acids (mmoles/day) is determined using a 96-well enzymatic assay system. A 20-μL aliquot of the fecal extract is added to two sets each of triplicate wells in a 96-well assay plate. A standardized sodium taurocholate solution and a standardized fecal extract solution (previously made from pooled samples and characterized for its bile acid concentration) are also analyzed for assay quality control. Aliquots of sodium taurocholate (20 μL), serially diluted to generate a standard curve, are similarly added to two sets of triplicate wells. A 230-μL reaction mixture containing 1M hydrazine hydrate, 0.1 M pyrophosphate and 0.46 mg/ml NAD is added to each well. A 50-μL aliquot of 3α-hydroxysteroid dehydrogenase enzyme (HSD; 0.8 units/ml) or assay buffer (0.1 M sodium pyrophosphate) is then added to one of the two sets of triplicates. All reagents are obtained from Sigma Chemical Co., St. Louis, Mo. Following 60 minutes of incubation at room temperature, the optical density at 340 nm is measured and the mean of each set of triplicate samples was calculated. The difference in optical density ±HSD enzyme is used to determine the bile acid concentration (mM) of each sample, based on the'sodium taurocholate standard curve. The bile acid concentration of the extract, the weight of the fecal homogenate (grams) and the body weight of the animal is used to calculate the corresponding FBA concentration in mmoles/kg/day for each animal. The mean FBA concentration (mmoles/kg/day) of the vehicle group is subtracted from the FBA concentration of each treatment group to determine the increase (delta value) in FBA concentration as a result of the treatment.

Hamster Intestinal Cholesterol Absorption Assay

[0156] Various compounds can be shown to inhibit cholesterol absorption from the intestinal tract. These compounds lower serum cholesterol levels by reducing intestinal absorption of cholesterol from both exogenous sources (dietary cholesterol) and endogenous cholesterol (secreted by the gall bladder into the intestinal tract).

[0157] In hamsters the use of a dual-isotope plasma ratio method to measure intestinal cholesterol absorption will be refined and evaluated as described by Turley et al. (J. Lipid Res., 35, 329-339 (1994)).

[0158] Male hamsters weighing 80-100 g are given food and water ad libitum in a room with 12-hour alternating periods of light and dark. Four hours into the light period, each hamster is administered an intravenous dose of 2.5 μCi of [1,2-3H]cholesterol suspended in Intralipid (20%), followed by an oral dose of [4-14C]cholesterol in an oil vehicle containing medium-chain triglycerides (MCT). The i.v. dose is given by injecting a 0.4-mL volume of the Intralipid mixture into the distal femoral vein. The oral dose is given by gavaging a 0.6-mL volume of the MCT oil mixture intragastrically via a polyethylene tube. After 72 hours the hamsters are bled and the amount of [3H] and [14C] in the plasma and in the original radiolabelled dosing mixtures are determined by liquid scintillation spectrometry. The cholesterol absorption is calculated from the following equation: 1$\text{Percent cholestrol absorbed}=\frac{\text{\% of oral dose per mL of 72-hour plasma sample}}{\text{\% of i.v. dose per mL of 72-hour plasma sample}}\times 100$

Evaluation of Plasma Lipids and Atherosclerotic Lesions in Rabbits

[0159] Rabbit plasma lipids are assayed using standard methods as reported by Schuh et al., J. Clin. Invest., 91, 1453-1458 (1993). Groups of male New Zealand white rabbits are placed on a standard diet (100 g/day) supplemented with 0.3% cholesterol and 2% corn oil (Zeigler Bothers, Inc., Gardners, Pa.). Water is available ad libitum. Groups of control and treated animals are sacrificed after one and three months of treatment. Blood samples are collected for determination of plasma lipid concentrations. Tissues are removed for characterization of atherosclerotic lesions and aorta vascular response.

[0160] a. Plasma Lipids

[0161] Plasma for lipid analysis is obtained by withdrawing blood from the ear vein into EDTA-containing tubes (Vacutainer; Becton Dickenson & Co., Rutherford, N.J.), followed by centrifugation of the cells. Total cholesterol is determined enzymatically, using the cholesterol oxidase reaction (C. A. Allain et al., Clin. Chem., 20, 470-475 (1974)). HDL cholesterol is also measured enzymatically, after selective precipitation of LDL and VLDL by dextran sulfate with magnesium (Warnick et al., Clin. Chem., 28, 1379-1388 (1982)). Plasma triglyceride levels are determined by measuring the amount of glycerol released by lipoprotein lipase through an enzyme-linked assay (G. Bucolo et al., Clin. Chem., 19, 476-482 (1973)).

[0162] b. Atherosclerotic Lesions

[0163] Animals are sacrificed by pentobarbital injection. Thoracic aortas are rapidly removed and fixed by immersion in 10% neutral buffered formalin, and stained with oil red O (0.3%). After a single longitudinal incision along the wall opposite the arterial ostia, the vessels are pinned open for evaluation of the plaque area. The percent plaque coverage is determined from the values for the total area examined and the stained area by threshold analysis using a true color image analyzer (Videometric 150; American Innovision, Inc., San Diego, Calif.) interfaced to a color camera (Toshiba 3CCD) mounted on a dissecting microscope. Tissue cholesterol is measured enzymatically as previously described, after extraction with a chloroform/methanol mixture (2:1, according to the method of Folch et al. (J. Biol. Chem., 226, 497-509 (1957)).

[0164] c. Aorta Vascular Response

[0165] The abdominal aortas are rapidly excised after injection of sodium pentobarbital and placed in oxygenated Krebs-bicarbonate buffer. After removal of perivascular tissue, 3-mm ring segments are cut, placed in a 37° C. muscle bath containing Krebs-bicarbonate solution, and suspended between two stainless steel wires, one of which is attached to a force transducer (Grass Instrument Co., Quincy, Mass.). Force changes in response to angiotensin II added to the bath will be recorded on a chart recorder.

Evaluation of Plasma Lipids and Atherosclerotic Lesions in Mouse Models of Atherosclerosis

[0166] Male LDL receptor (−/−) mice (6-8 weeks of age) are obtained from the Jackson Laboratories (Bar Harbor, Me.) and are permitted an acclimatization period of one week on normal diet. Mice are then placed on a diet enriched in saturated fat (21% wt/wt) and cholesterol (0.15% wt/wt; Harlan Teklad, catalog #88137). Pelleted diets are prepared by Research Diets, New Brunswick, N.J. Compounds are administered by mixing the drug in the diet at the indicated concentrations. On occasion, drugs can be administered in the drinking water. Mice are maintained on the above regimens for a minimum of 8 weeks and usually a total of 12 weeks.

[0167] Male ApoE (−/−) mice are obtained from the Jackson Laboratories (Bar Harbor, Me.) and are permitted an acclimatization period of one week on normal diet. Mice (6 weeks of age) are then placed on a normal chow diet (Purina Certified 5002 Diet) or on a saturated fat (21% wt/wt) and cholesterol (0.15% wt/wt; Harlan Teklad, catalog #88137) to accelerate the rate of atherosclerosis formation. Pelleted diets are prepared by Research Diets, New Brunswick, N.J. Compounds are administered by mixing the drug in the diet at the indicated concentrations. Mice are maintained on the above regimens for a minimum of 8 weeks and usually a total of 12 weeks.

[0168] a. Lipid Analyses

[0169] Serum cholesterol concentrations were determined by enzymatic assay and lipoprotein-cholesterol distribution was determined by size exclusion chromatography as described previously (Daugherty A and Rateri D, Coronary Artery Dis. 2: 775-787 (1991).

[0170] b. Quantification and Histological Analyses of the Atherosclerotic Lesions

[0171] The extent of the aortic intima covered by grossly discernable atherosclerotic lesions can be quantified by en face analysis of the aorta (from the top of the heart to the iliac bifurcation) as described previously (Daugherty A et al. J. Clin. Invest.100:1575-1580 (1997); Daugherty A at al. J. Clin. Invest. 105:1605-1612 (2000).

[0172] Alternatively, atherosclerotici lesion area can be determined in the aortic roots of animals which correlates extremely well with en face atherosclerotic lesion area assessment, but allows histologc evaluation of the quality of the lesions themselves. Mice are euthanized with CO2 gas and blood is removed by retroorbital collection. Hearts are immediately removed and fixed in phosphate buffered formalin. After 24 hours, the bottom two-thirds of the hearts are removed by carefully sectioning the heart just below the atria. The remaining top portions of the hearts are embedded in paraffin and 4 μm sections are cut. Every 6th section is evaluated for cross sectional area of atherosclerotic lesions by hematoxylin and eosin staining, beginning where the atrial valves appeared distinctly to where the valves disappear, as described earlier by Nishina et al. (Nishina PM et al, Lipids 28: 599-605 (1993).

[0173] Serial sections of the proximal aorta, within 50 microns of the valves and containing remnants of the valve leaflets are selected for immunolocalization of lymphocytes, (anti-CD3), macrophages (anti-CD1) and smooth muscle cells (SMA) and counterstained using hemotoxylin or methyl green. All lesions contained within one aortic section per individual are evaluated. Lesions are characterized as early (Stary classification I and II) or complex (Stary classification III and IV).

[0174] T cell quantification in atherosclerotic lesions is performed on sections stained with an anti-CD3 antibody followed by digital image analysis on a computer controlled Olympus AX-70 Provis microscope equipped with a Photometrix digital camera, liquid crystal tunable filter and Isee Imaging software (Inovison Corp, Raleigh, N.C.). Procedures for image acquisition and image analysis has been previously described (Ornberg RL. J. Histochem. Cytochem. 49:1059-1060 (2000); Ornberg RL et al. Journal of Histochemistry and Cytochemistry. 47(9): 1-7 (1999).

[0175] For smooth muscle cell content, aortic root section images were captured using a Zeiss Axiophot equipped with a Spot XX camera and a 10× objective with a 1.6× magnification ring. Lesion area positively stained for SMA was measured by selecting threshold criteria to detect 1% of a negative control tissue (lymph node) and >85% of a positive control, which was typically a normal media. All lesions are included in the analysis; early or complex lesion assignment is noted during data capture. All measurements are performed by blinded observers and analyzed with measured Area of smooth muscle actin by quantitative image analysis Optimus 6.1.3.

[0176] c. Statistical Analyses

[0177] Statistically significant differences among the means of different groups are tested using one-way analysis of variance (ANOVA).

j. EXAMPLES OF EMBODIMENTS

[0178] The following non-limiting examples serve to illustrate various aspects of the present invention.

Example 1

Pharmaceutical Compositions

[0179] 100 mg tablets of the composition set forth in Table X-1 can be prepared using wet granulation techniques:

TABLE X-1
Ingredient                    Weight (mg)
Compound A-7 (Benzothiepine)  5
Compound B-18 (Celecoxib)     20
Lactose                       54
Microcrystalline Cellulose    15
Hydroxypropyl Methylcellulose 3
Croscarmelose Sodium          2
Magnesium Stearate            1
Total Tablet Weight           100

Example 2

Pharmaceutical Compositions

[0180] 100 mg tablets of the composition set forth in Table X-2 can be prepared using direct compression techniques:

TABLE X-2
Ingredient                   Weight (mg)
Compound A-7 (Benzothiepine) 5
Compound B-18 (Celecoxib)    20
Microcrystalline Cellulose   69.5
Colloidal Silicon Dioxide    0.5
Talc                         2.5
Croscarmelose Sodium         2
Magnesium Stearate           0.5
Total Tablet Weight          100

[0181] Combinations

[0182] Tables X-3 and X-3A illustrate, by way of example and not limitation, some of the many combinations of the present invention wherein the combination comprises an amount of an ASBT inhibitor (Component 1) and an amount of a cyclooxygenase-2 selective inhibitor (Component 2), wherein the amount of the ASBT inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the ASBT inhibitor and the cyclooxygenase-2 selective inhibitor.

	TABLE X-3
	Example Number	Component 1	Component 2
	1x	A-3	B-18
	2x	A-3	B-19
	3x	A-3	B-20
	4x	A-3	B-21
	5x	A-3	B-22
	6x	A-3	B-23
	7x	A-3	B-24
	8x	A-5	B-18
	9x	A-5	B-19
	10x	A-5	B-20
	11x	A-5	B-21
	12x	A-5	B-22
	13x	A-5	B-23
	14x	A-5	B-24
	15x	A-7	B-18
	16x	A-7	B-19
	17x	A-7	B-20
	18x	A-7	B-21
	19x	A-7	B-22
	20x	A-7	B-23
	21x	A-7	B-24

[0183]

	TABLE X-3A
	Example Number	Component 1	Component 2
	22X	A-3	D-1
	23X	A-3	D-2
	24X	A-3	D-3
	25X	A-3	D-4
	26X	A-3	D-5
	27X	A-3	D-6
	28X	A-3	D-7
	29X	A-3	D-8
	30X	A-3	D-9
	31X	A-3	D-10
	32X	A-3	D-11
	33X	A-3	D-12
	34X	A-3	D-13
	35X	A-3	D-14
	36X	A-3	D-15
	37X	A-3	D-16
	38X	A-3	D-17
	39X	A-3	D-18
	40X	A-3	D-19
	41X	A-3	D-20
	42X	A-3	D-21
	43X	A-3	D-22
	44X	A-3	D-23
	45X	A-3	D-24
	46X	A-3	D-25
	47X	A-3	D-26
	48X	A-3	D-27
	49X	A-3	D-28
	50X	A-3	D-29
	51X	A-3	D-30
	52X	A-3	D-31
	53X	A-3	D-32
	54X	A-3	D-33
	55X	A-3	D-34
	56X	A-3	D-35
	57X	A-3	D-36
	58X	A-3	D-37
	59X	A-3	D-38
	60X	A-3	D-39
	61X	A-3	D-40
	62X	A-3	D-41
	63X	A-3	D-42
	64X	A-3	D-43
	65X	A-3	D-44
	66X	A-3	D-45
	67X	A-3	D-46
	68X	A-3	D-47
	69X	A-3	D-48
	70X	A-3	D-49
	71X	A-3	D-50
	72X	A-3	D-51
	73X	A-3	D-52
	74X	A-3	D-53
	75X	A-3	D-54
	76X	A-3	D-55
	77X	A-3	D-56
	78X	A-3	D-57
	79X	A-3	D-58
	80X	A-3	D-59
	81X	A-3	D-60
	82X	A-3	D-61
	83X	A-3	D-62
	84X	A-3	D-63
	85X	A-3	D-64
	86X	A-3	D-65
	87X	A-3	D-66
	88X	A-3	D-67
	89X	A-3	D-68
	90X	A-3	D-69
	91X	A-3	D-70
	92X	A-3	D-71
	93X	A-3	D-72
	94X	A-3	D-73
	95X	A-3	D-74
	96X	A-3	D-75
	97X	A-3	D-76
	98X	A-3	D-77
	99X	A-3	D-78
	100X	A-3	D-79
	101X	A-3	D-80
	102X	A-3	D-81
	103X	A-3	D-82
	104X	A-3	D-83
	105X	A-3	D-84
	106X	A-3	D-85
	107X	A-3	D-86
	108X	A-3	D-87
	109X	A-3	D-88
	110X	A-3	D-89
	111X	A-3	D-90
	112X	A-3	D-91
	113X	A-3	D-92
	114X	A-3	D-93
	115X	A-3	D-94
	116X	A-3	D-95
	117X	A-3	D-96
	118X	A-3	D-97
	119X	A-3	D-98
	120X	A-3	D-99
	121X	A-3	D-100
	122X	A-3	D-101
	123X	A-3	D-102
	124X	A-3	D-103
	125X	A-3	D-104
	126X	A-3	D-105
	127X	A-3	D-106
	128X	A-3	D-107
	129X	A-3	D-108
	130X	A-3	D-109
	131X	A-3	D-110
	132X	A-3	D-111
	133X	A-3	D-112
	134X	A-3	D-113
	135X	A-3	D-114
	136X	A-3	D-115
	137X	A-3	D-116
	138X	A-3	D-117
	139X	A-3	D-118
	140X	A-3	D-119
	141X	A-3	D-120
	142X	A-3	D-121
	143X	A-3	D-122
	144X	A-3	D-123
	145X	A-3	D-124
	146X	A-3	D-125
	147X	A-3	D-126
	148X	A-3	D-127
	149X	A-3	D-128
	150X	A-3	D-129
	151X	A-3	D-130
	152X	A-3	D-131
	153X	A-3	D-132
	154X	A-3	D-133
	155X	A-3	D-134
	156X	A-3	D-135
	157X	A-3	D-136
	158X	A-3	D-137
	159X	A-3	D-138
	160X	A-3	D-139
	161X	A-3	D-140
	162X	A-3	D-141
	163X	A-3	D-142
	164X	A-3	D-143
	165X	A-3	D-144
	166X	A-3	D-145
	167X	A-3	D-146
	168X	A-3	D-147
	169X	A-3	D-148
	170X	A-3	D-149
	171X	A-3	D-150
	172X	A-3	D-151
	173X	A-3	D-152
	174X	A-3	D-153
	175X	A-3	D-154
	176X	A-3	D-155
	177X	A-3	D-156
	178X	A-3	D-157
	179X	A-3	D-158
	180X	A-3	D-159
	181X	A-3	D-160
	182X	A-3	D-161
	183X	A-3	D-162
	184X	A-3	D-163
	185X	A-3	D-164
	186X	A-3	D-165
	187X	A-3	D-166
	188X	A-3	D-167
	189X	A-3	D-168
	190X	A-3	D-169
	191X	A-3	D-170
	192X	A-3	D-171
	193X	A-3	D-172
	194X	A-3	D-173
	195X	A-3	D-174
	196X	A-3	D-175
	197X	A-3	D-176
	198X	A-3	D-177
	199X	A-3	D-178
	200X	A-3	D-179
	201X	A-3	D-180
	202X	A-3	D-181
	203X	A-3	D-182
	204X	A-3	D-183
	205X	A-3	D-184
	206X	A-3	D-185
	207X	A-3	D-186
	208X	A-3	D-187
	209X	A-3	D-188
	210X	A-3	D-189
	211X	A-3	D-190
	212X	A-3	D-191
	213X	A-3	D-192
	214X	A-3	D-193
	215X	A-3	D-194
	216X	A-3	D-195
	217X	A-3	D-196
	218X	A-3	D-197
	219X	A-3	D-198
	220X	A-3	D-199
	221X	A-3	D-200
	222X	A-3	D-201
	223X	A-3	D-202
	224X	A-3	D-203
	225X	A-3	D-204
	226X	A-3	D-205
	227X	A-3	D-206
	228X	A-3	D-207
	229X	A-3	D-208
	230X	A-3	D-209
	231X	A-3	D-210
	232X	A-3	D-211
	233X	A-3	D-212
	234X	A-3	D-213
	235X	A-3	D-214
	236X	A-3	D-215
	237X	A-3	D-216
	238X	A-3	D-217
	239X	A-3	D-218
	240X	A-3	D-219
	241X	A-3	D-220
	242X	A-3	D-221
	243X	A-3	D-222
	244X	A-3	D-223
	245X	A-3	D-224
	246X	A-3	D-225
	247X	A-3	D-226
	248X	A-3	D-227
	249X	A-3	D-228
	250X	A-3	D-229
	251X	A-3	D-230
	252X	A-3	D-231
	253X	A-3	D-232
	254X	A-5	D-1
	255X	A-5	D-2
	256X	A-5	D-3
	257X	A-5	D-4
	258X	A-5	D-5
	259X	A-5	D-6
	260X	A-5	D-7
	261X	A-5	D-8
	262X	A-5	D-9
	263X	A-5	D-10
	264X	A-5	D-11
	265X	A-5	D-12
	266X	A-5	D-13
	267X	A-5	D-14
	268X	A-5	D-15
	269X	A-5	D-16
	270X	A-5	D-17
	271X	A-5	D-18
	272X	A-5	D-19
	273X	A-5	D-20
	274X	A-5	D-21
	275X	A-5	D-22
	276X	A-5	D-23
	277X	A-5	D-24
	278X	A-5	D-25
	279X	A-5	D-26
	280X	A-5	D-27
	281X	A-5	D-28
	282X	A-5	D-29
	283X	A-5	D-30
	284X	A-5	D-31
	285X	A-5	D-32
	286X	A-5	D-33
	287X	A-5	D-34
	288X	A-5	D-35
	289X	A-5	D-36
	290X	A-5	D-37
	291X	A-5	D-38
	292X	A-5	D-39
	293X	A-5	D-40
	294X	A-5	D-41
	295X	A-5	D-42
	296X	A-5	D-43
	297X	A-5	D-44
	298X	A-5	D-45
	299X	A-5	D-46
	300X	A-5	D-47
	301X	A-5	D-48
	302X	A-5	D-49
	303X	A-5	D-50
	304X	A-5	D-51
	305X	A-5	D-52
	306X	A-5	D-53
	307X	A-5	D-54
	308X	A-5	D-55
	309X	A-5	D-56
	310X	A-5	D-57
	311X	A-5	D-58
	312X	A-5	D-59
	313X	A-5	D-60
	314X	A-5	D-61
	315X	A-5	D-62
	316X	A-5	D-63
	317X	A-5	D-64
	318X	A-5	D-65
	319X	A-5	D-66
	320X	A-5	D-67
	321X	A-5	D-68
	322X	A-5	D-69
	323X	A-5	D-70
	324X	A-5	D-71
	325X	A-5	D-72
	326X	A-5	D-73
	327X	A-5	D-74
	328X	A-5	D-75
	329X	A-5	D-76
	330X	A-5	D-77
	331X	A-5	D-78
	332X	A-5	D-79
	333X	A-5	D-80
	334X	A-5	D-81
	335X	A-5	D-82
	336X	A-5	D-83
	337X	A-5	D-84
	338X	A-5	D-85
	339X	A-5	D-86
	340X	A-5	D-87
	341X	A-5	D-88
	342X	A-5	D-89
	343X	A-5	D-90
	344X	A-5	D-91
	345X	A-5	D-92
	346X	A-5	D-93
	347X	A-5	D-94
	348X	A-5	D-95
	349X	A-5	D-96
	350X	A-5	D-97
	351X	A-5	D-98
	352X	A-5	D-99
	353X	A-5	D-100
	354X	A-5	D-101
	355X	A-5	D-102
	356X	A-5	D-103
	357X	A-5	D-104
	358X	A-5	D-105
	359X	A-5	D-106
	360X	A-5	D-107
	361X	A-5	D-108
	362X	A-5	D-109
	363X	A-5	D-110
	364X	A-5	D-111
	365X	A-5	D-112
	366X	A-5	D-113
	367X	A-5	D-114
	368X	A-5	D-115
	369X	A-5	D-116
	370X	A-5	D-117
	371X	A-5	D-118
	372X	A-5	D-119
	373X	A-5	D-120
	374X	A-5	D-121
	375X	A-5	D-122
	376X	A-5	D-123
	377X	A-5	D-124
	378X	A-5	D-125
	379X	A-5	D-126
	380X	A-5	D-127
	381X	A-5	D-128
	382X	A-5	D-129
	383X	A-5	D-130
	384X	A-5	D-131
	385X	A-5	D-132
	386X	A-5	D-133
	387X	A-5	D-134
	388X	A-5	D-135
	389X	A-5	D-136
	390X	A-5	D-137
	391X	A-5	D-138
	392X	A-5	D-139
	393X	A-5	D-140
	394X	A-5	D-141
	395X	A-5	D-142
	396X	A-5	D-143
	397X	A-5	D-144
	398X	A-5	D-145
	399X	A-5	D-146
	400X	A-5	D-147
	401X	A-5	D-148
	402X	A-5	D-149
	403X	A-5	D-150
	404X	A-5	D-151
	405X	A-5	D-152
	406X	A-5	D-153
	407X	A-5	D-154
	408X	A-5	D-155
	409X	A-5	D-156
	410X	A-5	D-157
	411X	A-5	D-158
	412X	A-5	D-159
	413X	A-5	D-160
	414X	A-5	D-161
	415X	A-5	D-162
	416X	A-5	D-163
	417X	A-5	D-164
	418X	A-5	D-165
	419X	A-5	D-166
	420X	A-5	D-167
	421X	A-5	D-168
	422X	A-5	D-169
	423X	A-5	D-170
	424X	A-5	D-171
	425X	A-5	D-172
	426X	A-5	D-173
	427X	A-5	D-174
	428X	A-5	D-175
	429X	A-5	D-176
	430X	A-5	D-177
	431X	A-5	D-178
	432X	A-5	D-179
	433X	A-5	D-180
	434X	A-5	D-181
	435X	A-5	D-182
	436X	A-5	D-183
	437X	A-5	D-184
	438X	A-5	D-185
	439X	A-5	D-186
	440X	A-5	D-187
	441X	A-5	D-188
	442X	A-5	D-189
	443X	A-5	D-190
	444X	A-5	D-191
	445X	A-5	D-192
	446X	A-5	D-193
	447X	A-5	D-194
	448X	A-5	D-195
	449X	A-5	D-196
	450X	A-5	D-197
	451X	A-5	D-198
	452X	A-5	D-199
	453X	A-5	D-200
	454X	A-5	D-201
	455X	A-5	D-202
	456X	A-5	D-203
	457X	A-5	D-204
	458X	A-5	D-205
	459X	A-5	D-206
	460X	A-5	D-207
	461X	A-5	D-208
	462X	A-5	D-209
	463X	A-5	D-210
	464X	A-5	D-211
	465X	A-5	D-212
	466X	A-5	D-213
	467X	A-5	D-214
	468X	A-5	D-215
	469X	A-5	D-216
	470X	A-5	D-217
	471X	A-5	D-218
	472X	A-5	D-219
	473X	A-5	D-220
	474X	A-5	D-221
	475X	A-5	D-222
	476X	A-5	D-223
	477X	A-5	D-224
	478X	A-5	D-225
	479X	A-5	D-226
	480X	A-5	D-227
	481X	A-5	D-228
	482X	A-5	D-229
	483X	A-5	D-230
	484X	A-5	D-231
	485X	A-5	D-232
	486X	A-7	D-1
	487X	A-7	D-2
	488X	A-7	D-3
	489X	A-7	D-4
	490X	A-7	D-5
	491X	A-7	D-6
	492X	A-7	D-7
	493X	A-7	D-8
	494X	A-7	D-9
	495X	A-7	D-10
	496X	A-7	D-11
	497X	A-7	D-12
	498X	A-7	D-13
	499X	A-7	D-14
	500X	A-7	D-15
	501X	A-7	D-16
	502X	A-7	D-17
	503X	A-7	D-18
	504X	A-7	D-19
	505X	A-7	D-20
	506X	A-7	D-21
	507X	A-7	D-22
	508X	A-7	D-23
	509X	A-7	D-24
	510X	A-7	D-25
	511X	A-7	D-26
	512X	A-7	D-27
	513X	A-7	D-28
	514X	A-7	D-29
	515X	A-7	D-30
	516X	A-7	D-31
	517X	A-7	D-32
	518X	A-7	D-33
	519X	A-7	D-34
	520X	A-7	D-35
	521X	A-7	D-36
	522X	A-7	D-37
	523X	A-7	D-38
	524X	A-7	D-39
	525X	A-7	D-40
	526X	A-7	D-41
	527X	A-7	D-42
	528X	A-7	D-43
	529X	A-7	D-44
	530X	A-7	D-45
	531X	A-7	D-46
	532X	A-7	D-47
	533X	A-7	D-48
	534X	A-7	D-49
	535X	A-7	D-50
	536X	A-7	D-51
	537X	A-7	D-52
	538X	A-7	D-53
	539X	A-7	D-54
	540X	A-7	D-55
	541X	A-7	D-56
	542X	A-7	D-57
	543X	A-7	D-58
	544X	A-7	D-59
	545X	A-7	D-60
	546X	A-7	D-61
	547X	A-7	D-62
	548X	A-7	D-63
	549X	A-7	D-64
	550X	A-7	D-65
	551X	A-7	D-66
	552X	A-7	D-67
	553X	A-7	D-68
	554X	A-7	D-69
	555X	A-7	D-70
	556X	A-7	D-71
	557X	A-7	D-72
	558X	A-7	D-73
	559X	A-7	D-74
	560X	A-7	D-75
	561X	A-7	D-76
	562X	A-7	D-77
	563X	A-7	D-78
	564X	A-7	D-79
	565X	A-7	D-80
	566X	A-7	D-81
	567X	A-7	D-82
	568X	A-7	D-83
	569X	A-7	D-84
	570X	A-7	D-85
	571X	A-7	D-86
	572X	A-7	D-87
	573X	A-7	D-88
	574X	A-7	D-89
	575X	A-7	D-90
	576X	A-7	D-91
	577X	A-7	D-92
	578X	A-7	D-93
	579X	A-7	D-94
	580X	A-7	D-95
	581X	A-7	D-96
	582X	A-7	D-97
	583X	A-7	D-98
	584X	A-7	D-99
	585X	A-7	D-100
	586X	A-7	D-101
	587X	A-7	D-102
	588X	A-7	D-103
	589X	A-7	D-104
	590X	A-7	D-105
	591X	A-7	D-106
	592X	A-7	D-107
	593X	A-7	D-108
	594X	A-7	D-109
	595X	A-7	D-110
	596X	A-7	D-111
	597X	A-7	D-112
	598X	A-7	D-113
	599X	A-7	D-114
	600X	A-7	D-115
	601X	A-7	D-116
	602X	A-7	D-117
	603X	A-7	D-118
	604X	A-7	D-119
	605X	A-7	D-120
	606X	A-7	D-121
	607X	A-7	D-122
	608X	A-7	D-123
	609X	A-7	D-124
	610X	A-7	D-125
	611X	A-7	D-126
	612X	A-7	D-127
	613X	A-7	D-128
	614X	A-7	D-129
	615X	A-7	D-130
	616X	A-7	D-131
	617X	A-7	D-132
	618X	A-7	D-133
	619X	A-7	D-134
	620X	A-7	D-135
	621X	A-7	D-136
	622X	A-7	D-137
	623X	A-7	D-138
	624X	A-7	D-139
	625X	A-7	D-140
	626X	A-7	D-141
	627X	A-7	D-142
	628X	A-7	D-143
	629X	A-7	D-144
	630X	A-7	D-145
	631X	A-7	D-146
	632X	A-7	D-147
	633X	A-7	D-148
	634X	A-7	D-149
	635X	A-7	D-150
	636X	A-7	D-151
	637X	A-7	D-152
	638X	A-7	D-153
	639X	A-7	D-154
	640X	A-7	D-155
	641X	A-7	D-156
	642X	A-7	D-157
	643X	A-7	D-158
	644X	A-7	D-159
	645X	A-7	D-160
	646X	A-7	D-161
	647X	A-7	D-162
	648X	A-7	D-163
	649X	A-7	D-164
	650X	A-7	D-165
	651X	A-7	D-166
	652X	A-7	D-167
	653X	A-7	D-168
	654X	A-7	D-169
	655X	A-7	D-170
	656X	A-7	D-171
	657X	A-7	D-172
	658X	A-7	D-173
	659X	A-7	D-174
	660X	A-7	D-175
	661X	A-7	D-176
	662X	A-7	D-177
	663X	A-7	D-178
	664X	A-7	D-179
	665X	A-7	D-180
	666X	A-7	D-181
	667X	A-7	D-182
	668X	A-7	D-183
	669X	A-7	D-184
	670X	A-7	D-185
	671X	A-7	D-186
	672X	A-7	D-187
	673X	A-7	D-188
	674X	A-7	D-189
	675X	A-7	D-190
	676X	A-7	D-191
	677X	A-7	D-192
	678X	A-7	D-193
	679X	A-7	D-194
	680X	A-7	D-195
	681X	A-7	D-196
	682X	A-7	D-197
	683X	A-7	D-198
	684X	A-7	D-199
	685X	A-7	D-200
	686X	A-7	D-201
	687X	A-7	D-202
	688X	A-7	D-203
	689X	A-7	D-204
	690X	A-7	D-205
	691X	A-7	D-206
	692X	A-7	D-207
	693X	A-7	D-208
	694X	A-7	D-209
	695X	A-7	D-210
	696X	A-7	D-211
	697X	A-7	D-212
	698X	A-7	D-213
	699X	A-7	D-214
	700X	A-7	D-215
	701X	A-7	D-216
	702X	A-7	D-217
	703X	A-7	D-218
	704X	A-7	D-219
	705X	A-7	D-220
	706X	A-7	D-221
	707X	A-7	D-222
	708X	A-7	D-223
	709X	A-7	D-224
	710X	A-7	D-225
	711X	A-7	D-226
	712X	A-7	D-227
	713X	A-7	D-228
	714X	A-7	D-229
	715X	A-7	D-230
	716X	A-7	D-231
	717X	A-7	D-232

[0184] Tables X-4, X-4A and X-4B illustrate, by way of example and not limitation, some further combinations of the present invention wherein the combination comprises an amount of an ASBT inhibitor (Component 1), an amount of a cyclooxygenase-2 selective inhibitor (Component 2) and an amount of an HMG-CoA inhibitor (Component 3), wherein the amount of the ASBT inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the ASBT inhibitor and the cyclooxygenase-2 selective inhibitor and the HMG-CoA inhibitor.

	TABLE X-4
	Example	Component	Component	Component
	Number	1	2	3
	1y	A-3	B-18	C-1
	2y	A-3	B-19	C-1
	3y	A-3	B-20	C-1
	4y	A-3	B-21	C-1
	5y	A-3	B-22	C-1
	6y	A-3	B-23	C-1
	7y	A-3	B-24	C-1
	8y	A-5	B-18	C-1
	9y	A-5	B-19	C-1
	10y	A-5	B-20	C-1
	11y	A-5	B-21	C-1
	12y	A-5	B-22	C-1
	13y	A-5	B-23	C-1
	14y	A-5	B-24	C-1
	15y	A-7	B-18	C-1
	16y	A-7	B-19	C-1
	17y	A-7	B-20	C-1
	18y	A-7	B-21	C-1
	19y	A-7	B-22	C-1
	20y	A-7	B-23	C-1
	21y	A-7	B-24	C-1
	22y	A-3	B-18	C-2
	23y	A-3	B-19	C-2
	24y	A-3	B-20	C-2
	25y	A-3	B-21	C-2
	26y	A-3	B-22	C-2
	27y	A-3	B-23	C-2
	28y	A-3	B-24	C-2
	29y	A-5	B-18	C-2
	30y	A-5	B-19	C-2
	31y	A-5	B-20	C-2
	32y	A-5	B-21	C-2
	33y	A-5	B-22	C-2
	34y	A-5	B-23	C-2
	35y	A-5	B-24	C-2
	36y	A-7	B-18	C-2
	37y	A-7	B-19	C-2
	38y	A-7	B-20	C-2
	39y	A-7	B-21	C-2
	40y	A-7	B-22	C-2
	41y	A-7	B-23	C-2
	42y	A-7	B-24	C-2
	43y	A-7	B-18	C-3
	44y	A-3	B-19	C-3
	45y	A-3	B-20	C-3
	46y	A-3	B-21	C-3
	47y	A-3	B-22	C-3
	48y	A-3	B-23	C-3
	49y	A-3	B-24	C-3
	50y	A-5	B-18	C-3
	51y	A-5	B-19	C-3
	52y	A-5	B-20	C-3
	53y	A-5	B-21	C-3
	54y	A-5	B-22	C-3
	55y	A-5	B-23	C-3
	56y	A-5	B-24	C-3
	57y	A-7	B-18	C-3
	58y	A-7	B-19	C-3
	59y	A-7	B-20	C-3
	60y	A-7	B-21	C-3
	61y	A-7	B-22	C-3
	62y	A-7	B-23	C-3
	63y	A-7	B-24	C-3
	64y	A-3	B-18	C-4
	65y	A-3	B-19	C-4
	66y	A-3	B-20	C-4
	67y	A-3	B-21	C-4
	68y	A-3	B-22	C-4
	69y	A-3	B-23	C-4
	70y	A-3	B-24	C-4
	71y	A-5	B-18	C-4
	72y	A-5	B-19	C-4
	73y	A-5	B-20	C-4
	74y	A-5	B-21	C-4
	75y	A-5	B-22	C-4
	76y	A-5	B-23	C-4
	77y	A-5	B-24	C-4
	78y	A-7	B-18	C-4
	79y	A-7	B-19	C-4
	80y	A-7	B-20	C-4
	81y	A-7	B-21	C-4
	82y	A-7	B-22	C-4
	83y	A-7	B-23	C-4
	84y	A-7	B-24	C-4
	85y	A-3	B-18	C-5
	86y	A-3	B-19	C-5
	87y	A-3	B-20	C-5
	88y	A-3	B-21	C-5
	89y	A-3	B-22	C-5
	90y	A-3	B-23	C-5
	91y	A-3	B-24	C-5
	92y	A-5	B-18	C-5
	93y	A-5	B-19	C-5
	94y	A-5	B-20	C-5
	95y	A-5	B-21	C-5
	96y	A-5	B-22	C-5
	97y	A-5	B-23	C-5
	98y	A-5	B-24	C-5
	99y	A-7	B-18	C-5
	100y	A-7	B-19	C-5
	101y	A-7	B-20	C-5
	102y	A-7	B-21	C-5
	103y	A-7	B-22	C-5
	104y	A-7	B-23	C-5
	105y	A-7	B-24	C-5
	106y	A-3	B-18	C-6
	107y	A-3	B-19	C-6
	108y	A-3	B-20	C-6
	109y	A-3	B-21	C-6
	110y	A-3	B-22	C-6
	111y	A-3	B-23	C-6
	112y	A-3	B-24	C-6
	113y	A-5	B-18	C-6
	114y	A-5	B-19	C-6
	115y	A-5	B-20	C-6
	116y	A-5	B-21	C-6
	117y	A-5	B-22	C-6
	118y	A-5	B-23	C-6
	119y	A-5	B-24	C-6
	120y	A-7	B-18	C-6
	121y	A-7	B-19	C-6
	122y	A-7	B-20	C-6
	123y	A-7	B-21	C-6
	124y	A-7	B-22	C-6
	125y	A-7	B-23	C-6
	126y	A-7	B-24	C-6
	127y	A-3	B-18	C-7
	128y	A-3	B-19	C-7
	129y	A-3	B-20	C-7
	130y	A-3	B-21	C-7
	131y	A-3	B-22	C-7
	132y	A-3	B-23	C-7
	133y	A-3	B-24	C-7
	134y	A-5	B-18	C-7
	135y	A-5	B-19	C-7
	136y	A-5	B-20	C-7
	137y	A-5	B-21	C-7
	138y	A-5	B-22	C-7
	139y	A-5	B-23	C-7
	140y	A-5	B-24	C-7
	141y	A-7	B-18	C-7
	142y	A-7	B-19	C-7
	143y	A-7	B-20	C-7
	144y	A-7	B-21	C-7
	145y	A-7	B-22	C-7
	146y	A-7	B-23	C-7
	147y	A-7	B-24	C-7
	148y	A-3	B-18	C-8
	149y	A-3	B-19	C-8
	150y	A-3	B-20	C-8
	151y	A-3	B-21	C-8
	152y	A-3	B-22	C-8
	153y	A-3	B-23	C-8
	154y	A-3	B-24	C-8
	155y	A-5	B-18	C-8
	156y	A-5	B-19	C-8
	157y	A-5	B-20	C-8
	158y	A-5	B-21	C-8
	159y	A-5	B-22	C-8
	160y	A-5	B-23	C-8
	161y	A-5	B-24	C-8
	162y	A-7	B-18	C-8
	163y	A-7	B-19	C-8
	164y	A-7	B-20	C-8
	165y	A-7	B-21	C-8
	166y	A-7	B-22	C-8
	167y	A-7	B-23	C-8
	168y	A-7	B-24	C-8
	169y	A-3	B-18	C-9
	170y	A-3	B-19	C-9
	171y	A-3	B-20	C-9
	172y	A-3	B-21	C-9
	173y	A-3	B-22	C-9
	174y	A-3	B-23	C-9
	175y	A-3	B-24	C-9
	176y	A-5	B-18	C-9
	177y	A-5	B-19	C-9
	178y	A-5	B-20	C-9
	179y	A-5	B-21	C-9
	180y	A-5	B-22	C-9
	181y	A-5	B-23	C-9
	182y	A-5	B-24	C-9
	183y	A-7	B-18	C-9
	184y	A-7	B-19	C-9
	185y	A-7	B-20	C-9
	186y	A-7	B-21	C-9
	187y	A-7	B-22	C-9
	188y	A-7	B-23	C-9
	189y	A-7	B-24	C-9

[0185]

TABLE X-4A
Example
Number	Component 1	Component 2	Component 3
190y	Any one or more of	D-1	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21, A-22		Table 8
191y	Any one or more of	D-2	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
192y	Any one or more of	D-3	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
193y	Any one or more of	D-4	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
194y	Any one or more of	D-5	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
195y	Any one or more of	D-6	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
196y	Any one or more of	D-7	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
197y	Any one or more of	D-8	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
198y	Any one or more of	D-9	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
199y	Any one or more of	D-10	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
200y	Any one or more of	D-11	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
201y	Any one or more of	D-12	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
202y	Any one or more of	D-13	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
203y	Any one or more of	D-14	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
204y	Any one or more of	D-15	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
205y	Any one or more of	D-16	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
206y	Any one or more of	D-17	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
207y	Any one or more of	D-18	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
208y	Any one or more of	D-19	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
209y	Any one or more of	D-20	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
210y	Any one or more of	D-21	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
211y	Any one or more of	D-22	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
212y	Any one or more of	D-23	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
213y	Any one or more of	D-24	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
214y	Any one or more of	D-25	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
215y	Any one or more of	D-26	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
216y	Any one or more of	D-27	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
217y	Any one or more of	D-28	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
218y	Any one or more of	D-29	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
219y	Any one or more of	D-30	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
220y	Any one or more of	D-31	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
221y	Any one or more of	D-32	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
222y	Any one or more of	D-33	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
223y	Any one or more of	D-34	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
224y	Any one or more of	D-35	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
225y	Any one or more of	D-36	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
226y	Any one or more of	D-37	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
227y	Any one or more of	D-38	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
228y	Any one or more of	D-39	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
229y	Any one or more of	D-40	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
230y	Any one or more of	D-41	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
231y	Any one or more of	D-42	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
232y	Any one or more of	D-43	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
233y	Any one or more of	D-44	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
234y	Any one or more of	D-45	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
235y	Any one or more of	D-46	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
236y	Any one or more of	D-47	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
237y	Any one or more of	D-48	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
238y	Any one or more of	D-49	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
239y	Any one or more of	D-50	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
240y	Any one or more of	D-51	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
241y	Any one or more of	D-52	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
242y	Any one or more of	D-53	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
243y	Any one or more of	D-54	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
244y	Any one or more of	D-55	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
245y	Any one or more of	D-56	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
246y	Any one or more of	D-57	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
247y	Any one or more of	D-58	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
248y	Any one or more of	D-59	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
249y	Any one or more of	D-60	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
250y	Any one or more of	D-61	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
251y	Any one or more of	D-62	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
252y	Any one or more of	D-63	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
253y	Any one or more of	D-64	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
254y	Any one or more of	D-65	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
255y	Any one or more of	D-66	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
256y	Any one or more of	D-67	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
257y	Any one or more of	D-68	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
258y	Any one or more of	D-69	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
259y	Any one or more of	D-70	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
260y	Any one or more of	D-71	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
261y	Any one or more of	D-72	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
262y	Any one or more of	D-73	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
263y	Any one or more of	D-74	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
264y	Any one or more of	D-75	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
265y	Any one or more of	D-76	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
266y	Any one or more of	D-77	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
267y	Any one or more of	D-78	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
268y	Any one or more of	D-79	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
269y	Any one or more of	D-80	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
270y	Any one or more of	D-81	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
271y	Any one or more of	D-82	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
272y	Any one or more of	D-83	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
273y	Any one or more of	D-84	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
274y	Any one or more of	D-85	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
275y	Any one or more of	D-86	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
276y	Any one or more of	D-87	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
277y	Any one or more of	D-88	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
278y	Any one or more of	D-89	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
279y	Any one or more of	D-90	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
280y	Any one or more of	D-91	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
281y	Any one or more of	D-92	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
282y	Any one or more of	D-93	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
283y	Any one or more of	D-94	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
284y	Any one or more of	D-95	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
285y	Any one or more of	D-96	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
286y	Any one or more of	D-97	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
287y	Any one or more of	D-98	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
288y	Any one or more of	D-99	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
289y	Any one or more of	D-100	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
290y	Any one or more of	D-101	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
291y	Any one or more of	D-102	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
292y	Any one or more of	D-103	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
293y	Any one or more of	D-104	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
294y	Any one or more of	D-105	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
295y	Any one or more of	D-106	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
296y	Any one or more of	D-107	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
297y	Any one or more of	D-108	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
298y	Any one or more of	D-109	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
299y	Any one or more of	D-110	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
300y	Any one or more of	D-111	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
301y	Any one or more of	D-112	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
302y	Any one or more of	D-113	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
303y	Any one or more of	D-114	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
304y	Any one or more of	D-115	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
305y	Any one or more of	D-116	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
306y	Any one or more of	D-117	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
307y	Any one or more of	D-118	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
308y	Any one or more of	D-119	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
309y	Any one or more of	D-120	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
310y	Any one or more of	D-121	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
311y	Any one or more of	D-122	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
312y	Any one or more of	D-123	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
313y	Any one or more of	D-124	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
314y	Any one or more of	D-125	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
315y	Any one or more of	D-126	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
316y	Any one or more of	D-127	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
317y	Any one or more of	D-128	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
318y	Any one or more of	D-129	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
319y	Any one or more of	D-130	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
320y	Any one or more of	D-131	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
321y	Any one or more of	D-132	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
322y	Any one or more of	D-133	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
323y	Any one or more of	D-134	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
324y	Any one or more of	D-135	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
325y	Any one or more of	D-136	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
326y	Any one or more of	D-137	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
327y	Any one or more of	D-138	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
328y	Any one or more of	D-139	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
329y	Any one or more of	D-140	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
330y	Any one or more of	D-141	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
331y	Any one or more of	D-142	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
332y	Any one or more of	D-143	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
333y	Any one or more of	D-144	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
334y	Any one or more of	D-145	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
335y	Any one or more of	D-146	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
336y	Any one or more of	D-147	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
337y	Any one or more of	D-148	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
338y	Any one or more of	D-149	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
339y	Any one or more of	D-150	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
340y	Any one or more of	D-151	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
341y	Any one or more of	D-152	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
342y	Any one or more of	D-153	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
343y	Any one or more of	D-154	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
344y	Any one or more of	D-155	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
345y	Any one or more of	D-156	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
346y	Any one or more of	D-157	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
347y	Any one or more of	D-158	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
348y	Any one or more of	D-159	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
349y	Any one or more of	D-160	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
350y	Any one or more of	D-161	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
351y	Any one or more of	D-162	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
352y	Any one or more of	D-163	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
353y	Any one or more of	D-164	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
354y	Any one or more of	D-165	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
355y	Any one or more of	D-166	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
356y	Any one or more of	D-167	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
357y	Any one or more of	D-168	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
358y	Any one or more of	D-169	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
359y	Any one or more of	D-170	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
360y	Any one or more of	D-171	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
361y	Any one or more of	D-172	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
362y	Any one or more of	D-173	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
363y	Any one or more of	D-174	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
364y	Any one or more of	D-175	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
365y	Any one or more of	D-176	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
366y	Any one or more of	D-177	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
367y	Any one or more of	D-178	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
368y	Any one or more of	D-179	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
369y	Any one or more of	D-180	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
370y	Any one or more of	D-181	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
371y	Any one or more of	D-182	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
372y	Any one or more of	D-183	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
373y	Any one or more of	D-184	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
374y	Any one or more of	D-185	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
375y	Any one or more of	D-186	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
376y	Any one or more of	D-187	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
377y	Any one or more of	D-188	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
378y	Any one or more of	D-189	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
379y	Any one or more of	D-190	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
380y	Any one or more of	D-191	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
381y	Any one or more of	D-192	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
382y	Any one or more of	D-193	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
383y	Any one or more of	D-194	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
384y	Any one or more of	D-195	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
385y	Any one or more of	D-196	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
386y	Any one or more of	D-197	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
387y	Any one or more of	D-198	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
388y	Any one or more of	D-199	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
389y	Any one or more of	D-200	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
390y	Any one or more of	D-201	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
391y	Any one or more of	D-202	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
392y	Any one or more of	D-203	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
393y	Any one or more of	D-204	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
394y	Any one or more of	D-205	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
395y	Any one or more of	D-206	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
396y	Any one or more of	D-207	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
397y	Any one or more of	D-208	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
398y	Any one or more of	D-209	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
399y	Any one or more of	D-210	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
400y	Any one or more of	D-211	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
401y	Any one or more of	D-212	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
402y	Any one or more of	D-213	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
403y	Any one or more of	D-214	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
404y	Any one or more of	D-215	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
405y	Any one or more of	D-216	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
406y	Any one or more of	D-217	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
407y	Any one or more of	D-218	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
408y	Any one or more of	D-219	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
409y	Any one or more of	D-220	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
410y	Any one or more of	D-221	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
411y	Any one or more of	D-222	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
412y	Any one or more of	D-223	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
413y	Any one or more of	D-224	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
414y	Any one or more of	D-225	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
415y	Any one or more of	D-226	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
416y	Any one or more of	D-227	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
417y	Any one or more of	D-228	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
418y	Any one or more of	D-229	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
419y	Any one or more of	D-230	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
420y	Any one or more of	D-231	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8
421y	Any one or more of	D-232	Any one or more
	A-1, A-2, A-3, A-		of C-1, C-2, C-
	4, A-5, A-6, A-7,		3, C-4, C-5, C-
	A-8, A-9, A-10, A-		6, C-7, C-8, C-
	11, A-12, A-13, A-		9, and HMG-CoA
	14, A-15, A-16, A-		Reductase
	17, A-18, A-19, A-		Inhibitors of
	20, A-21 and A-22		Table 8

[0186]

TABLE X-4B
Example
Number	Component 1	Component 2	Component 3
422y	Any one or more	D-1 to D-5	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21,
	A-22
423y	Any one or more	D-6 to D-10	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
424y	Any one or more	D-11 to D-15	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
425y	Any one or more	D-16 to D-20	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
426y	Any one or more	D-21 to D-25	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
427y	Any one or more	D-26 to D-30	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
428y	Any one or more	D-31 to D-35	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
429y	Any one or more	D-36 to D-40	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
430y	Any one or more	D-41 to D-45	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
431y	Any one or more	D-46 to D-50	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
432y	Any one or more	D-51 to D-55	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
433y	Any one or more	D-56 to D-60	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
434y	Any one or more	D-61 to D-65	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
435y	Any one or more	D-66 to D-70	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
436y	Any one or more	D-71 to D-75	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
437y	Any one or more	D-76 to D-80	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
438y	Any one or more	D-81 to D-85	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
439y	Any one or more	D-86 to D-90	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
440y	Any one or more	D-91 to D-95	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
441y	Any one or more	D-96 to D-100	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
442y	Any one or more	D-101 to D-105	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
443y	Any one or more	D-106 to D-110	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
444y	Any one or more	D-111 to D-115	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
445y	Any one or more	D-116 to D-120	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
446y	Any one or more	D-121 to D-125	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
447y	Any one or more	D-126 to D-130	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
448y	Any one or more	D-131 to D-135	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
449y	Any one or more	D-136 to D-140	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
450y	Any one or more	D-141 to D-145	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
451y	Any one or more	D-146 to D-150	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
452y	Any one or more	D-151 to D-155	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
453y	Any one or more	D-156 to D-160	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
454y	Any one or more	D-161 to D-165	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
455y	Any one or more	D-166 to D-170	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
456y	Any one or more	D-171 to D-175	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
457y	Any one or more	D-176 to D-180	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
458y	Any one or more	D-181 to D-185	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
459y	Any one or more	D-186 to D-190	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
460y	Any one or more	D-191 to D-195	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
461y	Any one or more	D-196 to D-200	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
462y	Any one or more	D-201 to D-205	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
463y	Any one or more	D-206 to D-210	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
464y	Any one or more	D-211 to D-215	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
465y	Any one or more	D-216 to D-220	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
466y	Any one or more	D-221 to D-225	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
467y	Any one or more	D-226 to D-230	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22
468y	Any one or more	D-231 to D-232	Any one or more
	of A-1, A-2, A-		of C-1, C-2, C-
	3, A-4, A-5, A-		3, C-4, C-5, C-
	6, A-7, A-8, A-		6, C-7, C-8, C-
	9, A-10, A-11,		9, and HMG-CoA
	A-12, A-13, A-		Reductase
	14, A-15, A-16,		Inhibitors of
	A-17, A-18, A-		Table 8
	19, A-20, A-21
	and A-22

[0187] Table X-5 illustrates, by way of example and not limitation, some of the many combinations of the present invention wherein the combination comprises an amount of an HMG Co-A reductase inhibitor (Component 1) and an amount of a chromene cyclooxygenase inhibitor (Component 2), wherein the amount of the HMG Co-A reductase inhibitor and the amount of the chromene cyclooxygenase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the chromene cyclooxygenase inhibitor.

TABLE X-5
Example
Number	Component 1	Component 2
1z	Benfluorex	B-3
2z	Benfluorex	B-4
3z	Benfluorex	B-5
4z	Benfluorex	B-6
5z	Benfluorex	B-7
6z	Benfluorex	B-8
7z	Benfluorex	B-9
8z	Benfluorex	B-10
9z	Benfluorex	B-11
10z	Benfluorex	B-12
11z	Benfluorex	B-13
12z	Benfluorex	B-14
13z	Benfluorex	B-15
14z	Benfluorex	B-16
15z	Benfluorex	B-17
16z	Fluvastatin	B-3
17z	Fluvastatin	B-4
18z	Fluvastatin	B-5
19z	Fluvastatin	B-6
20z	Fluvastatin	B-7
21z	Fluvastatin	B-8
22z	Fluvastatin	B-9
23z	Fluvastatin	B-10
24z	Fluvastatin	B-11
25z	Fluvastatin	B-12
26z	Fluvastatin	B-13
27z	Fluvastatin	B-14
28z	Fluvastatin	B-15
29z	Fluvastatin	B-16
30z	Fluvastatin	B-17
31z	Lovastatin	B-3
32z	Lovastatin	B-4
33z	Lovastatin	B-5
34z	Lovastatin	B-6
35z	Lovastatin	B-7
36z	Lovastatin	B-8
37z	Lovastatin	B-9
38z	Lovastatin	B-10
39z	Lovastatin	B-11
40z	Lovastatin	B-12
41z	Lovastatin	B-13
42z	Lovastatin	B-14
43z	Lovastatin	B-15
44z	Lovastatin	B-16
45z	Lovastatin	B-17
46z	Pravastatin	B-3
47z	Pravastatin	B-4
48z	Pravastatin	B-5
49z	Pravastatin	B-6
50z	Pravastatin	B-7
51z	Pravastatin	B-8
52z	Pravastatin	B-9
53z	Pravastatin	B-10
54z	Pravastatin	B-11
55z	Pravastatin	B-12
56z	Pravastatin	B-13
57z	Pravastatin	B-14
58z	Pravastatin	B-15
59z	Pravastatin	B-16
60z	Pravastatin	B-17
61z	Simvastatin	B-3
62z	Simvastatin	B-4
63z	Simvastatin	B-5
64z	Simvastatin	B-6
65z	Simvastatin	B-7
66z	Simvastatin	B-8
67z	Simvastatin	B-9
68z	Simvastatin	B-10
69z	Simvastatin	B-11
70z	Simvastatin	B-12
71z	Simvastatin	B-13
72z	Simvastatin	B-14
73z	Simvastatin	B-15
74z	Simvastatin	B-16
75z	Simvastatin	B-17
76z	Atorvastatin	B-3
77z	Atorvastatin	B-4
78z	Atorvastatin	B-5
79z	Atorvastatin	B-6
80z	Atorvastatin	B-7
81z	Atorvastatin	B-8
82z	Atorvastatin	B-9
83z	Atorvastatin	B-10
84z	Atorvastatin	B-11
85z	Atorvastatin	B-12
86z	Atorvastatin	B-13
87z	Atorvastatin	B-14
88z	Atorvastatin	B-15
89z	Atorvastatin	B-16
90z	Atorvastatin	B-17
91z	Cerivastatin	B-3
92z	Cerivastatin	B-4
93z	Cerivastatin	B-5
94z	Cerivastatin	B-6
95z	Cerivastatin	B-7
96z	Cerivastatin	B-8
97z	Cerivastatin	B-9
98z	Cerivastatin	B-10
99z	Cerivastatin	B-11
100z	Cerivastatin	B-12
101z	Cerivastatin	B-13
102z	Cerivastatin	B-14
103z	Cerivastatin	B-15
104z	Cerivastatin	B-16
105z	Cerivastatin	B-17
106z	Vervastatin	B-3
107z	Vervastatin	B-4
108z	Vervastatin	B-5
109z	Vervastatin	B-6
110z	Vervastatin	B-7
111z	Vervastatin	B-8
112z	Vervastatin	B-9
113z	Vervastatin	B-10
114z	Vervastatin	B-11
115z	Vervastatin	B-12
116z	Vervastatin	B-13
117z	Vervastatin	B-14
118z	Vervastatin	B-15
119z	Vervastatin	B-16
120z	Vervastatin	B-17
121z	Rosuvastatin	B-3
	(ZD-4522)
122z	Rosuvastatin	B-4
	(ZD-4522)
123z	Rosuvastatin	B-5
	(ZD-4522)
124z	Rosuvastatin	B-6
	(ZD-4522)
125z	Rosuvastatin	B-7
	(ZD-4522)
126z	Rosuvastatin	B-8
	(ZD-4522)
127z	Rosuvastatin	B-9
	(ZD-4522)
128z	Rosuvastatin	B-10
	(ZD-4522)
129z	Rosuvastatin	B-11
	(ZD-4522)
130z	Rosuvastatin	B-12
	(ZD-4522)
131z	Rosuvastatin	B-13
	(ZD-4522)
132z	Rosuvastatin	B-14
	(ZD-4522)
133z	Rosuvastatin	B-15
	(ZD-4522)
134z	Rosuvastatin	B-16
	(ZD-4522)
135z	Rosuvastatin	B-17
	(ZD-4522)
136z	Itavastatin	B-3
137z	Itavastatin	B-4
138z	Itavastatin	B-5
139z	Itavastatin	B-6
140z	Itavastatin	B-7
141z	Itavastatin	B-8
142z	Itavastatin	B-9
143z	Itavastatin	B-10
144z	Itavastatin	B-11
145z	Itavastatin	B-12
146z	Itavastatin	B-13
147z	Itavastatin	B-14
148z	Itavastatin	B-15
149z	Itavastatin	B-16
150z	Itavastatin	B-17
151z	Delvastatin	B-3
152z	Delvastatin	B-4
153z	Delvastatin	B-5
154z	Delvastatin	B-6
155z	Delvastatin	B-7
156z	Delvastatin	B-8
157z	Delvastatin	B-9
158z	Delvastatin	B-10
159z	Delvastatin	B-11
160z	Delvastatin	B-12
161z	Delvastatin	B-13
162z	Delvastatin	B-14
163z	Delvastatin	B-15
164z	Delvastatin	B-16
165z	Delvastatin	B-17
166z	Mevastatin	B-3
167z	Mevastatin	B-4
168z	Mevastatin	B-5
169z	Mevastatin	B-6
170z	Mevastatin	B-7
171z	Mevastatin	B-8
172z	Mevastatin	B-9
173z	Mevastatin	B-10
174z	Mevastatin	B-11
175z	Mevastatin	B-12
176z	Mevastatin	B-13
177z	Mevastatin	B-14
178z	Mevastatin	B-15
179z	Mevastatin	B-16
180z	Mevastatin	B-17

[0188] TableS X-5A and X-5B illustrate, by way of example and not limitation, some of the many combinations of the present invention wherein the combination comprises an amount of an HMG Co-A reductase inhibitor (Component 1) and an amount of a cyclooxygenase-2 selective inhibitor (Component 2), wherein the amount of the HMG Co-A reductase inhibitor and the amount of the cyclooxygenase-2 selective inhibitor tqgether constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the cyclooxygenase-2 selective inhibitor.

TABLE 5A
Example Number	Component 1	Component 2
181z	Any one or more of	D-1
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
182z	Any one or more of	D-2
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
183z	Any one or more of	D-3
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
184z	Any one or more of	D-4
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
185z	Any one or more of	D-5
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
186z	Any one or more of	D-6
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
187z	Any one or more of	D-7
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
188z	Any one or more of	D-8
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
189z	Any one or more of	D-9
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
190z	Any one or more of	D-10
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
191z	Any one or more of	D-11
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
192z	Any one or more of	D-12
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
193z	Any one or more of	D-13
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
194z	Any one or more of	D-14
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
195z	Any one or more of	D-15
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
196z	Any one or more of	D-16
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
197z	Any one or more of	D-17
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
198z	Any one or more of	D-18
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
199z	Any one or more of	D-19
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
200z	Any one or more of	D-20
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
201z	Any one or more of	D-21
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
202z	Any one or more of	D-22
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
203z	Any one or more of	D-23
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
204z	Any one or more of	D-24
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
205z	Any one or more of	D-25
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
206z	Any one or more of	D-26
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
207z	Any one or more of	D-27
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
208z	Any one or more of	D-28
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
209z	Any one or more of	D-29
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
210z	Any one or more of	D-30
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
211z	Any one or more of	D-31
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
212z	Any one or more of	D-32
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
213z	Any one or more of	D-33
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
214z	Any one or more of	D-34
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
215z	Any one or more of	D-35
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
216z	Any one or more of	D-36
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
217z	Any one or more of	D-37
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
218z	Any one or more of	D-38
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
219z	Any one or more of	D-39
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
220z	Any one or more of	D-40
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
221z	Any one or more of	D-41
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
222z	Any one or more of	D-42
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
223z	Any one or more of	D-43
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
224z	Any one or more of	D-44
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
225z	Any one or more of	D-45
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
226z	Any one or more of	D-46
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
227z	Any one or more of	D-47
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
228z	Any one or more of	D-48
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
229z	Any one or more of	D-49
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
230z	Any one or more of	D-50
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
231z	Any one or more of	D-51
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
232z	Any one or more of	D-52
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
233z	Any one or more of	D-53
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
234z	Any one or more of	D-54
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
235z	Any one or more of	D-55
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
236z	Any one or more of	D-56
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
237z	Any one or more of	D-57
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
238z	Any one or more of	D-58
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
239z	Any one or more of	D-59
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
240z	Any one or more of	D-60
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
241z	Any one or more of	D-61
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
242z	Any one or more of	D-62
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
243z	Any one or more of	D-63
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
244z	Any one or more of	D-64
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
245z	Any one or more of	D-65
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
246z	Any one or more of	D-66
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
247z	Any one or more of	D-67
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
248z	Any one or more of	D-68
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
249z	Any one or more of	D-69
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
250z	Any one or more of	D-70
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
251z	Any one or more of	D-71
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
252z	Any one or more of	D-72
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
253z	Any one or more of	D-73
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
254z	Any one or more of	D-74
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
255z	Any one or more of	D-75
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
256z	Any one or more of	D-76
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
257z	Any one or more of	D-77
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
258z	Any one or more of	D-78
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
259z	Any one or more of	D-79
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
260z	Any one or more of	D-80
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
261z	Any one or more of	D-81
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
262z	Any one or more of	D-82
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
263z	Any one or more of	D-83
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
264z	Any one or more of	D-84
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
265z	Any one or more of	D-85
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
266z	Any one or more of	D-86
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
267z	Any one or more of	D-87
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
268z	Any one or more of	D-88
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
269z	Any one or more of	D-89
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
270z	Any one or more of	D-90
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
271z	Any one or more of	D-91
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
272z	Any one or more of	D-92
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
273z	Any one or more of	D-93
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
274z	Any one or more of	D-94
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
275z	Any one or more of	D-95
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
276z	Any one or more of	D-96
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
277z	Any one or more of	D-97
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
278z	Any one or more of	D-98
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
279z	Any one or more of	D-99
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
280z	Any one or more of	D-100
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
281z	Any one or more of	D-101
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
282z	Any one or more of	D-102
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
283z	Any one or more of	D-103
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
284z	Any one or more of	D-104
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
285z	Any one or more of	D-105
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
286z	Any one or more of	D-106
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
287z	Any one or more of	D-107
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
288z	Any one or more of	D-108
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
289z	Any one or more of	D-109
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
290z	Any one or more of	D-110
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
291z	Any one or more of	D-111
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
292z	Any one or more of	D-112
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
293z	Any one or more of	D-113
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
294z	Any one or more of	D-114
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
295z	Any one or more of	D-115
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
296z	Any one or more of	D-116
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
297z	Any one or more of	D-117
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
298z	Any one or more of	D-118
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
299z	Any one or more of	D-119
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
300z	Any one or more of	D-120
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
301z	Any one or more of	D-121
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
302z	Any one or more of	D-122
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
303z	Any one or more of	D-123
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
304z	Any one or more of	D-124
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
305z	Any one or more of	D-125
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
306z	Any one or more of	D-126
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
307z	Any one or more of	D-127
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
308z	Any one or more of	D-128
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
309z	Any one or more of	D-129
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
310z	Any one or more of	D-130
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
311z	Any one or more of	D-131
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
312z	Any one or more of	D-132
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
313z	Any one or more of	D-133
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
314z	Any one or more of	D-134
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
315z	Any one or more of	D-135
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
316z	Any one or more of	D-136
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
317z	Any one or more of	D-137
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
318z	Any one or more of	D-138
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
319z	Any one or more of	D-139
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
320z	Any one or more of	D-140
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
321z	Any one or more of	D-141
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
322z	Any one or more of	D-142
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
323z	Any one or more of	D-143
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
324z	Any one or more of	D-144
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
325z	Any one or more of	D-145
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
326z	Any one or more of	D-146
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
327z	Any one or more of	D-147
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
328z	Any one or more of	D-148
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
329z	Any one or more of	D-149
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
330z	Any one or more of	D-150
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
331z	Any one or more of	D-151
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
332z	Any one or more of	D-152
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
333z	Any one or more of	D-153
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
334z	Any one or more of	D-154
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
335z	Any one or more of	D-155
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
336z	Any one or more of	D-156
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
337z	Any one or more of	D-157
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
338z	Any one or more of	D-158
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
339z	Any one or more of	D-159
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
340z	Any one or more of	D-160
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
341z	Any one or more of	D-161
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
342z	Any one or more of	D-162
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
343z	Any one or more of	D-163
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
344z	Any one or more of	D-164
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
345z	Any one or more of	D-165
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
346z	Any one or more of	D-166
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
347z	Any one or more of	D-167
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
348z	Any one or more of	D-168
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
349z	Any one or more of	D-169
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
350z	Any one or more of	D-170
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
351z	Any one or more of	D-171
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
352z	Any one or more of	D-172
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
353z	Any one or more of	D-173
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
354z	Any one or more of	D-174
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
355z	Any one or more of	D-175
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
356z	Any one or more of	D-176
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
357z	Any one or more of	D-177
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
358z	Any one or more of	D-178
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
359z	Any one or more of	D-179
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
360z	Any one or more of	D-180
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
361z	Any one or more of	D-181
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
362z	Any one or more of	D-182
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
363z	Any one or more of	D-183
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
364z	Any one or more of	D-184
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
365z	Any one or more of	D-185
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
366z	Any one or more of	D-186
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
367z	Any one or more of	D-187
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
368z	Any one or more of	D-188
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
369z	Any one or more of	D-189
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
370z	Any one or more of	D-190
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
371z	Any one or more of	D-191
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
372z	Any one or more of	D-192
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
373z	Any one or more of	D-193
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
374z	Any one or more of	D-194
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
375z	Any one or more of	D-195
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
376z	Any one or more of	D-196
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
377z	Any one or more of	D-197
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
378z	Any one or more of	D-198
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
379z	Any one or more of	D-199
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
380z	Any one or more of	D-200
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
381z	Any one or more of	D-201
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
382z	Any one or more of	D-202
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
383z	Any one or more of	D-203
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
384z	Any one or more of	D-204
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
385z	Any one or more of	D-205
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
386z	Any one or more of	D-206
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
387z	Any one or more of	D-207
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
388z	Any one or more of	D-208
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
389z	Any one or more of	D-209
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
390z	Any one or more of	D-210
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
391z	Any one or more of	D-211
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
392z	Any one or more of	D-212
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
393z	Any one or more of	D-213
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
394z	Any one or more of	D-214
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
395z	Any one or more of	D-215
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
396z	Any one or more of	D-216
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
397z	Any one or more of	D-217
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
398z	Any one or more of	D-218
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
399z	Any one or more of	D-219
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
400z	Any one or more of	D-220
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
401z	Any one or more of	D-221
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
402z	Any one or more of	D-222
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
403z	Any one or more of	D-223
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
404z	Any one or more of	D-224
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
405z	Any one or more of	D-225
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
406z	Any one or more of	D-226
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
407z	Any one or more of	D-227
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
408z	Any one or more of	D-228
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
409z	Any one or more of	D-229
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
410z	Any one or more of	D-230
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
411z	Any one or more of	D-231
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
412z	Any one or more of	D-232
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin

[0189]

TABLE 5B
Example Number	Component 1	Component 2
413z	Any one or more of	D-1 to D-5
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
414z	Any one or more of	D-6 to D-10
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
415z	Any one or more of	D-11 to D-15
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
416z	Any one or more of	D-16 to D-20
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
417z	Any one or more of	D-21 to D-25
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
418z	Any one or more of	D-26 to D30
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
419z	Any one or more of	D-31 to D-35
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
420z	Any one or more of	D-36 to D-40
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
421z	Any one or more of	D-41 to D-45
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
422z	Any one or more of	D-46 to D-50
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
423z	Any one or more of	D-51 to D-55
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
424z	Any one or more of	D-56 to D-60
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
425z	Any one or more of	D-61 to D-65
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
426z	Any one or more of	D-66 to D-70
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
427z	Any one or more of	D-71 to D-75
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
428z	Any one or more of	D-76 to D-80
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
429z	Any one or more of	D-81 to D-85
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
430z	Any one or more of	D-86 to D-90
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
431z	Any one or more of	D-91 to D-95
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
432z	Any one or more of	D-96 to D-100
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
433z	Any one or more of	D-101 to D-105
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
434z	Any one or more of	D-106 to D-110
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
435z	Any one or more of	D-111 to D-115
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
436z	Any one or more of	D-116 to D-120
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
437z	Any one or more of	D-121 to D-125
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
438z	Any one or more of	D-126 to D-130
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
439z	Any one or more of	D-131 to D-135
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
440z	Any one or more of	D-136 to D-140
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
441z	Any one or more of	D-141 to D-145
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
442z	Any one or more of	D-146 to D-150
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
443z	Any one or more of	D-151 to D-155
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
444z	Any one or more of	D-156 to D-160
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
445z	Any one or more of	D-161 to D-165
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
446z	Any one or more of	D-166 to D-170
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
447z	Any one or more of	D-171 to D-175
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
448z	Any one or more of	D-176 to D-180
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
449z	Any one or more of	D-181 to D-185
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
450z	Any one or more of	D-186 to D-190
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
451z	Any one or more of	D-191 to D-195
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
452z	Any one or more of	D-196 to D-200
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
453z	Any one or more of	D-201 to D-205
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
454z	Any one or more of	D-206 to D-210
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
455z	Any one or more of	D-211 to D-215
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
456z	Any one or more of	D-216 to D-220
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
457z	Any one or more of	D-221 to D-225
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
458z	Any one or more of	D-226 to D-230
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin
459z	Any one or more of	D-231 to D-232
	Benfluorex,
	Fluvastatin,
	Lovastatin,
	Pravastatin,
	Simvastatin,
	Atavastatin,
	Cerivastatin,
	Vervastatin,
	Rosuvastatin,
	Itavastatink
	Delvastatin, and
	Mevastatin

[0190] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor, and (3) COX-2 selective inhibitor and HMG Co-A reductase inhibitor may independently be used to reduce total serum cholesterol in mammals including humans.

[0191] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor and (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor may independently be used to reduce serum thromboxane levels in mammals including humans.

[0192] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor, and (3) COX-2 selective inhibitor and HMG Co-A reductase inhibitor may independently be used to reduce serum soluble intercellular cell adhesion molecule levels in mammals including humans.

[0193] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor, and (3) COX-2 selective inhibitor and HMG Co-A reductase inhibitor may independently be used to reduce the T-cell content of an atherosclerotic lesion developing in mammals including humans.

[0194] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor, and (3) COX-2 selective inhibitor and HMG Co-A reductase inhibitor may independently be used to increase smooth muscle cell content of an atherosclerotic lesion developing in the vasculature of mammals including humans.

[0195] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor, and (3) COX-2 selective inhibitor and HMG Co-A reductase inhibitor may independently be used to reduce the aortic root atherosclerotic lesion area in mammals including humans.

[0196] The above-noted combinations of: (1) ASBT inhibitor and COX-2 selective inhibitor (2) ASBT inhibitor, COX-2 selective inhibitor, and HMG Co-A reductase inhibitor, and (3) COX-2 selective inhibitor and HMG Co-A reductase inhibitor may independently be used either as a treatment or as a prophylactic use in the treatment or prophylaxis of a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention.

[0197] Various Embodiments of the present invention are presented below for illustration.

EMBODIMENTS

[0198] Various Embodiments are:

[0199] 1. A method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependant bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor.

[0200] 2. The method of Embodiment 1 wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase inhibitor.

[0201] 3. The method of Embodiment 1 wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor.

[0202] 4. The method of Embodiment 1 wherein the condition is selected from the group consisting of gout, pancreatitis, cholelithiasis, biliary obstruction, ulcerative colitis, Crohn's disease, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation, and inflammation wherein the inflammation is associated with a surgical procedure involving an artery, a vein or a capillary.

[0203] 5. The method of Embodiment 4 wherein the condition is selected from the group consisting of coronary artery disease, atherosclerosis, and thrombosis.

[0204] 6. The method of Embodiment 5 wherein the condition is coronary artery disease.

[0205] 7. The method of Embodiment 1 wherein the cyclooxygenase-2 selective inhibitor is D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8, D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17, celecoxib (D-18), D-19, D-20, rofecoxib (D-21), D-22, D-23, D-24, D-25, D-26, D-27, D-28, D-29, D-30, D-31, D-32, D-33, D-34, D-35, D-36, D-37, D-38, D-39, D-40, D-41, D-42, D-43, D-44, D-45, D-46, D-47, D-48, D-49, D-50, D-51, D-52, D-53, D-54, D-55, D-56, D-57, D-58, D-59, D-60, D-61, D-62, D-63, D-64, D-65, D-66, D-67, D-68, D-69, D-70, D-71, D-72, D-73, D-74, D-75, D-76, D-77, D-78, D-79, D-80, D-81, D-82, D-83, D-84, D-85, D-86, D-87, D-88, D-89, D-90, D-91, D-92, D-93, D-94, D-95, D-96, D-97, D-98, D-99, D-100, D-101, D-102, D-103, D-104, D-105, D-106, D-107, D-108, D-109, D-110, D-111, D-112, D-113, D-114, D-115, D-116, D-117, D-118, D-119, D-120, D-121, D-122, D-123, D-124, D-125, D-126, D-127, D-128, D-129, D-130, D-131, D-132, D-133, D-134, D-135, D-136, D-137, D-138, D-139, D-140, D-141, D-142, D-143, D-144, D-145, D-146, D-147, D-148, D-149, D-150, D-151, D-152, D-153, D-154, D-155, D-156, D-157, D-158, D-159, D-160, D-161, D-162, D-163, D-164, D-165, D-166, D-167, D-168, D-169, D-170, D-171, D-172, D-173, D-174, D-175, D-176, D-177, D-178, D-179, D-180, D-181, D-182, D-183, D-184, D-185, D-186, D-187, D-188, D-189, D-190, D-191, D-192, D-193, D-194, D-195, D-196, D-197, D-198, D-199, D-200, D-201, D-202, D-203, D-204, D-205, D-206, D-207, D-208, D-209, D-210, D-211, D-212, D-213, D-214, D-215, D-216, D-217, D-218, D-219, D-220, D-221, D-222, D-223, D-224, D-225, D-226, D-227, D-228, D-229, D-230, D-231, D-232, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0206] 8. The method of Embodiment 1 wherein the cyclooxygenase-2 nonselective inhibitor is D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36 to D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-110, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-216 to D-220, D-221 to D-225, D-226 to D-230, D-231 to D-232, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0207] 9. The method of Embodiment 1 wherein the cyclooxygenase-2 selective inhibitor is selected from the group consisting of meloxicam, celecoxib, valdecoxib, deracoxib, rofecoxib, etoricoxib (MK-663), 4-cyclohexyl-5-[3-fluoro-4-(methylsulphonyl)phenyl]-2-methyl-oxazole (JTE-522), and 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone (RS 57067), or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0208] 10. The method of Embodiment 9 wherein the cyclooxygenase-2 selective inhibitor is celecoxib.

[0209] 11. The method of Embodiment 9 wherein the cyclooxygenase-2 selective inhibitor is rofecoxib.

[0210] 12. The method of embodiment 9 wherein parecoxib, CAS 198470-84-7, is employed as a prodrug and source of the cyclooxygenase-2 selective inhibitor valdecoxib.

[0211] 13. The method of Embodiment 1 wherein the cyclooxygenase-2 selective inhibitor is a substituted benzopyran or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0212] 14. The method of Embodiment 1 wherein the cyclooxygenase-2 selective inhibitor is a substituted benzopyran analog selected from the group consisting of substituted benzothiopyrans, dihydroquinolines, and dihydronaphthalenes, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0213] 15. The method of Embodiments 7-14 wherein the condition is selected from the group consisting of gout, pancreatitis, cholelithiasis, biliary obstruction, ulcerative colitis, Crohn's disease, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation, and inflammation wherein the inflammation is associated with a surgical procedure involving an artery, a vein or a capillary.

[0214] 16. The method of Embodiment 1 wherein the apical sodium bile acid transport inhibitor is a substituted benzothiepine compound.

[0215] 17. The method of Embodiment 1 wherein the apical sodium bile acid transport inhibitor is a substituted benzothiazepine compound.

[0216] 18. The method of Embodiments 16-17 wherein the condition is selected from the group consisting of gout, pancreatitis, cholelithiasis, biliary obstruction, ulcerative colitis, Crohn's disease, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis., angina, coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation, and inflammation wherein the inflammation is associated with a surgical procedure involving an artery, a vein or a capillary.

[0217] 19. The method of Embodiment 1 further comprising treating the subject with an amount of an HMG-CoA reductase inhibitor wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor, the cyclooxygenase-2 selective inhibitor and the HMG-CoA reductase inhibitor.

[0218] 20. The method of Embodiment 19 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, rosuvastatin, and itavastatin, or a pharmaceutically acceptable salt or ester or lactone thereof.

[0219] 21. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is fluvastatin.

[0220] 22. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is lovastatin.

[0221] 23. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is pravastatin.

[0222] 24. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is simvastatin.

[0223] 25. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is atorvastatin.

[0224] 26. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is cerivastatin.

[0225] 27. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is bervastatin.

[0226] 28. The method of Embodiment 20 wherein the HMG-CoA reductase inhibitor is rosuvastatin.

[0227] 29. The method of Embodiment 20 wherein the HKG-CoA reductase inhibitor is itavastatin.

[0228] 30. The method of Embodiments 19-29 wherein the condition is selected from the group consisting of gout, pancreatitis, cholelithiasis, biliary obstruction, ulcerative colitis, Crohn's disease, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation, and inflammation wherein the inflammation is associated with a surgical procedure involving an artery, a vein or a capillary.

[0229] 31. A pharmaceutical combination comprising an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or prodrug, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor.

[0230] 32. The combination of Embodiment 31 wherein the cyclooxygenase-2 selective inhibitor is D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8, D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17, celecoxib (D-18), D-19, D-20, rofecoxib (D-21), D-22, D-23, D-24, D-25, D-26, D-27, D-28, D-29, D-30, D-31, D-32, D-33, D-34, D-35, D-36, D-37, D-38, D-39, D-40, D-41, D-42, D-43, D-44, D-45, D-46, D-47, D-48, D-49, D-50, D-51, D-52, D-53, D-54, D-55, D-56, D-57, D-58, D-59, D-60, D-61, D-62, D-63, D-64, D-65, D-66, D-67, D-68, D-69, D-70, D-71, D-72, D-73, D-74, D-75, D-76, D-77, D-78, D-79, D-80, D-81, D-82, D-83, D-84, D-85, D-86, D-87, D-88, D-89, D-90, D-91, D-92, D-93, D-94, D-95, D-96, D-97, D-98, D-99, D-100, D-101, D-102, D-103, D-104, D-105, D-106, D-107, D-108, D-109, D-110, D-111, D-112, D-113, D-114, D-115, D-116, D-117, D-118, D-119, D-120, D-121, D-122, D-123, D-124, D-125, D-126, D-127, D-128, D-129, D-130, D-131, D-132, D-133, D-134, D-135, D-136, D-137, D-138, D-139, D-140, D-141, D-142, D-143, D-144, D-145, D-146, D-147, D-148, D-149, D-150, D-151, D-152, D-153, D-154, D-155, D-156, D-157, D-158, D-159, D-160, D-161, D-162, D-163, D-164, D-165, D-166, D-167, D-168, D-169, D-170, D-171, D-172, D-173, D-174, D-175, D-176, D-177, D-178, D-179, D-180, D-181, D-182, D-183, D-184, D-185, D-186, D-187, D-188, D-189, D-190, D-191, D-192, D-193, D-194, D-195, D-196, D-197, D-198, D-199, D-200, D-201, D-202, D-203, D-204, D-205, D-206, D-207, D-208, D-209, D-210, D-211, D-212, D-213, D-214, D-215, D-216, D-217, D-218, D-219, D-220, D-221, D-222, D-223, D-224, D-225, D-226, D-227, D-228, D-229, D-230, D-231, D-232, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0231] 33. The combination of Embodiment 31 wherein the cyclooxygenase-2 selective inhibitor is D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36 to D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-110, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-216 to D-220, D-221 to D-225, D-226 to D-230, D-231 to D-232, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0232] 34. The combination of Embodiment 31 wherein the cyclooxygenase-2 selective inhibitor is selected from the group consisting of meloxicam, celecoxib, valdecoxib, deracoxib, rofecoxib, etoricoxib (MK-663), 4-cyclohexyl-5-[3-fluoro-4-(methylsulphonyl)phenyl]-2-methyl-oxazole (JTE-522), and 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone (RS 57067), or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0233] 35. The combination of Embodiment 34 wherein the cyclooxygenase-2 selective inhibitor is celecoxib.

[0234] 36. The combination of Embodiment 34 wherein the cyclooxygenase-2 selective inhibitor is rofecoxib.

[0235] 37. The combination of embodiment 34 wherein parecoxib, CAS 198470-84-7, is employed as a prodrug and source of the cyclooxygenase-2 selective inhibitor valdecoxib.

[0236] 38. The combination of Embodiment 31 wherein the cyclooxygenase-2 selective inhibitor is a substituted benzopyran or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0237] 39. The combination of Embodiment 34 wherein the cyclooxygenase-2 selective inhibitor is a substituted benzopyran analog selected from the group consisting of substituted benzothiopyrans, dihydroquinolines, and dihydronaphthalenes, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0238] 40. The combination of Embodiment 31 wherein the apical sodium bile acid transport inhibitor is a substituted benzothiepine compound.

[0239] 41. The combination of Embodiment 31 wherein the apical sodium bile acid transport inhibitor is a substituted benzothiazepine compound.

[0240] 42. A process for preparing the pharmaceutical combination of Embodiment 31 comprising combining an amount of the apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or prodrug, and a pharmaceutically acceptable carrier.

[0241] 43. The combination of Embodiment 31 further comprising an amount of an HMG-CoA reductase inhibitor wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor and the HMG-CoA reductase inhibitor.

[0242] 44. The combination of Embodiment 43 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, rosuvastatin, and itavastatin, or a pharmaceutically acceptable salt or ester or lactone thereof.

[0243] 45. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is fluvastatin.

[0244] 46. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is lovastatin.

[0245] 47. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is pravastatin.

[0246] 48. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is simvastatin.

[0247] 49. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is atorvastatin.

[0248] 50. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is cerivastatin.

[0249] 51. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is bervastatin.

[0250] 52. The combination of Embodiment 44 wherein the HMG-CoA reductase inhibitor is rosuvastatin.

[0251] 53. The combination method of Embodiment 44 wherein the HMG-CoA reductase inhibitor is itavastatin.

[0252] 54. The process of Embodiment 42 further comprising combining an amount of an HMG-CoA reductase inhibitor, an amount of the apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or prodrug, and a pharmaceutically acceptable carrier.

[0253] 55. A kit comprised of an amount of an apical sodium co-dependent bile acid transport inhibitor in a dosage formulation and an amount of a cyclooxygenase-2 selective inhibitor or prodrug in a separate dosage formulation wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor.

[0254] 56. The kit of Embodiment 55 wherein the cyclooxygenase-2 selective inhibitor is D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8, D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17, celecoxib (D-18), D-19, D-20, rofecoxib (D-21), D-22, D-23, D-24, D-25, D-26, D-27, D-28, D-29, D-30, D-31, D-32, D-33, D-34, D-35, D-36, D-37, D-38, D-39, D-40, D-41, D-42, D-43, D-44, D-45, D-46, D-47, D-48, D-49, D-50, D-51, D-52, D-53, D-54, D-55, D-56, D-57, D-58, D-59, D-60, D-61, D-62, D-63, D-64, D-65, D-66, D-67, D-68, D-69, D-70, D-71, D-72, D-73, D-74, D-75, D-76, D-77, D-78, D-79, D-80, D-81, D-82, D-83, D-84, D-85, D-86, D-87, D-88, D-89, D-90, D-91, D-92, D-93, D-94, D-95, D-96, D-97, D-98, D-99, D-100, D-101, D-102, D-103, D-104, D-105, D-106, D-107, D-108, D-109, D-110, D-111, D-112, D-113, D-114, D-115, D-116, D-117, D-118, D-119, D-120, D-121, D-122, D-123, D-124, D-125, D-126, D-127, D-128, D-129, D-130, D-131, D-132, D-133, D-134, D-135, D-136, D-137, D-138, D-139, D-140, D-141, D-142, D-143, D-144, D-145, D-146, D-147, D-148, D-149, D-150, D-151, D-152, D-153, D-154, D-155, D-156, D-157, D-158, D-159, D-160, D-161, D-162, D-163, D-164, D-165, D-166, D-167, D-168, D-169, D-170, D-171, D-172, D-173, D-174, D-175, D-176, D-177, D-178, D-179, D-180, D-181, D-182, D-183, D-184, D-185, D-186, D-187, D-188, D-189, D-190, D-191, D-192, D-193, D-194, D-195, D-196, D-197, D-198, D-199, D-200, D-201, D-202, D-203, D-204, D-205, D-206, D-207, D-208, D-209, D-210, D-211, D-212, D-213, D-214, D-215, D-216, D-217, D-218, D-219, D-220, D-221, D-222, D-223, D-224, D-225, D-226, D-227, D-228, D-229, D-230, D-231, D-232, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0255] 57. The kit of Embodiment 55 wherein the cyclooxygenase-2 selective inhibitor is D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36 to D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-110, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-216 to D-220, D-221 to D-225, D-226 to D-230, D-231 to D-232, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0256] 58. The kit of Embodiment 55 wherein the cyclooxygenase-2 selective inhibitor is selected from the group consisting of meloxicam, celecoxib, valdecoxib, deracoxib, rofecoxib, etoricoxib (MK-663), 4-cyclohexyl-5-[3-fluoro-4-(methylsulphonyl)phenyl]-2-methyl-oxazole (JTE-522), and 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone (RS 57067), or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0257] 59. The kit of Embodiment 58 wherein the cyclooxygenase-2 selective inhibitor is celecoxib.

[0258] 60. The kit of Embodiment 58 wherein the cyclooxygenase-2 selective inhibitor is rofedoxib.

[0259] 61. The kit of embodiment 58 wherein parecoxib, CAS 198470-84-7, is employed as a prodrug and source of the cyclooxygenase-2 selective inhibitor valdecoxib.

[0260] 62 . The kit of Embodiment 55 wherein the cyclooxygenase-2 selective inhibitor is a substituted benzopyran or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0261] 63. The kit of Embodiment 55 wherein the cyclooxygenase-2 selective inhibitor is a substituted benzopyran analog selected from the group consisting of substituted benzothiopyrans, dihydroquinolines, and dihydronaphthalenes, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

[0262] 64. The kit of Embodiment 55 wherein the apical sodium bile acid transport inhibitor is a substituted benzothiepine compound.

[0263] 65. The kit of Embodiment 55 wherein the apical sodium bile acid transport inhibitor is a substituted benzothiazepine compound.

[0264] 66. The kit of Embodiment 55 further comprising an amount of an HMG-CoA reductase inhibitor wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor, the cyclooxygenase-2 selective inhibitor and the HMG-CoA reductase inhibitor.

[0265] 67. The kit of Embodiment 66 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, rosuvastatin, and itavastatin, or a pharmaceutically acceptable salt or ester or lactone thereof.

[0266] 68. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is fluvastatin.

[0267] 69. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is lovastatin.

[0268] 70. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is pravastatin.

[0269] 71. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is simvastatin.

[0270] 72. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is atorvastatin.

[0271] 73. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is cerivastatin.

[0272] 74. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is bervastatin.

[0273] 75. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is rosuvastatin.

[0274] 76. The kit of Embodiment 67 wherein the HMG-CoA reductase inhibitor is itavastatin.

[0275] 77. A method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an apical sodium co-dependent bile acid transport inhibitor and an amount of a chromene cyclooxygenase-2 selective inhibitor or prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the chromene cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the chromene cyclooxygenase-2 selective inhibitor.

[0276] 78. A method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an HMG Co-A reductase inhibitor and an amount of a chromene cyclooxygenase-2 selective inhibitor or prodrug, wherein the amount of the HMG Co-A reductase inhibitor and the amount of the chromene cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the HMG Co-A reductase inhibitor and the chromene cyclooxygenase-2 selective inhibitor.

[0277] The examples herein can be performed by substituting the generically or specifically described therapeutic compounds or inert ingredients for those used in the preceding examples.

[0278] The invention being thus described, it is apparent that the same can be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications and equivalents as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

Claims

1. A method for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention, comprising treating the subject with an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or prodrug, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 inhibitor.

2. The method of claim 1 wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase inhibitor.

3. The method of claim 1 wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor.

4. The method of claim 1 wherein the condition is selected from the group consisting of gout, pancreatitis, cholelithiasis, biliary obstruction, ulcerative colitis, Crohn's disease, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation, and inflammation wherein the inflammation is associated with a surgical procedure involving an artery, a vein or a capillary.

5. The method of claim 4 wherein the condition is selected from the group consisting of coronary artery disease, atherosclerosis, and thrombosis.

6. The method of claim 5 wherein the condition is coronary artery disease.

7. The method of claim 1 wherein the cyclooxygenase-2 selective inhibitor is [2-(2,4-Dichloro-6-ethyl-3,5-dimethyl-phenylamino)-5-propyl-phenyl]-acetic acid (D-1); 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone or RS 57067 (D-2); 6-Nitro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-3); 6-Chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-4); ((S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-5); 2-Trifluoromethyl-2H-naphtho[2,3-b]pyran-3-carboxylic acid (D-6); 6-Chloro-7-(4-nitrophenoxy)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-7); ((S)-6,8-Dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-8); 6-Chloro-2-(trifluoromethyl)-4-phenyl-2H-1-benzopyran-3-carboxylic acid (D-9); 6-(4-Hydroxybenzoyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-10); 2-(Trifluoromethyl)-6-[(trifluoromethyl)thio]-2H-1-benzothiopyran-3-carboxylic acid (D-11); 6,8-Dichloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-12); 6-(1,1-Dimethylethyl)-2-(trifluoromethyl)-2H-1-benzothiopyran-3-carboxylic acid (D-13); 6,7-Difluoro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-14); 6-Chloro-1,2-dihydro-1-methyl-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-15); 6-Chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine-3-carboxylic acid (D-16); ((S)-6-Chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-17); celecoxib (D-18); valdecoxib (D-19); deracoxib (D-20); rofecoxib (D-21); etoricoxib (D-22); JTE-522 (D-23); parecoxib (D-24) ABT-963 (D-25); N-(2-cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide or NS-398 (D-26); 6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-27); 6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-28); 8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-29); 6-chloro-8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-30); 2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid (D-31); 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-32); 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-33); 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-34); 6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-35); 5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-36); 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-37); 7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-38); 6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-39); 7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-40); 7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-41); 6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-42); 6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-43); 6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-44); 6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-45); 6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-46); 2-trifluoromethyl-3H-naptho[2,1-b]pyran-3-carboxylic acid (D-29); 8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-48 8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-49); 6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-50); 8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-51); 8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-52); 8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-53); 6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-54); 6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-55); 6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-56); 6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-57); 6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-58); 6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-59); 6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-60); 6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-61); 6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-62); 8-chloro-6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-63); 6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-64); 6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-65); 8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-66); 6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-67); 6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-68); 6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-69); 6-[[N-(2-phenylethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-70); 6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-71); 7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carboxylic acid (D-72); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-73); BMS-347070 (D-74); 8-acetyl-3-(4-fluorophenyl)-2-(4-methylsulfonyl)phenyl-imidazo(1,2-a)pyridine (D-75); 5,5-dimethyl-4-(4-methylsulfonyl)phenyl-3-phenyl-2-(5H)-furanone (D-76); 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole (D-77); 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole (D-78); 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-79); 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-80); 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide(D-81); 4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-82); 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-83); 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-84); 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-85); 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide(D-86); 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide(D-87); 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-88); 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-89); 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-90); 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-91); 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-92); 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-93); 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-94); 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide (D-95); 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-96); 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-97); 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-98); 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-99); 4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide (D-100); 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-101); 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-102); 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-103); 4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-104); 6-(4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene (D-105); 5-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-106); 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-107); 5-(3,5-dichloro-4-methoxyphenyl)-6-[4--(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-108); 5-(3-chloro-4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-109); 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-110); 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole (D-111); 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole (D-112); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole (D-113); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole (D-114); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole (D-115); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole (D-116); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole (D-117); 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]thiazole (D-118); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole (D-119); 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene (D-120); 4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-yl]benzenesulfonamide (D-121); 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene (D-122); 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5-yl]benzenesulfonamide (D-123); 6-(4-fluorophenyl)-2-methoxy-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile (D-124); 2-bromo-6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile (D-125); 6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyl-pyridine-3-carbonitrile (D-126); 4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-127); 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-128); 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-129); 3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-130); 2-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-131); 2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-132); 2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-133); 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-134); 2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole (D-135); 4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-136); 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole (D-137); 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole (D-138); 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-1H-imidazole (D-139); 2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazole (D-140); 1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole (D-141); 2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole (D-142); 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-143); 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole (D-144); 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-145); 2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole (D-146); 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-147); 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole (D-148); 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-149); 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-150); 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-151); 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (D-152); 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide (D-153); N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide (D-154); ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate (D-155); 4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole (D-156); 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole (D-157); 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (D-158); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-1H-imidazole (D-159); 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-1H-imidazole (D-160); 5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-161); 2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-162); 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-propynyloxy)-6-(trifluoromethyl)pyridine (D-163); 2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-164); 4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide (D-165); 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene (D-166); 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole (D-167); 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide (D-168); 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-169); 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-170); 4-(5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide (D-171); 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-172); 1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-173); 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-174); 1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-175); 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-176); 1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-177); 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-178); 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide (D-179); 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-180); 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide (D-181); 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-182); 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-183); 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-184); 1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-185); 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide (D-186); 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-187); 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-188); 4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide (D-189); ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl-acetate (D-190); 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid (D-191); 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole (D-192); 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole (D-193); 4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole (D-194); 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl]benzenesulfonamide (D-195); 6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-196); 6-chloro-8-methyl-2-trifluoromethyl-2h-1-benzopyran-3-carboxylic acid (D-197); 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methyl-sulphonyl-2(5H)-fluranone (D-198); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-199); 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-200); 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-201); 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-202); 3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (D-203); 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (D-204); 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-205); 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-206); 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-207); [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide (D-208); 4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide (D-209); 4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide (D-210); [2-(2-Chloro-6-fluoro-phenylamino)-5-methyl-phenyl]-acetic acid, COX 189 (D-211); N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide, Nimesulide (D-212); N-[6-(2,4-Difluoro-phenoxy)-1-oxo-indan-5-yl]-methanesulfonamide, Flosulide (D-213); N-[6-(2,4-difluoro-phenylsulfonyl)-1-1-oxo-1H-inden-5-yl]-methanesulfonmaide, sodium salt, or L-745337 (D-214); N-[5,(4-fluoro-phenylsulfanyl)-thiophen-2-yl]methanesulfonamide or RWJ-63556 (D-215); (5Z)-2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4(5H)-thiazolone, Darbufelone (D-217); N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanesulfonamide, T-614 (D-224); (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid, CT3 (D-227); 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]dihydro-2-methyl-2H-1,2-oxazin-3(4H)-one, BF-389 (D-229); or 6-dioxo-9H-purin-8-yl-cinnamic acid (D-231); or a pharmaceutically acceptable salt or derivative or prodrug thereof.

8. The method of claim 7 wherein the cyclooxygenase-2 selective inhibitor is D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36 to D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-110, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-217, D-224, D-227, D-229, D-231, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

9. The method of claim 1 further comprising treating the subject with an amount of an HMG-CoA reductase inhibitor wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor, the cyclooxygenase-2 selective inhibitor and the HMG-CoA reductase inhibitor.

10. The method of claim 9 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, rosuvastatin, and itavastatin, or a pharmaceutically acceptable salt or ester or lactone thereof.

11. A pharmaceutical combination comprising an amount of an apical sodium co-dependent bile acid transport inhibitor, an amount of a cyclooxygenase-2 selective inhibitor or prodrug, and a pharmaceutically acceptable carrier, wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selective inhibitor.

12. The combination of claim 11 wherein the cyclooxygenase-2 selective inhibitor is [2-(2,4-Dichloro-6-ethyl-3,5-dimethyl-phenylamino)-5-propyl-phenyl]-acetic acid (D-1); 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone or RS 57067 (D-2); 6-Nitro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-3); 6-Chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-4); ((S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-5); 2-Trifluoromethyl-2H-naphtho[2,3-b]pyran-3-carboxylic acid (D-6); 6-Chloro-7-(4-nitrophenoxy)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-7); ((S)-6,8-Dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-8); 6-Chloro-2-(trifluoromethyl)-4-phenyl-2H-1-benzopyran-3-carboxylic acid (D-9); 6-(4-Hydroxybenzoyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-10); 2-(Trifluoromethyl)-6-[(trifluoromethyl)thio]-2H-1-benzothiopyran-3-carboxylic acid (D-11); 6,8-Dichloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-12); 6-(1,1-Dimethylethyl)-2-(trifluoromethyl)-2H-1-benzothiopyran-3-carboxylic acid (D-13); 6,7-Difluoro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-14); 6-Chloro-1,2-dihydro-1-methyl-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-15); 6-Chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine-3-carboxylic acid (D-16); ((S)-6-Chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-17); celecoxib (D-18); valdecoxib (D-19); deracoxib (D-20); rofecoxib (D-21); etoricoxib (D-22); JTE-522 (D-23); parecoxib (D-24) ABT-963 (D-25); N-(2-cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide or NS-398 (D-26); 6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-27); 6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-28); 8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-29); 6-chloro-8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-30); 2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid (D-31); 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-32); 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-33); 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-34); 6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-35); 5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-36); 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-37); 7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-38); 6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-39); 7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-40); 7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-41); 6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-42); 6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-43); 6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-44); 6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-45); 6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-46); 2-trifluoromethyl-3H-naptho[2,1-b]pyran-3-carboxylic acid (D-29); 8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-48 8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-49); 6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-50); 8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-51); 8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-52); 8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-53); 6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-54); 6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-55); 6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-56); 6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-57); 6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-58); 6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-59); 6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-60); 6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-61); 6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-62); 8-chloro-6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-63); 6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-64); 6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-65); 8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-66); 6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-67); 6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-68); 6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-69); 6-[[N-(2-phenylethyl)aminolsulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-70); 6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-71); 7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carboxylic acid (D-72); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-73); BMS-347070 (D-74); 8-acetyl-3-(4-fluorophenyl)-2-(4-methylsulfonyl)phenyl-imidazo(1,2-a)pyridine (D-75); 5,5-dimethyl-4-(4-methylsulfonyl)phenyl-3-phenyl-2-(5H)-furanone (D-76); 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole (D-77); 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole (D-78); 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-79); 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-80); 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide(D-81); 4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-82); 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-83); 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-84); 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-85); 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide(D-86); 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide(D-87); 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-88); 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-89); 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-90); 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-91); 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-92); 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-93); 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-94); 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide (D-95); 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-96); 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-97); 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-98); 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-99); 4-[4-chloro-5-phenyl-1-H-pyrazol-1-yl]benzenesulfonamide (D-100); 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-101); 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-102); 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-103); 4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-104); 6-(4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene (D-105); 5-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-106); 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-107); 5-(3,5-dichloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-108); 5-(3-chloro-4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-109); 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-110); 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole (D-111); 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole (D-112); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole (D-113); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole (D-114); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole (D-115); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole (D-116); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole (D-117); 2-[(3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]thiazole (D-118); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole (D-119); 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene (D-120); 4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-yl]benzenesulfonamide (D-121); 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene (D-122); 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5-yl]benzenesulfonamide (D-123); 6-(4-fluorophenyl)-2-methoxy-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile (D-124); 2-bromo-6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile (D-125); 6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyl-pyridine-3-carbonitrile (D-126); 4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-127); 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-128); 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-129); 3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-130); 2-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-131); 2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-132); 2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-133); 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-134); 2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole (D-135); 4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-136); 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole (D-137); 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole (D-138); 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]1-imidazole (D-139); 2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazole (D-140); 1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole (D-141); 2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole (D-142); 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-143); 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole (D-144); 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-145); 2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole (D-146); 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-147); 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole (D-148); 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-149); 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-150); 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-151); 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (D-152); 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide (D-153); N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide (D-154); ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate (D-155); 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole (D-156); 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole (D-157); 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (D-158); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-1H-imidazole (D-159); 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-1H-imidazole (D-160); 5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-161); 2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-162); 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-propynyloxy)-6-(trifluoromethyl)pyridine (D-163); 2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-164); 4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide (D-165); 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene (D-166); 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole (D-167); 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide (D-168); 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-169); 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-170); 4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide (D-171); 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-172); 1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-173); 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-174); 1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-175); 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-176); 1-[2-(4-methylthiophenyl) cyclopenten-yl]-4-(methylsulfonyl)benzene (D-177); 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-178); 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-i-yl]benzenesulfonamide (D-179); 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-180); 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide (D-181); 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-182); 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-183); 1-[2-(4-methoxyphenyl)cyclopenten-1-yl -4-(methylsulfonyl)benzene (D-184); 1-[2-(2, 3-difluorophenyl)cyclopenten-1-yl -4-(methylsulfonyl)benzene (D-185); 4-[2-(3-f luoro-4-methoxyphenyl) cyclopenten-1-yl]benzenesulfonamide (D-186); 1-[2-(3-chloro-4-methoxyphenyl) cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-187); 4-[2-(3-chloro-4-fluorophenyl) cyclopenten-1-yl]benzenesulfonamide (D-188); 4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide (D-189); ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl-acetate (D-190); 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid (D-191); 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole (D-192); 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl)-2-phenyloxazole (D-193); 4-(4-fluorophenyl)-2-methyl-5-f4-(methylsulfonyl)phenyl]oxazole (D-194); 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl]benzenesulfonamide (D-195); 6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-196); 6-chloro-8-methyl-2-trifluoromethyl-2h-1-benzopyran-3-carboxylic acid (D-197); 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methyl-sulphonyl-2(5H)-fluranone (D-198); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-199); 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-200); 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-201); 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-202); 3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (D-203); 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (D-204); 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-205); 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-206); 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-207); [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide (D-208); 4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide (D-209); 4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl)benzenesulfonamide (D-210); [2-(2-Chloro-6-fluoro-phenylamino)-5-methyl-phenyl]-acetic acid, COX 189 (D-211); N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide, Nimesulide (D-212); N-[6-(2,4-Difluoro-phenoxy)-1-oxo-indan-5-yl]-methanesulfonamide, Flosulide (D-213); N-[6-(2,4-difluoro-phenylsulfonyl)-1-1-oxo-1H-inden-5-yl]-methanesulfonmaide, sodium salt, or L-745337 (D-214); N-[5, (4-fluoro-phenylsulfanyl)-thiophen-2-yl]methanesulfonamide or RWJ-63556 (D-215); (5Z)-2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4(5H)-thiazolone, Darbufelone (D-217); N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanesulfonamide, T-614 (D-224); (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid, CT3 (D-227); 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]dihydro-2-methyl-2H-1,2-oxazin-3(4H)-one, BF-389 (D-229); 6-dioxo-9H-purin-8-yl-cinnamic acid (D-231); or a pharmaceutically acceptable salt or derivative or prodrug thereof.

13. The combination of claim 11 wherein the cyclooxygenase-2 selective inhibitor is D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36 to D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-110, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-217, D-224, D-227, D-229, D-231, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

14. The combination of claim 11 further comprising an amount of an HMG-CoA reductase inhibitor wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor, the cyclooxygenase-2 selective inhibitor and the HMG-CoA reductase inhibitor.

15. The combination of claim 14 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, rosuvastatin, and itavastatin, or a pharmaceutically acceptable salt or ester or lactone thereof.

16. A kit comprised of an amount of an apical sodium co-dependent bile acid transport inhibitor in a dosage formulation and an amount of a cyclooxygenase-2 selective inhibitor or prodrug in a separate dosage formulation wherein the amount of the apical sodium co-dependent bile acid transport inhibitor and the amount of the cyclooxygenase-2 selective inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor and the cyclooxygenase-2 selecti e inhibitor.

17. The kit of claim 16 wherein the cyclooxygenase-2 selective inhibitor is [2-(2,4-Dichloro-6-ethyl-3,5-dimethyl-phenylamino)-5-propyl-phenyl]acetic acid (D-1); 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone or RS 57067 (D-2); 6-Nitro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-3); 6-Chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-4); ((S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-5); 2-Trifluoromethyl-2H-naphtho[2,3-b]pyran-3-carboxylic acid (D-6); 6-Chloro-7-(4-nitrophenoxy)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-7); ((S)-6,8-Dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-8); 6-Chloro-2-(trifluoromethyl)-4-phenyl-2H-1-benzopyran-3-carboxylic acid (D-9); 6-(4-Hydroxybenzoyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (D-10); 2-(Trifluoromethyl)-6-[(trifluoromethyl)thio]-2H-1-benzothiopyran-3-carboxylic acid (D-11); 6,8-Dichloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-12); 6-(1,1-Dimethylethyl)-2-(trifluoromethyl)-2H-1-benzothiopyran-3-carboxylic acid (D-13); 6,7-Difluoro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-14); 6-Chloro-1,2-dihydro-1-methyl-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-15); 6-Chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine-3-carboxylic acid (D-16); ((S)-6-Chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid (D-17); celecoxib (D-18); valdecoxib (D-19); deracoxib (D-20); rofecoxib (D-21); etoricoxib (D-22); JTE-522 (D-23); parecoxib (D-24) ABT-963 (D-25); N-(2-cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide or NS-398 (D-26); 6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-27); 6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-28); 8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-29); 6-chloro-8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-30); 2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid (D-31); 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-32); 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-33); 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-34); 6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-35); 5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-36); 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-37); 7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-38); 6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-39); 7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-40); 7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-41); 6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-42); 6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-43); 6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-44); 6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-45); 6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-46); 2-trifluoromethyl-3H-naptho[2,1-blpyran-3-carboxylic acid (D-29); 8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-48 8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-49); 6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-50); 8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-51); 8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-52); 8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-53); 6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-54); 6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-55); 6-[[((phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-56); 6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-57); 6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-58); 6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-59); 6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-60); 6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-61); 6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-62); 8-chloro-6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-63); 6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-64); 6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-65); 8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-66); 6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-67); 6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-68); 6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-69); 6-[[N-(2-phenylethyl) amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-70); 6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-71); 7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carboxylic acid (D-72); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-73); BMS-347070 (D-74); 8-acetyl-3-(4-fluorophenyl)-2-(4-methylsulfonyl)phenyl-imidazo(1,2-a)pyridine (D-75); 5,5-dimethyl-4-(4-methylsulfonyl)phenyl-3-phenyl-2-(5H)-furanone (D-76); 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole (D-77); 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole (D-78); 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-79); 4-(3,5-bis (4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-80); 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (D-81); 4-(3, 5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-82); 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-83); 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide (D-84); 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide(D-85); 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide(D-86); 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide(D-87); 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-88); 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-89); 4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-90); 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-91); 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-92); 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-93); 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-94); 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide (D-95); 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-96); 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-97); 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-98); 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-99); 4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide (D-100); 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-101); 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-102); 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-103); 4-[6-(4-fluorophenyl) spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-104); 6-(4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene (D-105); 5-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-106); 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-107); 5-(3,5-dichloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-108); 5-(3-chloro-4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene (D-109); 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide (D-110); 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole (D-111); 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole (D-112); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole (D-113); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole (D-114); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole (D-115); 4-(4-f luorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole (D-116); 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole (D-117); 2-[(3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]thiazole (D-118); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole (D-119); 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene (D-120); 4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-yl)benzenesulfonamide (D-121); 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene (D-122); 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5-yl]benzenesulfonamide (D-123); 6-(4-fluorophenyl)-2-methoxy-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile (D-124); 2-bromo-6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile (D-125); 6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyl-pyridine-3-carbonitrile (D-126); 4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-127); 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-128); 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-129); 3-[1-[4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-130); 2-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-131); 2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-132); 2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (D-133); 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-134); 2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole (D-135); 4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-136); 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole (D-137); 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole (D-138); 2-(4-chlorophenyl)-4-(4-fluorophehyl)-1-[4-(methylsulfonyl)phenyl]-1H-imidazole (D-139); 2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazole (D-140); 1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole (D-141); 2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole (D-142); 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-143); 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole (D-144); 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-145); 2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole (D-146); 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-147); 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole (D-148); 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol1-yl]benzenesulfonamide (D-149); 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-150); 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide (D-151); 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (D-152); 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide (D-153); N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide (D-154); ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate (D-155); 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole (D-156); 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-l-(2-phenylethyl)-5-(trifluoromethyl)pyrazole (D-157); 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (D-158); 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-1H-imidazole (D-159); 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-1H-imidazole (D-160); 5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl)-6-(trifluoromethyl)pyridine (D-161); 2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-162); 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-propynyloxy)-6-(trifluoromethyl)pyridine (D-163); 2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine (D-164); 4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide (D-165); 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene (D-166); 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole (D-167); 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide (D-168); 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-169); 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-170); 4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide (D-171); 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-172); 1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-173); 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-174); 1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-175); 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-176); 1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-177); 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-178); 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide (D-179); 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-180); 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide (D-181); 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-182); 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-183); 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-184); 1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-185); 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-y]benzenesulfonamide (D-186); 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene (D-187); 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide (D-188); 4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide (D-189); ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl-acetate (D-190); 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid (D-191); 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole (D-192); 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole (D-193); 4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole (D-194); 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl]benzenesulfonamide (D-195); 6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (D-196); 6-chloro-8-methyl-2-trifluoromethyl-2h-1-benzopyran-3-carboxylic acid (D-197); 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methyl-sulphonyl-2(5H)-fluranone (D-198); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (D-199); 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-200); 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-201); 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (D-202); 3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (D-203); 2-methyl-5-[1-[4-(methylsulfonyl)phenyl)-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (D-204); 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide (D-205); 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-206); 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide (D-207); [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide (D-208); 4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide (D-209); 4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide (D-210); [2-(2-Chloro-6-fluoro-phenylamino)-5-methyl-phenyl]-acetic acid, COX 189 (D-211); N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide, Nimesulide (D-212); N-[6-(2,4-Difluoro-phenoxy)-1-oxo-indan-5-yl]-methanesulfonamide, Flosulide (D-213); N-[6-(2,4-difluoro-phenylsulfonyl)-1-1-oxo-1H-inden-5-yl]-methanesulfonmaide, sodium salt, or L-745337 (D-214); N-[5, (4-fluoro-phenylsulfanyl)-thiophen-2-yl]methanesulfonamide or RWJ-63556 (D-215); (5Z)-2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4(5H)-thiazolone, Darbufelone (D-217); N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanesulfonamide, T-614 (D-224); (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid, CT3 (D-227); 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]dihydro-2-methyl-2H-1,2-oxazin-3(4H)-one, BF-389 (D-229); 6-dioxo-9H-purin-8-yl-cinnamic acid (D-231); or a pharmaceutically acceptable salt or derivative or prodrug thereof.

18. The kit of claim 16 wherein the cyclooxygenase-2 selective inhibitor is D-1 to D-5, D-6 to D-10, D-11 to D-15, D-16 to D-20, D-21 to D-25, D-26 to D-30, D-31 to D-35, D-36 to D-40, D-41 to D-45, D-46 to D-50, D-51 to D-55, D-56 to D-60, D-61 to D-65, D-66 to D-70, D-71 to D-75, D-76 to D-80, D-81 to D-85, D-86 to D-90, D-91 to D-95, D-96 to D-100, D-101 to D-105, D-106 to D-110, D-111 to D-115, D-116 to D-120, D-121 to D-125, D-126 to D-130, D-131 to D-135, D-136 to D-140, D-141 to D-145, D-146 to D-150, D-151 to D-155, D-156 to D-160, D-161 to D-165, D-166 to D-170, D-171 to D-175, D-176 to D-180, D-181 to D-185, D-186 to D-190, D-191 to D-195, D-196 to D-200, D-201 to D-205, D-206 to D-210, D-211 to D-215, D-217, D-224, D-227, D-229, D-231, or a pharmaceutically acceptable salt or derivative or prodrug thereof.

19. The kit of claim 16 further comprising an amount of an HMG-CoA reductase inhibitor wherein the amount of the apical sodium co-dependent bile acid transport inhibitor, the amount of the cyclooxygenase-2 selective inhibitor and the amount of the HMG-CoA reductase inhibitor together constitute a hypercholesterolemia-related condition effective amount or an inflammation-related condition effective amount of the apical sodium co-dependent bile acid transport inhibitor, the cyclooxygenase-2 selective inhibitor and the HMG-CoA reductase inhibitor.

20. The kit of claim 19 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, rosuvastatin, and itavastatin, or a pharmaceutically acceptable salt or ester or lactone thereof.